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Abstract 
 
Background 
Para-aminosalicylic acid (PAS) is one of the first effective anti-tuberculosis agents 
and has become one of the principal second-line drugs to treat patients with an 
extended resistance spectrum. Despite being one of the oldest anti-tuberculosis 
drugs, little data is available regarding its pharmacokinetics, drug interactions, 
genetic factors and dosing regimens, especially for the relative new granular slow 
release PAS (GSR-PAS) preparation. 
Objectives  
The aim of the study was to investigate the pharmacokinetics, tolerability and safety 
of a single 8 g once- or 4 g twice-daily GSR-PAS dose in a multidrug- or extensively 
drug resistant tuberculosis (M/XDR-TB) population, in which some subjects were also 
co-infected with the human immunodeficiency virus (HIV). An additional objective 
was to investigate the potential covariates (i.e. genetic factors and drug interactions) 
that can alter the pharmacokinetics of PAS. 
Study design and methodology 
A randomised, two-period, open-label cross-over study was conducted in 32 adults 
(≥18 years old) with M/XDR-TB admitted at Brooklyn Chest Hospital, Cape Town, 
South Africa and treated for drug resistant tuberculosis with a multidrug regimen 
containing GSR-PAS. The subjects were randomised to follow a single 8 g once-daily 
GSR-PAS regimen or a 4 g twice-daily GSR-PAS regimen for 8 days. On the eighth 
day blood samples were obtained at 0, 1, 2, 3, 4, 6, 8, 12 and 24 hours. After the 24-
hour sample (Day 9) the regimens were crossed-over. The tolerability and safety of 
the two regimens were determined using Visual Analogue Scales and interviews. 
PAS plasma concentrations were determined by a developed HPLC-MS/MS method. 
N-acetyltransferase (NAT1 and NAT2) genotyping was performed. The data of this 
study together with unpublished data of a previous study in a very similar population 
were used in a pharmacometric analysis to determine the PK parameters and any 
subject covariates.  
Results and Discussion 
In comparison to the 4 g twice-daily GSR-PAS dose, the single 8 g once-daily GSR-
PAS dose generated a pharmacokinetic profile with a significantly higher maximum 
concentration (Cmax), concentration at 12 hours (C12) and area under the curve 0 to 
Stellenbosch University http://scholar.sun.ac.za
| iii 
  
 
12 hours (AUC12). The concentrations of all subjects on the twice-daily regimen were 
maintained above a minimum inhibitory concentration (MIC) throughout a 12-hour 
interval, while the single 8 g dose was able to sustain the PAS plasma concentrations 
above the MIC in 18 out of 29 subjects (62.1%) for the entire 24-hour dosing interval. 
Both regimens were reasonably well tolerated but most subjects preferred the twice-
daily dosing. The clearance of PAS was increased by 45% in HIV positive subjects 
prescribed antiretroviral treatment (ART), possibly due to interaction with efavirenz 
(EFV). No significant associations were found for any of the individual NAT1 or NAT2 
genotypes, but a difference between mean concentrations of the different genotypic 
groups was reported. 
Conclusions 
The 8 g once-daily dose has the potential to be included in future regimens. The 
higher peak concentrations achieved can be expected to increase the bactericidal 
effect of GSR-PAS without significant loss of bacteriostatic effect, i.e. time over MIC. 
The 8 g once-daily dose has a reasonable tolerability and is potentially easier to 
supervise in an outpatient setting. Since antiretrovirals (ARVs) increase PAS 
clearance and decrease PAS exposure in HIV co-infected subjects on ART, the 8 g 
once-daily dose will be less suitable for maintaining bacteriostasis in these patients 
(inadequate PAS exposure). Therefore, PAS and ARV interactions need to be 
clarified before the 8 g once-daily dose can be recommended for the HIV co-infected 
patients on ART. 
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Abstrak 
 
Agtergrond 
Para-aminosalisielsuur (PAS) is een van die eerste effektiewe anti-tuberkulose 
middels en het een van die hoof tweede-lyn middels geword om pasiënte met 'n 
uitgebreide weerstand spektrum te behandel. Ondanks die feit dat PAS die oudste 
anti-tuberkulose middel is, is daar baie min data beskikbaar met betrekking tot die 
farmakokinetika, middel interaksies, genetiese faktore en dosering, veral in die geval 
van die relatiewe nuwe granulêre stadige vrystelbare PAS voorbereiding (GSV-PAS).  
 
Doel 
Die doel van die studie was om navorsing te doen oor die farmakokinetika, 
verdraagsaamheid en veiligheid van ŉ enkele 8 g een keer daaglikse en 4 g twee 
keer daaglikse GSV-PAS dosering in ŉ multi- of uitgebreide weerstandige 
tuberkulose (M/XDR-TB) populasie, waar sommige proefpersone ook met die 
Menslike Immuniteitsgebreksvirus (MIV) geko-infekteer is. ŉ Verdere doel van die 
studie was om te bepaal of potensiële kovariate soos genetika en medisyne 
interaksies die farmakokinetika van PAS verander. 
 
Metodes 
ŉ Onwillekeurige, twee-periode, oop-etiket oorkruisingstudie was op 32 M/XDR-TB 
volwassenes (≥ 18 jaar oud) uitgevoer terwyl hulle vir middel weerstandige 
tuberkulose in Brooklyn Chest hospitaal (Kaapstad, Suid-Afrika) behandel is. Die 
deelnemers was onwillekeurig ingedeel om ŉ 8 g eenkeer daaglikse GSV-PAS 
dosering of ŉ 4 g twee keer daaglikse GSV-PAS dosering vir agt dae te volg. Op die 
agste dag was bloedmonsters op die volgende ure 0, 1, 2, 3, 4, 6, 8, 12, en 24 
geneem. Na die 24-uur monster (Dag 9) was die doserings omgekeer. Die 
verdraagsaamheid en veiligheid van die twee doserings is bepaal deur gebruik te 
maak van Visueel Analogiese Skale en onderhoude. PAS plasma konsentrasies is 
bepaal deur 'n ontwikkelde HPLC-MS/MS metode. N-asetieltransferase (NAT1 en 
NAT2) genotipering is uitgevoer. Die data van hierdie studie saam met 
ongepubliseerde data van 'n vorige studie is gebruik in farmakometriese analise om 
die farmakokinetiese parameters en enige kovariate te bepaal. 
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Resultate en Bespreking  
In vergelyking met die 4 g GSV-PAS twee keer daaglikse dosis, het die enkele 8 g 
daaglikse dosis, ‘n pharmakokinetiese profiel met ‘n beduidende hoër maksimum 
konsentrasie (Cmax), 12-uur konsentrasie (C12) en area onder die kurwe van 0 tot 12 
uur (AUC12), gegenereer. 
Die PAS plasma konsentrasies van alle proefpersone, wat op die twee keer 
daaglikse dosis was, was tydens die 12-uur interval bo die die minimum inhiberende 
konsentrasie (MIK) gehou. Terwyl die enkele 8 g dosis die PAS plasma 
konsentrasies vir die duur van die 24 uur interval bo die MIK in 18 van 29 (62%) 
proefpersone gehandhaaf het. Die meeste proefpersone het die twee-daaglikse 
dosering verkies, maar beide doserings was redelik goed verdra. Die verwydering 
van PAS het met 45% toegeneem in HIV positiewe proefpersone wat antiretrovirale 
behandeling ontvang het, moontlik weens interaksies met efavirenz. Geen 
beduidende assosiasies vir enige van die individuele NAT1 of NAT2 genotiepes was 
gevind nie, maar ‘n verskil tussen die gemiddelde konsentrasies van die verskillende 
genotiepes is gerapporteer. 
Gevolgtrekking 
Die 8 g een keer daaglikse dosis het die potensiaal om in toekomstige doserings 
ingesluit te word. Die hoër piek konsentrasies van die 8 g daaglikse dosis, kan 
moontlik die bakterisidiese (kiem-dodende) effek van GSV-PAS verhoog, sonder om 
die beduidende bakteriostatiese (kiem-inhiberende) effek (o.a. tyd oor MIK), te 
verloor. Die 8 g een keer daaglikse dosis is redelik verdraagsaam en kan potensieël 
makliker gekontrolleer word in die geval van buite-pasiënte. Serdert antiretrovirale 
middels (ARVs) PAS verwydering verhoog en gevolglik die PAS plasma 
konsentrasies verlaag in die MIV ko-infekteerde proefpersone wat op ARVs is, sal die 
8 g een keer daaglikse dosis minder geskik wees vir die handhawing van 
bakteriostasis in hierdie pasiënte (onvoldoende PAS blootstelling). Dus moet daar 
klarigheid verkry word oor PAS en ARV interaksies voordat die 8 g een keer 
daaglikse dosis vir MIV ko-infekteerde pasiënte op ARVs aanbeveel kan word. 
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Chapter One:  
Introduction and Rationale 
 
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium 
tuberculosis and is a leading cause of morbidity and mortality worldwide 1, 2. This 
global epidemic accounts for approximately 8.8 million (range: 8.5-9.2 million) cases 
and 1.45 million deaths in which 0.35 million deaths were among HIV positive 
patients3. Although effective anti-tuberculosis (anti-TB) treatment is available, 
resistant strains of M. tuberculosis have emerged 4. The World Health Organisation 
(WHO) 5 has estimated that 17% of 9.2 million new cases of active TB had some 
form of drug-resistant tuberculosis (DR-TB), in which 3.1% were multi-drug resistant 
(MDR). Approximately, 4.9% of MDR cases are characterised by extensively drug-
resistant tuberculosis (XDR-TB), which is associated with incredibly high mortality 
rates, especially when co-infected with HIV 1,4,6.  
Treatment of drug-resistant tuberculosis is difficult and involves complex multiple 
drug regimens, which often includes second-line drug such para-aminosalicylic acid 
1,4. Para-aminosalicylic acid (PAS) is one of the first anti-bacterial chemotherapy 
agents used to treat TB and has become one of the principal second-line drugs to 
treat patients with an extended resistance spectrum 7,8,9. Despite being one of the 
oldest anti-TB drugs, little data is available regarding the pharmacokinetics, drug 
interactions and dosing regimens, especially for the relatively new slow/delayed 
release preparation. 
The dosing regimens for PAS are relatively diverse, with multiple daily dosing being 
the preferable regimen, although it has never been demonstrated that twice or three 
times daily dosing provides better results than once-daily dosing. According to the 
WHO and the guidelines for the programmatic management of drug-resistant 
tuberculosis 10, PAS administration must rely on a balance between its tolerance in 
the subject and the resources available to observe doses. In resource-poor settings, 
however, complex dosing procedures are not practical as there is notably poor 
patient compliance and the need for directly observed treatment (DOT). An ideal 
treatment regimen in this setting is clearly one in which medications are taken only 
once-daily.  
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In addition, patient management is complicated by the treatment of both TB and 
AIDS, increasing the potential for drug-drug interactions 11. Only a few interactions 
between PAS and other medications such as isoniazid (INH) have been reported 
12,13. The current knowledge of metabolic pathways and screening methods for 
interactions were not available when older drugs were developed 14. Therefore, the 
mechanisms for interactions between PAS and other TB treatments, especially the 
newer medications and with antiretroviral drugs have not yet been investigated or 
reported. 
 
Besides the drug interactions, several other co-factors/covariates (i.e. genetics, 
weight, age, and disease) can also alter an individual’s drug response. Inter-and 
intraindividual variability in drug response is a major problem in clinical practice and 
drug development. Genetic factors are often described as one of these co-factors. 
Several studies 15, 16,17,18 have investigated the genetic variants and enzyme activity 
of N-acetyltransferase, the enzyme involved in the acetylation of PAS. However, only 
a few studies 19,20,21 investigated the influence of genetic variations on PAS plasma 
concentrations.  
 
 
The present study provided a comprehensive overview of the pharmacokinetics and 
tolerability of a single 8 g once-daily or 4 g twice-daily granular slow release PAS 
dose in an M/XDR-TB population, in which some subjects were also co-infected with 
HIV/AIDS. Furthermore, the factors (i.e. covariates such as genetics, drug 
interactions age, weight, disease) that may influence the pharmacokinetics of PAS 
were investigated. 
 
Since pharmacokinetics is an important element in the study; the literature review 
provided a general overview of the pharmacological concepts of antimicrobial agents; 
the co-factors (i.e. patient variability) that alter the pharmacology of a drug; and the 
clinical aspects of PAS. The first part of the literature review focused on DR-TB and 
treatment. The next section reviewed the general aspects of 
pharmacokinetics/pharmacodynamics, dosing, and the influencing co-factors of 
antimicrobial agents. Finally all the clinical aspects of PAS were summarized. 
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Chapter Two:  
Literature Review 
 
2.1. Burden of drug resistant tuberculosis 
TB has afflicted mankind for thousands of years and was believed to be virtually 
incurable until about 70 years ago, when the first monotherapy a  anti-TB drugs, 
streptomycin and PAS, showed promising results. The introduction of these drugs 
into therapy was followed by the development of a rapid succession of anti-TB drugs 
including rifampicin, INH, pyrazinamide and ethambutol. The availability of a large 
number of drugs has become increasingly important following the appearance of 
drug resistant strains after a few months of treatment 22. In order to greatly reduce the 
emergence of resistant strains, a combination of two or more drugs was introduced 
into the recommended treatment regimens 23. 
Poor patient compliance to these multidrug regimens has led to the emergence of a 
global epidemic of multi-drug resistant TB (MDR-TB). MDR-TB is caused by M. 
tuberculosis strains that are resistant to the first-line TB drugs - rifampicin and INH 
1,24. More recently, the emergence of XDR-TB has been seen worldwide. Here the M. 
tuberculosis strains are additionally resistant to second-line drugs such as the 
fluoroquinolones and the aminoglycosides - amikacin, capreomycin or kanamycin 10. 
Despite the fact that the global TB incidence has slightly decreased, morbidity and 
mortality resulting from TB in Africa remains unacceptably high 3,25, 26. During 2006, a 
total of 464 patients were diagnosed (by NHLS) with XDR-TB in South Africa and 
increased to 741 patients in 2010 10. TB/HIV co-infection is one of the largest 
contributing factors for the high prevalence of TB in this part of the world 25. Since the 
first described outbreak of XDR-TB in patients co-infected with HIV (XDR-TB/HIV) in 
KwaZulu-Natal Province, South Africa, these most resistant isolates have been 
diagnosed in 49 countries 6,25,27. This outbreak has increased the concerns in South 
Africa with its high prevalence of HIV, as it is likely to lead to an epidemic 25. In 2006, 
a report was published from a rural sub-district in KwaZulu-Natal (KZN), showing that 
                                                 
a
 Monotherapy: treatment of a condition by means of a single drug  
  (Dorland’s Medical Dictionary of Health Consumers. Elseriver Inc. 2007) 
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221 (41%) of 542 TB patients had MDR-TB and 53 (9.7%) of these were XDR-TB 
patients 28. All XDR-TB patients were sero-positive for HIV and had a median survival 
of 16 days after specimen collection 28. Delayed results of drug-susceptibility testing 
(DST), which took several weeks meant that appropriate drug therapy could not be 
administered early enough.  
XDR-TB is difficult to treat in both HIV positive and negative patients, and has a 
significantly worse treatment outcome than MDR-TB 29. Various factors contribute to 
this outcome, but drug interactions and resistance to the most potent anti-TB drugs 
are often the main issues. 
 
2.1.1. Treatment of Drug resistant Tuberculosis 
Drug resistant TB is treated with second-line drugs, which are much more expensive, 
less effective and have more side effects than first-line drugs 1,14. As with drug 
susceptible TB, the use of a combination of several antibiotics is imperative to 
prevent additional resistance 10. If the patient with MDR-TB has a history of using 
second-line drugs, an individualised regimen based on the DST results is essential 
for designing such a regimen. In addition, patients with resistance to a 
fluoroquinolone and an injectable drug will also require drugs such as capreomycin, 
PAS granules, terizidone, moxifloxacin or levofloxacin, high dose INH and 
clofazimine among other drugs in their regimens. In the case of XDR-TB, 
individualized treatment regimens are equally essential in order to design a suitable 
regimen 10,30. Table 1 summarises the different groups of anti-TB drugs used in drug-
resistant TB. According to the Management of Drug-Resistant Tuberculosis: South 
Africa Policy Guidelines, 2011 10, the recommended standardised regimen for MDR 
and XDR-TB in South Africa is as follows, but this may be modified based on DST 
results:  
 MDR-TB; 6 months: kanamycin/amikacin-moxifloxacin-ethionamide-terizidone-
pyrazinamide/ 18 months: moxifloxacin-ethionamide-terizidone-pyrazinamide 
 XDR-TB; 6 months: capreomycin-moxifloxacin-ethionamide-terizidone–
pyrazinamide-PAS-clofazimine/ 18 months: moxifloxacin-ethionamide-
terizidone or cycloserine-pyrazinamide–PAS/clofazimine  
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Table 1 Grouping of DR-TB drugs 
Group Drugs 
Group 1: First-line oral drugs Ethambutol (E) Pyrazinamide (Z) 
Group 2: Injectable drugs Kanamycin (Km) Amikacin (Am) Capreomycin (Cm) 
Viomycin (Vm) 
Group 3:Fluoroquinolones Levofloxacin (Lvx) Moxifloxacin (Mfx) Gatifloxacin (Gfx) 
Ofloxacin (Ofx) 
Group 4: Oral bacteriostatic 
second-line drugs 
Ethionamide (Eto) Prothionamide (Pto) Cycloserine 
(Cs) Terizidone (Trd) Para-aminosalicylic acid (PAS) 
Group 5: Drugs of unclear efficacy 
(Not recommended for routine use 
in MDR-TB subjects) 
Clofazimine (Cfz) Amoxicillin/clavulanate (Amx/Clv) 
Clarithromycin (Clr) Azithromycin (Azr) Linezolid (Lzd) 
Thioacetazone (Th) High-dose isoniazid (INH) 
Imipenem  
(Adapted from: WHO 
30
) 
 
 
The desired properties of an anti-TB agent are to rapidly eliminate metabolising 
bacilli, sterilize TB lesions and prevent resistance to companion drugs 2,31. The 
actions of anti-microbial drugs are dependent on the dynamic combination of the 
host, microbe and drug factors 31. This relationship is often studied in 
pharmacokinetics and pharmacodynamics.  
 
Pharmacokinetics involves the dose-concentration relationship, while 
pharmacodynamics governs the concentration-effect relationship or the clinical effect 
of a drug 32. 
 
2.1.2. Pharmacokinetics (PK) 
Pharmacokinetics (PK) is a quantitative study of the time a drug is absorbed, 
distributed, metabolised and excreted (ADME) 2,33,34. Each process of ADME is 
associated with one or two parameter(s) that are dependent on a drug, its 
metabolites and the subject 35. 
 
A pharmacokinetic profile of a drug can be developed when plasma concentrations 
are plotted over time. With this drug profile several pharmacokinetic parameters can 
be calculated using mathematical models 33. These parameters include maximum 
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and minimum concentrations (Cmax and Cmin), time to reach the maximum 
concentration (tmax), area under the curve (AUC), bioavailability (F), clearance (CL), 
half-life, or volume of distribution (Vd); and can be used to calculate optimum drug 
dosages for an individual or a group of individuals.  
 
2.1.3. Pharmacodynamics (PD) 
Pharmacodynamics is the study of how a drug acts on a living organism, including 
the pharmacologic response and the duration and magnitude of response observed 
relative to the concentration of the drug at an active site in the organism. The 
pharmacodynamics of an anti-tubercular agent describes the relationship of the drug 
concentration to the pharmacologic effects of a drug that enables eradication of the 
pathogen 32,36. Based on anti-microbial pharmacodynamic properties an antimicrobial 
can be classified as bactericidal or bacteriostatic. Bactericidal agents such as INH 
will rapidly decrease the colony forming units in the sputum of TB patients after 
starting the treatment 31.  
 
In contrast to the bactericidal group, the bacteriostatic agents such as PAS, 
ethionamide and terizidone inhibit the growth of bacilli 32,37,38. This group requires the 
assistance of the host defence mechanisms to clear the tissue of bacilli. If the host 
defences mechanisms are inadequate to remove the microbe, it will resume growth 
after discontinuing of the bacteriostatic agent 39. Therefore, a combination of 
bacteriostatic and bactericidal agents is prescribed in TB regimens.  
 
The antimicrobial activity of an antimicrobial agent can be determined in vivo or in 
vitro. The early bactericidal activity (EBA) of a drug is the decreasing rate of colony 
forming units (CFU/ml) in a patient’s sputum during the first two days of drug 
administration and is expressed as log10 (CFU/ml)/day. A drug’s sterilizing activity is 
the rapid sterilization of the sputum and prevention of relapse 2. In contrast to EBA 
and sterilizing activity, the minimum inhibitory concentration (MIC) or minimum 
bactericidal concentration (MBC) can quantify the drug potency in vitro 2,39,40. The 
MIC is the lowest drug concentration that inhibits microbial growth after incubation of 
16-20 hours with a standard inoculum (1-5x105 CFU/ml). The MBC is the drug 
concentration that kills 99.99% of the initial inoculum 2.  
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The concentration of the bacteriostatic agents must exceed the MIC to actively inhibit 
the pathogen. Isolates of microbe species can have variable MICs. Resistant isolates 
have relative high MICs, while sensitive isolates have low MICs 39,41. The MBC of a 
bacteriostatic agent is many-fold higher than its MIC, while a bactericidal agent’s 
MBC is usually the same or less than four-fold of its MIC 39. 
 
Bactericidal agents can be subdivided as either time-dependent bactericidal activity 
(concentration independent) or concentration-dependent bactericidal activity. For 
drugs with time-dependent bactericidal activity such as beta-lactam agents, the 
concentration must exceed the MIC for the pathogen. Killing of the bacteria depends 
on the time that the bacteria are exposed to the drug. The rate of eradication does 
not increase even if concentration increases beyond four to five times that of the MIC 
38,39,41,42. The clinical success is based on the percentage of time that the drug 
concentration at the site of action is above the MIC (T>MIC) 32. Therefore, the 
duration of exposure needs to be optimised based on the correlation between the 
time above the MIC, and the bacteriologic and clinical outcome 37.  
 
For antibiotics with concentration-dependent bactericidal activity, such as rifampicin, 
INH, aminoglycosides and fluoroquinolones, a sufficient maximum concentration at 
the site of infection is required. The eradication rate increases over a wide range of 
concentrations 32,39. The Cmax to MIC and/or the AUC to MIC ratios correlate best with 
the eradication rate 32, 38,40. In contrast to a time-dependent agent, this group of drugs 
has a more significant post-antibiotic effect. This is the phenomenon whereby there is 
a maintained suppression of the bacterial growth after exposure to the drug, even 
when the concentrations are below the MIC 32,37,38. 
 
2.1.4. PK/PD and dosing of anti-TB agents 
The purpose of therapeutics is to achieve a desired beneficial effect with minimal 
adverse effects. A rational approach in determining the appropriate drug and dose for 
a certain disease such as TB is to combine the principles of pharmacodynamics and 
pharmacokinetics, and to clarify the dose-effect relationship43. Both pharmacokinetics 
and pharmacodynamics are involved in the determination of dosing regimens of 
antimicrobial agents 37. Figure 1 illustrates the relationship between pharmacokinetics 
and pharmacodynamics for antimicrobials. The pharmacokinetics of a drug 
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determines the drug concentration in serum and tissues over time whilst the 
pharmacodynamic parameters integrate the antimicrobial activity 32.  
 
In antimicrobial therapy, complex interactions between the pathogen, the individual 
and the drug are inevitable. In clinical situations, the complexity is usually reflected 
by high variability in the dose-response relationship 42. To reduce the variability in 
drug and dose response, the pathogen, the host and the pharmacological properties 
of the drug need to be taken into account when determining the ideal drug and dose 
to be used in a clinical situation 40,42. 
 
The PD/PK parameters that correlate with clinical outcome are different for time-
dependent and concentration-dependent antimicrobials, and therefore dosing 
strategies are also different 32. For the time-dependent and bacteriostatic drugs, the 
dosing strategies should maximise the time the drug concentration is above the MIC 
at the site of action. For the concentration–dependent drugs, the highest possible 
peak concentration is preferable to maximise the effect of the drug 38. However, high 
concentrations can be toxic to the host. For example, high doses of fluoroquinolones 
can result in CNS toxicity 32,44. Each drug has a specific therapeutic range, where the 
drug concentration is considered safe and effective in the general population. Figure 
2 illustrates the relationship between the efficacy and toxicity of a drug. The 
adjustable elements of dose, dose frequency, dosage form and route of 
Figure 1 Inter-relationship of pharmacokinetics and pharmacodynamics of antimicrobial 
agents 
32 
 
 
Stellenbosch University http://scholar.sun.ac.za
   L i t e r a t u r e  R e v i e w | 9 
 
 
administration are directly related to toxicity or therapy failure 45. For example if the 
dosage exceeds the drug removal rate, the drug will accumulate and can reach toxic 
levels 45. Accumulation of the drug is often seen after several doses of the drug. If the 
dose is too low, the levels will fall below the therapeutic range and the drug will fail to 
work.  
 
Intraindividual/interoccasion b  and interindividual c  variability of pharmacokinetics is 
often a result of variability in the ADME of the drugs, for example as a result of the 
patient’s general state of health, organ dysfunction, or genetic factors 35.  
 
2.2. Factors influencing the PK/PD profile of a drug 
The ideal dose of a drug is the one that is clinically effective and results in no 
adverse effects. Unfortunately, medication is seldom both safe and effective in all 
subjects 46. Interindividual variability in drug response is a major problem in the 
clinical practice and drug development. It often leads to therapeutic failure of drugs or 
adverse events in individuals from various sub-populations 47. Mehta et al. 48 found 
                                                 
b 
Intraindividual/interoccasion: variation within an individual 
c 
Interindividual: variation within a population 
Figure 2 Therapeutic range of a drug [medicinescomplete.com] 
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that adverse drug reactions contribute significantly to morbidity and patient 
hospitalization in South Africa. The adverse drug reactions rate of 14% occurring in 
their study population was double that reported in a systematic review of international 
studies. 
 
Several factors can be involved in the large variation observed in interindividual drug 
response and includes the patient’s age, body weight, gender, genetic factors, renal 
and liver function, disease, drug-drug interactions, and lifestyle such as smoking and 
alcohol.  
 
2.2.1. Age 
The aging process can significantly affect the drug pharmacokinetics due to 
impairment in the function of many regulatory processes49. The reduced 
gastrointestinal blood flow and higher gastric pH in elderly affects the extent of 
absorption of the drug. The physical changes in aging such as muscle atrophy and 
increased body fat can also affect the volume of distribution. Drug elimination is 
affected by decreased kidney function (decrease in renal plasma flow and glomerular 
filtration resulting in decrease of drug excretion) and reduced enzymatic capacity 
(reduced metabolism) in the elderly 49,50,51.  
Furthermore, elderly patients often use more drugs, therefore increasing the potential 
of drug-drug interactions 52. 
 
2.2.2. Body weight 
Patients with different body weights given similar doses will produce different drug 
plasma concentrations. A large body weight is associated with a larger volume of 
distribution and clearance, especially for highly lipophilic drugs which may result in 
lower drug plasma concentrations 53. In the case of an obese patient the drug 
distribution will be affected due to more fat. Therefore, adjustment of the dose may 
be necessary in such cases. Decreased body weight and wasting are more relevant 
in TB-patients, e.g. with wasting, the albumin and leptin concentrations will be 
reduced, affecting the protein binding of drugs 54. Dose adjustment of drugs should 
therefore be considered in patients with large increase or decrease in body weight. 
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2.2.3. Diseases 
Diseases cause physiological and pathological changes, which can change the drug 
pharmacokinetics. Absorption, distribution and elimination can be altered by diseases 
affecting the organ responsible for these functions. For example, patients with 
congestive heart failure have reduced cardiac output and liver blood flow, which will 
decrease the hepatic drug elimination 35. Another example is the high drug 
concentrations observed in patients suffering from renal disease. The clearance of 
the drug or metabolites through the kidneys decreases in patients with renal 
dysfunction, and the compounds will accumulate in the body.  
 
Infection such as empyema or abscess can also affect drug activity by decreasing 
the pH or reduce the oxygen content at the site of action consequently reducing the 
activity of certain drugs such as aminoglycosides 40. 
 
2.2.4. Genetic factors (Pharmacogenetics) 
Pharmacogenetic/genomics is a growing field in industry and has become an 
important element in drug and dose design. This field explores the interactions of 
drugs with genetically determined effectors and metabolic pathways, and has an 
influence on drug safety, drug efficacy and disease progression 55.  
Forty years ago researchers realized that some adverse drug reactions and 
inefficacy could be a result of genetically determined variations in enzyme activity 56, 
57. Many of these variations were identified by the occurrence of adverse reactions 
after standard doses of the drugs in healthy volunteers or patients 58. Treatment 
failure in individuals and their family members confirmed that genetic variations in 
drug metabolising enzymes were the cause of these outcomes 56, 57. 
There are several types of genetic variations that have a direct or indirect effect on 
drug response and development of various diseases. Variations in the genes 
encoding any of the proteins involved in the ADME of a drug can alter the drug 
response and pathological outcome.  
 
Drug transporters expressed in the brain, intestine, liver and kidney play an essential 
role in the ADME of several drugs. Genetic heterogeneity on drug transporters can 
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contribute to interindividual variation in drug disposition and drug response 55. The 
transporter, P-glycoprotein (P-pg) functions as a transmembrane efflux pump and will 
move drug molecules from intracellular to extracellular domain 55. Therefore, 
variations in the gene encoding this protein will have an indirect effect on drug 
availability, since the protein controls the efflux of drugs in the cellular domain. 
Genetic polymorphisms have been described for several phase I (cytochrome P450 
isoforms) and phase II (N-acetyltransferase, uridine diphosphate-
glucuronosyltransferase) drug-metabolising enzymes, and can influence the plasma 
concentrations of the drugs that are a substrate for these enzymes. For example, 
genetic variants in N-acetyltransferase 2 (NAT2) gene alters the patient’s ability to 
acetylate INH and will result in toxic levels of the drug, which can lead to peripheral 
neuropathy or hepatotoxicity 59,60. Another well-known clinical example is the 
CYP2B6 polymorphism which is well defined as an important predictor of the 
efavirenz (EFV) pharmacokinetic parameters 61. 
It was noted that pharmacogenetic variations occur at different frequencies in the 
population, especially in a population with different ethnic groups. For example, the 
NAT2 divides the population into homozygous fast, heterozygous fast and 
homozygous slow NAT2 acetylators of INH 17,59. Another example is the variation in 
CYP2B6 (CYP2B6*6) that is more common in African-Americans compared to 
Caucasians 55. The CYP2B6*6 variant is associated with an increased liver toxicity; 
hence more African-Americans than Caucasians will develop liver toxicity 62. 
Therefore, ethnic origin and population differences have to be considered in 
pharmacotherapy 59. 
Variable drug response and efficacy reflects the combined influence of environment, 
gender, disease, concomitant drugs, nutrition and genetic factors 55,59. The 
individual’s enzymes together with the other co-factors and drug pharmacology will 
therefore determine the individual’s drug response 46. 
Environmental compounds and different drugs can alter gene expression by 
interacting with nuclear receptors such as CAR, PXR, PPAR and AhR 59. The CYP 
group of enzymes is often induced or inhibited by various compounds and drugs, 
even if these chemicals are not a substrate for the specific isoform. The following 
section describes the influence of drug interactions on drug response and PK. 
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2.2.5. Drug interactions 
Polypharmacy is essential in the treatment of tuberculosis, especially in DR-TB. 
Several drugs are used in order to prevent resistance to certain susceptible drugs. 
However with the use of multiple drugs, the risk for potential drug-drug interactions 
increases. In addition to DR-TB, it is common to treat several other concurrent health 
conditions such as HIV/AIDS or non-communicable diseases such as diabetes or 
hypertension increasing the potential for drug interactions. Drug interactions are 
defined as a modification of the effect of a drug when co-administered with another 
drug. This effect may enhance or reduce the action of either drug which can result in 
possible over- or under-dosing and lead to a lack of drug efficacy or toxicity 63. Drug 
interactions can be divided in three groups: pharmacodynamic, pharmacokinetic or 
combined interactions 64,65,66.  
 
2.2.5.1. Pharmacodynamic interactions 
Pharmacodynamic interactions amongst others occur when the effect of a drug is 
changed by another drug at the site of actions, without changing the plasma 
concentrations of either drug. It arises from an antagonistic (drug effect is 
decreased), additive or synergistic effect (drug effect is increased), and may alter the 
pharmacological response, such as toxicity and efficacy.  
Antagonism of antimicrobial agents occurs when the combined killing effect or 
inhibitory effects of two or more antimicrobial drugs are significantly less than the 
activity of individual drugs. For example, rifampin can antagonise vancomycin action 
against staphylococci 67. 
 
Additive/synergistic effect occurs when the activity or toxicity of a drug is enhanced 
due to the presence of another drug with a similar pharmacological action. An 
example is the great delay in development of resistance to streptomycin when co-
administered with PAS 68 . 
 
2.2.5.2. Pharmacokinetic interactions 
Pharmacokinetic interactions are the most common interactions 66. Interactions of this 
kind may either alter the drug plasma concentration and/or its tissue distribution, 
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consequently affecting the concentration or availability of the drug to the target site. 
 
These particular interactions occur when absorption, distribution, metabolism and/or 
excretion of a drug is altered 63,64,69. 
 
2.2.5.2.1. Drug interactions associated with absorption  
Absorption is the movement of compounds into the circulatory system from site of 
administration (e.g. gastrointestinal, skin, subcutaneous site, nasal/pulmonary sites, 
and muscles). The absorption of drugs can be altered by several physiological 
factors such as intestinal motility, gastric emptying time, gastric pH, transport, 
intestinal metabolism, and the presence of gastrointestinal disease 69. In addition, 
concomitant substances such as drugs, can also affect the drug absorption by having 
a large surface area upon which the drug can be absorbed; alternating the gastric 
pH; binding or chelating; altering gastrointestinal motility or affecting the transport 
proteins 61,63,65. 
The most common interaction affecting drug absorption is chelating, which is the 
binding of metal ions or other substances to the drugs in the gastrointestinal tract 61. 
For example, PAS absorption is decrease due to the binding of divalent cations (iron, 
magnesium and calcium) to PAS molecules 70. 
 
2.2.5.2.2. Drug interactions associated with distribution 
The important mechanisms by which drug interactions can alter drug distribution are 
the competition for protein binding; displacement from tissue binding sites and 
alterations of the local tissue barriers 65. The competition of the drugs for protein 
binding affects the degree of the free drug (pharmacologically active form). 
Theoretically the plasma concentration of the free drug will increase, but in this case 
the concentration is maintained due to an increase in free drug elimination 63. 
Therefore, protein binding displacements are usually considered to be of less clinical 
significance 69,71.  
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2.2.5.2.3. Drug interactions associated with drug metabolism 
Co-administered drugs may directly or indirectly alter the concentration and activity of 
another drug by inhibiting or inducing the enzyme activity responsible for the 
metabolism of the drug.  
 
Several clinically important drug interactions have been reported. Some drug 
interactions can be beneficial, by increasing the activity or bio variability of an 
effective drug. However, this can also result in high drug levels, which can be toxic 
and life-threatening 45,61. For example, co-administration of PAS and INH can be 
beneficial, but can also result in severe neurotoxicity and/or hepatotoxicity. PAS 
inhibits the acetylation of INH, consequently increasing the INH levels 72. 
 
Both phase I and II enzyme activities can be altered by their substrate or other 
compounds. Even the transporters such as P-pg are susceptible to drug induction or 
inhibition 61. 
 
The CYP enzyme group consisted out of 12 isoforms and are the major enzyme 
group involved in the drug metabolism 73. Several anti-TB and ARV drugs are 
metabolised by the CYP group and therefore are susceptible to drug interactions. 
Some of these drugs are also inducers and inhibitors of the CYP group, which 
complicates the design of regimens for DR-TB subjects that are also co-infected by 
HIV/AIDS 61. Alterations in the plasma levels of an antimicrobial or antiretroviral agent 
can cause sub-therapeutic drug concentrations, which can result in developing of 
pathogen drug resistance. In risk patients the plasma levels should be monitored to 
ensure that toxicity is reduced and the MIC is exceeded 45. The Clinical 
Pharmacology Division of Indiana University summarised the clinically relevant drug 
interactions of the CYPs. This can be found at:  
 
http://medicine.iupui.edu/clinpharm/DDIs/ClinicalTable.aspx. 
 
2.2.5.3. Combined toxicity 
The use of combinations of drugs for a prolonged period, as in TB treatment, often 
results in drug toxicity 38. Several drugs have similar toxicities which can lead to 
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increased toxicity when co-administered (shared toxicity). In combining these drugs 
in a regimen, the potential of organ damage is increased. For example, ethionamide 
and PAS have toxic effects on the thyroid. These drugs are often prescribed in a 
regimen and long term use can lead to hypothyroidism. In some cases, a drug(s) can 
enhance the organ toxicity of another drug, even if the enhancing drug has no 
intrinsic toxicity effect on the organ 65.  
 
DR-TB patients often develop hepatotoxicity and renal dysfunction since multiple 
drugs including more toxic second-line drugs, are prescribed to these patients. These 
drugs are often metabolised in the liver and excreted by the kidneys. Therefore, 
monitoring of liver and kidney functions are important in these patients 10. 
 
2.3. Para-aminosalicylic acid (PAS)  
Para-aminosalicylic acid (PAS, p-aminosalicylic acid, 4-aminosalicylic acid, 4-ASA), 
is a second-line anti-TB agent that has been found to be effective in preventing drug-
resistance and has formed part of the standard treatment for TB for several 
decades6. However, due to its significant gastrointestinal intolerance, it was replaced 
by ethambutol, an equivalent drug in terms of efficacy, but with a better tolerability 
profile11. Due to the relatively low use of PAS over the last three decades, most 
isolates of TB remained susceptible to this drug 11;14. Therefore, PAS was brought 
back in clinical use for the management of MDR-TB and later XDR-TB.  
A new granular slow-release PAS formulation (GSR-PAS) with fewer gastrointestinal 
adverse effects was developed which supported the use of PAS as one of the 
principal second-line drugs in M/XDR-TB treatments8. Currently, the GSR-PAS 
(PASER® granules, Para-aminosalicylic Acid Delayed-Release Granules-JACOBUS 
Pharmaceutical Company Inc., Princeton, NJ 08540) is the only form available in 
most countries including South Africa. 
 
2.3.1. Indications 
GSR-PAS (PASER) is classified as a tuberculostatic agent. It is mainly used to treat 
drug resistant tuberculosis (M/XDR-TB) or in cases where therapy with INH and 
rifampicin is not possible due to intolerance and/or a combination of resistance. PAS 
Stellenbosch University http://scholar.sun.ac.za
   L i t e r a t u r e  R e v i e w | 17 
 
 
is prescribed together with other anti-TB agents to which the specific pathogen strain 
of the individual patient is expected to be susceptible 12. 
 
2.3.2. Mechanism of action  
PAS is a highly specific bacteriostatic agent against M. tuberculosis and valuable in 
preventing resistance to other drugs such as INH and streptomycin 9,12. It has a 
molecular weight (Mw) of 153.14 (Figure 3) and inhibits the growth of M. tuberculosis 
in vitro at a concentration of 1-2 µg/ml 2.  
 
The mechanism of PAS is still unclear, but it has an influence on the folate pathway 
of bacteria. Bacteria use folate derivatives as co-factors in the biosynthesis of 
important molecules such as amino acids, thymidylate, pyrimidines and purines2. 
Bacteria are unable to use external sources of folic acid; therefore a deficiency in 
these important molecules inhibits bacterial growth. 
 
PAS is structurally similar to sulphonamides (Figure 4), which is an analogue of para-
amino benzoic acid (PABA) (Figure 5). PABA is a substrate for dihydropteroate 
synthase (DHPS), which is an important enzyme in folate biosynthesis of bacteria 8;74. 
PAS has therefore been considered to interfere with bacterial DHPS by functioning 
as a competitive inhibitor (competing with PABA). However, PAS inhibitory activity of 
folP1 (encodes DHPS) appears to be poor in vitro 75 (Figure 6).  
 
 
 
Figure 3 Structural formula 
of PAS 
 
 
Figure 4 Structural formula 
of sulphonamides 
 
 
Figure 5 Structural 
formula of PABA 
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A mutation in the thy A gene of clinical PAS-resistant isolates (PASr) was identified 
and found to be related to a mechanism for drug resistance to PAS 8 (Figure 6). The 
thy A gene encodes thymidylate synthase A, which is required for thymine 
biosynthesis in the bacterial folate pathway. This finding implies that PAS acts as a 
folate antagonist which inhibits folic acid synthesis, but without potentiating anti-folic 
compounds 8. 
 
A recent study 76 investigated the mechanism of action of PAS and reported that 
PAS, in contrast to the initial speculation, serves as a replacement substrate for 
DHPS and not as a competitive inhibitor. The PAS metabolites and the subsequent 
steps in folate metabolism inhibit the enzymes and compete with their substrates. 
According to the authors, PAS is a pro-drug that blocks the growth of M. tuberculosis 
when its active forms are generated by enzymes in the pathway, which functions as a 
poison to the bacteria.  
PAS is also thought to inhibit the synthesis of the cell wall component, mycobactin, 
which decreases iron uptake of the bacteria 2,13.  
 
Figure 6 Postulated mechanism of the action of PAS [Modified from Rengarajan
8
 
and Mathys
74
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2.3.3. Pharmacokinetics of PAS 
With GSR-PAS preparation, the PAS is encapsulated in an acid resistant enteric 
coating to prevent early breakdown in the stomach. Once the GSR-PAS formulation 
reaches the more alkaline smaller intestine, it dissolves and is readily absorbed. It is 
therefore recommended to be taken with an acidic beverage or food, enhancing the 
delayed-release properties of the GSR-PAS 12. The rate of drug absorption depends 
on the rate of release from the formulation 35. With the controlled-release formula, the 
drug is released at a constant rate over a longer period and fluctuations in the drug 
plasma concentrations are reduced in comparison to the immediate-release 
formulations such as the sodium-PAS.  
PAS is well absorbed from the gastrointestinal tract. A plasma concentration of 2 
μg/ml is reached within 2 hours after a 4 g GSR-PAS dose. In a study in healthy 
volunteers a mean maximum concentration (Cmax) of 20 μg/ml (range: 9-35 μg/ml) 
with a mean peak time of 6 hours (range: 1.5-24 hours) was achieved after a single 4 
g GSR-PAS dose 12,77,.  
In a study in twelve MDR-TB patients a mean Cmax of 51.3 μg/ml (range: 25.8-93.1 
μg/ml) and a mean peak time of 5.2 hours (range: 0-8 hours) was achieved after a 4 
g GSR-PAS dose 78. 
PAS is 50-60% protein bound and is well distributed throughout the body. It is only 
detected in the cerebrospinal fluid (CSF) if the meninges are inflamed (10-50% of the 
plasma levels) 2,12,77. PAS has a plasma half-life (t½) of 1-2 hours. It is rapidly 
metabolised in the intestinal mucosa and liver through acetylation by N-
acetyltransferase 1 (NAT1), in which more than 50-70% of the drug is acetylated to 
N-acetyl-para-aminosalicylic acid (APAS) 2, 11, 77, 79. Twenty five present (25%) of the 
absorbed PAS dose is conjugated to form p-aminosalicyluric acid (PASU) 79. 
Although PAS is the active form, it is reported that PASU has a 75% inhibitory effect 
in comparison to APAS which shows little, if any tuberculostatic affect 80. 
The drug and its metabolites are excreted by tubular secretion and glomerular 
filtration. Approximately 80% of the drug is excreted in the urine, with about 50% is in 
the acetylated form. PAS plasma concentrations are not significantly changed by 
hepatic or renal insufficiency, but with severe renal insufficiency the PAS and its 
metabolite will accumulate 77. 
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2.3.4. PAS dosing regimens 
The current prescription for GSR-PAS is 8-12 g in divided doses10. Since PAS is 
bacteriostatic, several daily doses are recommended in order to maintain the 
concentration of PAS above the MIC of 1 µg/ml 76,81. It was noted that divided doses 
reduce the intolerance to PAS 81. However, it has been reported in several early 
studies that once-daily dosing of PAS was better tolerated than multiple dosing 
80,82,83. 
Early studies experimented with various doses of PAS in combination with other 
drugs such as INH. A study 84 in 1957 found that dosage of 10-12 mg/kg PAS in 
divided doses accompanied by INH provided better results than 5-6 mg/kg PAS 
which was also accompanied by INH, implying that higher concentrations of PAS will 
enhance the drug activity. 
Clinical 82 and animal 85 studies have investigated the possibility of decreasing the 
frequency of PAS administration to a single daily dose. Karlson and Carr 85 
experimented with a 125 mg single daily sodium PAS dose in guinea pigs and 
reported that the once-daily dose was as effective as the twice-daily dose, despite 
the fact that PAS is rapidly absorbed and excreted.  
Bridge and Carr 82 investigated the effect of a single 5 g dose of PAS combined with 
150 mg of INH given twice-daily to 70 subjects. They compared these results to 192 
subjects that followed a regimen of 3 g PAS three times a day. In the 5 g daily group 
negative sputum cultures were reported in nine subjects (12.9%) after two months 
and in five subjects (7.1%) after four months. Thirty one patients (16.1%) of the 3 g 
PAS three times daily group discontinued the PAS treatment due to intolerance, 
while only three subjects (4%) who used the single 5 g dose developed intolerance. 
According to Bridge and Carr 82, the once-daily dosing was not only better tolerated 
as multiple doses, but equally effective.  
Bang et al.86 investigated various PAS preparations in single and divided doses and 
concluded that divided doses of PAS give lower PAS concentrations. Although 
multiple doses still maintain the PAS concentration above the MIC, a single daily 
dose is considered to be a more rational treatment because it increases the free PAS 
levels in the plasma. 
PAS was previously available as potassium, sodium or calcium salts and as an acid 
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preparation. Sodium salt preparations, which are still marketed, are completely and 
rapidly absorbed, and a peak is seen within 90-120 minutes after drug administration 
13,79. Since PAS has a short half-life, more frequent dosing is required, especially 
when using the salt formulations. The salt formulations are not as well tolerated as 
the GSR-PAS preparation.  
Not only is the GSR-PAS preparation better tolerated, but maximum concentrations 
of PAS are seen after 4-6 hours 12,13. Therefore, the drug is longer present in the 
systemic circulation, and less frequent dosing is needed to maintain the PAS 
concentration above the MIC. 
Only one study 81 investigated different dosing strategies with the GSR-PAS 
preparation. The investigators compared a single 4 g once-daily and 4 g twice-daily 
GSR-PAS dose to determine if a once-daily dosing regimen will be sufficient. PAS 
concentrations were maintained above the MIC throughout the twice-daily dosing 
interval, but not with the once-daily regimen. The granules were generally well 
tolerated in this study; however a few subjects reported nausea and gastrointestinal 
discomfort. 
 
2.3.5. Resistance  
M. tuberculosis isolates have developed resistance to various antibiotics and 
antimicrobial chemotherapy agents, including PAS 8. However, resistance to PAS 
has been reported to be less common than to other antibiotics. Since PAS is a 
bacteriostatic agent, it is important to maintain the plasma concentration above the 
MIC in order to inhibit bacteria growth and the development of resistance as 
discussed above.  
The MIC of PAS is different among the various multi-drug resistant strains. The MIC 
for M. tuberculosis in 7H11 agar was less than 1.0 µg/ml for nine strains including 
three multidrug resistant strains tested, but 4 and 8 µg/ml was measured for two 
other multidrug resistant strains. Little dose response was seen with the 90% 
inhibition in 7H12 broth (Bactec), but the MIC was interpreted as being less than or 
equal to 0.12-0.25 µg/ml for eight strains12.Therefore, a MIC of 1 µg/ml can be seen 
as the natural MIC of M. tuberculosis for PAS. 
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2.3.6. Tolerability and safety 
The most common side effects of PAS are hypothyroidism and gastrointestinal 
intolerance which includes nausea, vomiting, abdominal pain, diarrhoea and anorexia 
12,13,77. Prolonged administration of PAS often results in hypothyroidism and is 
increased with the co-administration of ethionamide.  
Hepatitis has been reported in 0.3-0.5% of patients receiving PAS. In a review of 
7,492 patients treated with PAS, 0.5% developed hepatitis12. This condition emerges 
within three months of therapy, is often associated with rash and fever, and less 
frequently with anorexia, nausea or diarrhoea12. In a few days or weeks, 90% of the 
patients show symptoms of jaundice. Hepatitis is usually accompanied by 
hepatomegaly, and often by leucocytosis, lymphadenopathy, and eosinophilia 87  
Other rare side effects include leukopenia, hypoprothrombinemia, agranulocytosis, 
goitre, thrombocytopenia, Coomb’s positive haemolytic anaemia, and lupus-like 
syndrome. The side effects of PAS are summarised in Table 2 12, 87. More information 
regarding the side effects is available in Appendix A: PASER package insert. 
 
 
Table 2 Reported side effects of PAS 
Disorder Side effects 
Blood dyscrasias and lymphatic systems 
disorders 
 
Leucopoenia, agranulocytosis, 
thrombocytopenia, eosinophilia,  
Coombs positive haemolytic anaemia may 
develop in patients with G6PD deficiency 
 
Cardiovascular  Pericarditis 
  
Coagulopathy Hypoprothrombinaemia has been reported. 
  
Dermatological side effects 
 
Skin rash, erythematous 
maculopapular and pruritic lesions  
Exfoliative dermatitis 
 
Dysglycaemia Hypoglycaemia has been reported  
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Table 2 Reported side effects of PAS 
Disorder Side effects 
Endocrine effects Hypothyroidism and goitre relatively common 
  
‘Flu-like’ syndrome Löffler's syndrome, an infectious 
mononucleosis-or lymphoma-like syndrome, 
has been reported 
 
Gastrointestinal disorders 
 
Nausea, vomiting, abdominal pain  
Diarrhoea 
Rarely, associated with peptic ulcers gastric 
haemorrhage 
  
General disorders  Fever; thrombocytopenia 
 
Hepatobiliary disorders Jaundice, hepatitis  
 
Hypersensitivity Lymphadenopathy, leucocytosis,  
conjunctivitis, headache, joint pain, vasculitis,  
  
Metabolism and nutrition disorders  
 
Malabsorption syndrome, including: 
steatorrhea, an abnormal small bowel pattern 
on X-ray, villus atrophy, reduced cholesterol, 
D-xylose and iron absorption.  
Malabsorption of vitamin B12, folate, iron and 
lipids may results in clinically important 
erythrocyte abnormalities 
 
Nervous system disorders Optic neuritis, encephalopathy, psychosis 
 
Renal and urinary disorders  Hypocalcaemia 
  
Respiratory, thoracic and  
mediastinal disorders 
Eosinophilic pneumonia 
 
 
Vascular disorders Vasculitis 
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2.3.7. Pharmacogenetics of PAS 
The N-acetyltransferase 1 (NAT1) is the only gene that has been studied in the 
pharmacogenetics of PAS, since it is predominantly involved in PAS 
metabolism.2,79,88. N-acetyltransferase (NAT) enzymes are involved in the metabolism 
of various drugs such as PAS, INH and dapsone. Belonging to the phase II enzymes, 
they are important in the detoxification of harmful chemicals, and in deactivation and 
elimination of certain drugs. This group of enzymes catalyse the N-acetylation and O-
acetylation of heterocyclic amine, aromatic amine and various aryl amine and 
hydrazine drugs15,89. Both genes of the isoforms (NAT1 and NAT2) are located on the 
short arm of chromosome 8 (NAT18p21.3-23.1 and NAT2 8p21.3-23.1 and 8p22). 
These genes are 87% similar on the nucleotide level, which translates to an 81% 
homology at an amino acid level 90.  
 
Both NAT1 and NAT2 are known to be polymorphic. NAT2 is more extensively 
studied than NAT1, due to its clinical relevance in the metabolism of INH 15. Initially it 
has been believed that NAT1 is monomorphic, with no distinct differences in its 
phenotype or genetics91. However, it was soon discovered that this assumption is 
incorrect. Studies have identified NAT1 allelic variants that are associated with 
increased enzyme activity92. Several oncology studies 89,93 have also reported the 
association of NAT1 polymorphisms with cancer development, especially bladder 
and breast cancers. It seems that NAT1 and NAT2 polymorphisms can interact with 
each other and increase or decrease the risk for cancer development 93. 
 
Several distinct allelic polymorphisms at the NAT1 locus cause a large variability in 
the human population 58. So far, 26 alleles have been described 94. The NAT1*3, 
NAT1*4, NAT1*5, NAT1*10 and NAT1*11 are the most common alleles. The allelic 
variations are single polymorphisms or a combination of a number of nucleotide 
substitutions and insertions/deletions, which will increase (e.g. NAT1*10, NAT1*21, 
NAT1*24 and NAT1*25) or decrease (NAT1*14, NAT1*15, NAT1*17, NAT1*19 and 
NAT1*22) or have no effect (e.g. NAT1*11, NAT1*20 and NAT1*23) on acetylation 
activity with respect to enzyme encoded by the NAT1*4 (wild typed) 20,94,95. The 
NAT1*11 allele has been considered as a rapid allele in Caucasians and Black South 
Africans 96. 
 
                                                 
d
 The normal, non-mutated version of a gene common in nature 
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NAT1*4 has been found in higher frequency among Caucasian populations than in 
Asian and African populations, whilst the opposite may be true for the NAT1*10 15,95. 
The NAT1*3 allele is found in a higher frequency among Chinese than in Caucasian 
or African Americans 97. 
 
2.3.8. Drug interactions of PAS 
Only a few drug interactions with PAS have been described. One of the most 
important interactions is the decrease in INH acetylation. PAS administered as a 12 g 
dose has been reported to reduce the acetylation of INH by 20%, especially in rapid 
acetylators in the population 98. 
 
PAS reduces the absorption of vitamin B12, folate, lipids, rifampicin, digoxin and iron.  
PAS (5 g) can reduce the absorption of vitamin B12 by 55%, which can lead to 
erythrocyte abnormalities 12,87,.  
 
So far no interactions have been described between PAS and any of ARVs14. Table 3 
summarises the known drug-drug interactions between PAS and other medications. 
 
 
Table 3 Drug-drug interactions between PAS and other medications 
Concomitant drugs Effect 
Angiotensin converting  
enzyme inhibitors 
PAS may reduce the antihypertensive effect  
 
  
Azathioprine PAS may increase the toxicity 
  
Carbonic anhydrase inhibitors 
 
Potentiate adverse events of both PAS and the 
inhibitors 
 
Corticosteroids Increase the adverse events of corticosteroids 
  
Digoxin  PAS decreases absorption with 20% 
Diphenhydramine Impaired absorption of PAS 
  
Ethionamide Potentially increased risk of hepatotoxicity 
Folate, lipids, iron. PAS reduces the absorption of folate, lipids, iron 
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Table 3 Drug-drug interactions between PAS and other medications 
Concomitant drugs Effect 
  
INH Inhibited acetylation of INH and may lead or increase 
concentrations 
  
Loop diuretics 
 
PAS may reduce the effect of loop diuretics, and the 
loop diuretics can increase the serum levels of PAS 
  
Mercaptopurine PAS may increase the toxicity 
  
Methotrexate PAS may increase toxicity 
  
Non-selective NSAIDS (except 
diclofenac) 
Increase adverse effects of PAS 
  
Oral anticoagulants, thrombolytics 
or salicylates 
PAS may increase the risk of bleeding 
  
Probenecid Competitive excretion: increased PAS levels  
  
Rifampicin  PAS reduces the absorption of rifampicin 
 
Sulfonylurea PAS may increase the hypoglycaemic effect   
  
Sulindac PAS may decrease the serum concentration  
Vitamin B12 PAS decrease absorption of vitamin B12 
  
Systemic corticosteroids Increase the number and severity of adverse effects, 
especially gastrointestinal 
 
Thioguanine PAS may increase the toxicity 
  
Tolmetin PAS may increase the risk of GI bleeding 
  
Treprostinil PAS may increase the risk of bleeding 
Adapted from http://www.drugbank.ca/drugs/DB00233, Mllleron 
87
, Arbex et al.
13
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Chapter Three:  
Study Objectives 
 
3.1. Primary objective:  
The primary objective of the study was to investigate the pharmacokinetics of GSR-
PAS given 8 g once-daily vs. 4 g twice-daily and to establish whether once-daily 
dosing results in concentrations above the MIC of M. tuberculosis for a period 
comparable to twice-daily dosing in adult M/XDR-TB subjects.  
 
3.2. Secondary objectives: 
– To investigate the safety and tolerability of PAS when given once-daily vs. 
twice-daily 
 
– To investigate the pharmacokinetics of PAS in subjects on antiretroviral 
treatment and those not on antiretroviral treatment 
 
– To investigate the pharmacokinetic effects of genetic variations of the genes 
involved in PAS metabolism (NAT1 and NAT2) 
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Chapter Four:  
Materials and Methods 
 
Unpublished data of the pharmacokinetic profile of GSR-PAS given twice-daily were 
available from a previous project performed by the Division of Pharmacology 
(samples collected partly by Dr A Liwa) and by a team of researchers under Prof A 
Diacon in Brooklyn Chest Hospital. These data were analysed and used as a pilot 
study to plan the main study comparing once vs. twice-daily GSR-PAS (study 
outlined in the title of the dissertation). The pilot study will be referred to as study 1 
and the main study as study 2.  
 
Both studies were conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki, South Africa Guidelines for Good Clinical 
Practice and the Medical Research Council Ethical Guidelines for Research. Both 
had received ethical approval from the Health Research Ethics Committee at the 
University of Stellenbosch (study 1: N09/08/212; study 2: M12/01/006), the Western 
Cape Department of Health and the director of the hospital. The final approved 
versions of the protocols for studies 1e and 2 are given in Appendix B and C.  
 
4.1. Study 1: Pharmacokinetic profile of GSR-PAS given twice-daily 
The aim of the study was to describe the pharmacokinetic profile of GSR-PAS 
(PASER® granules, Para-aminosalicylic Acid Delayed-Release Granules-JACOBUS 
Pharmaceutical Company Inc., Princeton, NJ 08540) given twice-daily. The data of 
all subjects in the study were documented for non-compartmental pharmacokinetics 
analysis and for population pharmacokinetic evaluation (see pharmacokinetic 
analysis and population pharmacokinetic sections).  
Forty one adults hospitalised at Brooklyn Chest Hospital, Cape Town, South Africa 
participated in the study in 2010 and 2011. Written informed consent for the study 
                                                 
e
 It is important to note that the protocol of study 1 in Appendix B is the original protocol of Dr Liwa. His 
study mainly focused on the pharmacokinetics of PAS in children; the adults were used as the reference 
group. As extension of this study, the pharmacokinetics of PAS was investigated in adults receiving the 
drug as twice-daily doses of 4 g on two separate occasions. 
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and separately for genotyping was obtained from each subject after all study 
procedures, risks and benefits had clearly been explained in their preferred language 
(Appendix D).  
The first twelve subjects received their 12-hourly 4 g GSR-PAS dose a day before 
and on the pharmacokinetic blood sampling day (6:00 and 18:00 hours). The blood 
samples were scheduled to be collected at 0, 2, 3, 4, 5, 6, 8 and 12 hours. The 12 
hour blood sample was taken before the subjects received their second daily dose.  
The following twenty nine subjects also received GSR-PAS (4 g) twice-daily, but the 
second dose was given at 16h00. The blood samples were scheduled to be collected 
at 0, 2, 3, 4, 5, 6, 8 and 12 hours.  
In both groups the pharmacokinetic blood sampling was repeated after two to four 
weeks. All relevant information was recorded on a case report form (CRF) (See 
Appendix E).  
 
4.2. Study 2: Pharmacokinetic profile of once-daily vs. twice-daily GSR-PAS 
4.2.1. Study design and subjects 
Adults (≥18 years old) admitted and treated for DR-TB at Brooklyn Chest Hospital, 
Cape Town, South Africa were enrolled. Written informed consent for the study and 
separately for genotyping was obtained from each subject after all study procedures, 
risks and benefits had clearly been explained in their preferred language. The subject 
information and consent forms were available in English, Afrikaans and IsiXhosa 
(Appendix F).  
Subjects were enrolled into the study if they were stable on an unchanged TB 
regimen for two weeks, including PAS; and had no concurrent illness that according 
to the investigator made the participation inadvisable because of potential 
interference with the study or increased risk to the subject.  
The study was a randomized, two-period, open-label cross-over trial, where each 
subject received two different dosing regimens for GSR-PAS. All subjects had 
reached pharmacokinetic steady state conditions (>2 weeks treatment duration) for 
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GSR-PAS. In this cross-over studyf each subject received PAS orally either as a 
single daily (24-hourly) 8 g dose (1x 8 g GSR-PAS) or as a twice-daily (12-hourly) 4 g 
dose (2x 4 g GSR-PAS) on 2 separate occasions. The subjects were assigned to one 
of the two regimens using a randomisation schedule drawn up by the statistician. The 
dosing regimen was followed for 8 days and on the eighth day blood samples were 
collected at 0, 1, 2, 3, 4, 6, 8, 12 and 24 hours. After the 24 hour sample (Day 9) the 
regimens were crossed-over, therefore subjects who received 2x 4 g GSR-PAS, 
were switched to 1x 8 g GSR-PAS and vice versa. The study procedures are outlined 
in Table 4 and Figure 7.  
 
Table 4 Summary of study events 
 
  
                                                 
f
 Cross-over study: The administration of two or more experimental therapies one after the other in a 
specified or random order to the same group of subjects(www.medicine.ox.ac.uk) 
 Days 
Test -7 to -1 1 to 7 8 9 10 to 15 16 17 to 22 23 
Screening X        
Randomisation  X       
Prescribed PAS routine X      X X 
GSR-PAS 2x 4g*  X X (X) (X) (X)   
GSR-PAS 1x 8g*  (X) (X) X X X   
PK sampling   X   X   
Cross over*    X     
VAS  X X (X) (X)    
Follow up        X 
(X)-GSR-PAS 1x 8 g*; X-GSR-PAS 2x 4 g* 
*Subjects were randomised to start with either treatment and switched to the alternative 
treatment at Day 9  
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4.2.2. Demographic and medical information 
All relevant demographic and medical information; dosing and blood sampling 
events; as well the concomitant medication were well recorded in three separate 
case report forms (CRF) at enrolment and at the two sampling days (Appendix G). 
The weight and height were measured on the sampling days. 
 
4.2.3. Drug administration 
GSR-PAS (PASER® granules, Para-aminosalicylic Acid Delayed-Release Granules-
JACOBUS Pharmaceutical Company Inc., Princeton, NJ 08540) were prescribed by 
the attending physicians for all the subjects as part of their multi-drug regimens (See 
Appendix A for PASER package insert). Concomitant medication was allowed 
according to the resistance pattern of each subject and to concurrent illnesses.  
The subjects were assigned to the following regimens using a randomisation 
schedule. 
 
2x 4 g GSR-PAS: Twice-daily dosing- Subjects received a 12-hourly 4 g oral GSR-
PAS dose with other already prescribed medicines (ARVs, anti-TB drugs and other 
drugs).  
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2x 4 g GSR-PAS: 8 days of dosing with PAS 4 g twice-daily; 
1x 8 g GSR-PAS: 8 days of dosing with PAS 8 g once-daily 
Figure 7 Schematic illustration of the study procedure 
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1x 8 g GSR-PAS: Once-daily dosing- Subjects received a single 8 g once-daily oral 
GSR-PAS dose along with other already prescribed medicines (ARVs, anti-TB drugs 
and other drugs).  
 
GSR-PAS was given 1-2 hours prior (06h45-07h30) to breakfast and other 
medications; and the second dose (12-hourly) for the 2x 4 g GSR-PAS was given 1¼   
- 2 hours after dinner (18h45-19h30). All doses were taken either with yoghurt (100 
g) or amasig (125 ml) under direct observation. These acidic beverages prevent early 
release of the drug in the stomach 81. Subjects had the option to take the 8 g GSR-
PAS (once-daily) either with one or two 100 g yoghurts or amasi. Each subject’s 
dosing event was recorded on a dosing form (Appendix H). 
 
4.2.4. Tolerability and Safety 
Tolerability and safety were assessed by using self-rating Visual Analogue Scales 
(VAS). These scales were 10-point scales, with the far left indicating no symptoms 
and far right as severe symptoms (Appendix I). Gastrointestinal intolerance is 
frequently reported for PAS and is manifested by vomiting, diarrhoea, nausea, 
bloatedness and abdominal pain; therefore these side effects were included in the 
VAS. 
On a daily basis the subjects were individually interviewed and the scales were 
thoroughly explained before completion. These activities took place before the 
second dose (twice-daily), one to two hours after the last meal in order to record the 
daily food consumption.  
On the last blood sampling day, the subjects were asked about their experiences 
during the study and their response was recorded. A follow-up interview was done 
after a week.  
4.2.5. Sampling days 
The sampling days were scheduled to be on Day 8 and Day 16 of the study. Three 
millilitre blood specimens were collected in EDTA-containing tubes through a 
                                                 
g
  Amasi is the common African word for fermented milk that tastes like cottage cheese or plain yoghurt. 
This is the renowned drink of the Masai warrior tribes in Northern Tanzania and Kenya. This drink is 
renowned for its rich variety of beneficial microorganisms and highly bioavailable nutrients 
(naturalnews). 
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catheter inserted into a forearm vein at time 0 (pre-dose), 1, 2, 3, 4, 6, 8, 12 (pre-
dose, second daily dose) and 24 hours after dosing. The second dose for the twice-
daily dosing was scheduled to be immediately after the 12-hourly blood sample.  
 
4.3. Experimental method 
4.3.1. Blood samples 
All blood samples were collected on ice and centrifuged for 10 minutes at 3500 g. 
Thereafter, the plasma was promptly harvested and frozen at -80ºC for analysis. The 
cellular matter was kept in the EDTA tubes for genetic analysis. 
 
4.3.2. Bio analysis of PAS 
A HPLC-MS/MS method for the quantitative determination of PAS in plasma was 
developed by the Division of Pharmacology and applied to analysis the samples.  
 
4.3.2.1. Chemicals and reagents 
Pure PAS (A 7,960-4) powder and the internal standard (IS), thiazetazone, were 
purchased from Sigma-Aldrich (St Louis, USA). Methanol was purchased from Merck 
(Darmstadt, Germany) and formic acid (FA) from Fluka Chemie GmBH (Buchs, 
Switzerland).  
 
4.3.2.2. Preparation of calibration curves and quality controls 
Pure PAS compound specifications were used for calibrations and development of 
respective calibration curves. In each sample batch 8-10 calibrators of different 
concentrations were included in the run as quality control (QC) samples. For the 
preparation of the calibrators an appropriate amount of the working solutions and the 
internal standard were added to blank serum samples to achieve a specific range 
(1.0 to 100 μg/ml.) of calibration concentrations. All stock solutions were stored at -
80°C and were thawed to room temperature prior to use. 
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4.3.2.3. Stability  
The stability of PAS in frozen (-80˚C) samples was determined over a time period of 
six months; no degradation could be detected within this time period. The samples 
were analysed within 2 weeks after collection.  
 
4.3.2.4. Sample preparation  
The frozen plasma samples were first thawed to room temperature prior to the 
extraction procedure. Once thawed, the samples for HPLC analysis were prepared 
by pipetting 100 μl of subject plasma and 300 μl of methanol (Merck, Darmstadt, 
Germany), containing 1.0 μg/ml thiazetazone (IS) (Sigma, St Louis, USA) into a 2 ml 
test tube in order to precipitate the plasma proteins. The test tube was vortexed for 5 
minutes to ensure complete mixing of all substances. Thereafter, the samples were 
centrifuged at 11 000 g for 5 minutes. Two hundred and fifty micro litres (250 μl) of 
the supernatant was transferred into suitable auto sampler vials for analysis and was 
placed in the auto sampler set at 6°C. 
 
4.3.2.5. Chromatographic system 
PAS concentrations were determined by a binary high performance liquid 
chromatography (Agilent Series 1100 HPLC, Agilent Technologies, Waldbronn, 
Germany) equipped with an Agilent Zorbax analytical column (150 mm x 2.1 mm), 
3.5 μm particle size.  
Concentrations were determined by means of a gradient method. For elution, a 
gradient of water with 0.1% formic acid (FA) as the hydrophilic phase (mobile phase 
A), and methanol with 0.1% FA as the lipophilic phase (mobile phase B) was used. 
All the solvents were of HPLC grade and were filtered through a 0.45 μm filter to 
remove possible particular matter. The gradients started with 90% A and 10% B, 
which was maintained for 95 seconds. Then, it was changed within 5 seconds to 10% 
A and 90% B, and maintained for 7 minutes. Then, the gradient was changed within 
10 seconds to 90% A and 10% B, and maintained for 4.4 minutes before returning to 
the initial conditions. The flow rate was 300 μl/min and the column temperature at 
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40˚C. The volume injected from each sample vial was 5 μl and the samples were 
kept at 6°C.  
 
4.3.2.6. MS/MS Analysis 
The concentration of PAS was determined by means of an API 2000 tandem mass 
spectrometer (MS/MS) (Applied Biosystems, MDS Sciax, Foster City, Canada) 
equipped with an atmospheric turbulon ionization chamber. A single quantifier 
transition range for the thiazetazone (IS) with a precursor and product ion of m/z 
237.12/119.96 (dwell 500 msec) was used, while a transition of m/z 237.12/134.10 
(dwell 500 msec) was used as qualifier. The m/z quantifier transition for PAS was 
154.20/136.20 (dwell 500 msec) and the qualifier transitions were 154.2/119.2 and 
154.2/108.2 (dwell 500 msec). The quantifier m/z transition was used for 
quantification, while the indicated qualifier m/z transition was used to ensure 
selectivity of the compound. Thiazetazone (IS) eluted after 7.0 minutes and PAS after 
5.42 minutes. The lowest limit of detection was 0.25 μg/ml. A switching valve was 
used to only introduce the column effluent into the nebulising chamber (375 ˚C) at 
specified time ranges to avoid unnecessary contamination of the nebulising chamber. 
The time range for PAS was from 4.5 to 6.0 minutes and 6.5 to 7.5 minutes for the 
IS.  
 
4.3.2.7. Accuracy, precision and recovery 
The accuracy and intra-day precision of the method were determined by measuring 
replicate serum samples of the test compound at various concentrations. Intra-day 
variation was less than 3% while daily variation was found to be less than 5% over 
the respective calibration range. A variation of more or less 5% was found over the 
entire duration of the analysis.  
 
4.4. Pharmacokinetic analysis 
The non-compartmental pharmacokinetic analysis was utilized to obtain the steady 
state pharmacokinetic parameters of concentration-time profile for each subject, 
using the software WinNonLin v5.3 (Pharsight, Mountain View, CA). The following 
parameters were determined: 
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Cmax maximum observed concentration 
Cmin minimum observed concentration 
Clast last observed concentration 
C0 observed plasma concentration at 0 hours pre-dose 
C12 observed plasma concentration at 12 hours post-dose 
C24 observed plasma concentration at 24 hours post-dose 
tmax time from dosing to when Cmax was reached. 
tmin time from dosing to when Cmin was observed. 
tlast time from dosing to when Clast was observed. 
AUClast area under the concentration-time curve from dosing to the last time point 
with measurable drug concentration. AUClast was calculated by the linear 
trapezoidal method. 
t½ apparent plasma half-life of each analyte, calculated as: 
     
     
  
 
where z, the apparent first order elimination rate constant, was 
determined by fitting a log-linear least-square regression to the terminal 
phase of the plasma time-concentration data; the slope of the terminal 
phase is the z. At least three time points starting from the last observed 
concentration was used to define the slope of the terminal phase. 
 
AUC area under the plasma concentration-time curve extrapolated to infinity 
which is calculated by: 
          
     
  
 
where Clast was the last measurable concentration. 
AUC12 area under the concentration-time curve from dosing to the 12 hour post-
dose.  
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AUC24 area under the concentration-time curve from dosing to the 24 hour post-
dose. If the 24 hour drug concentration is missing, the 24-hour drug 
concentration is extrapolated from the slope of the regression and the 
area is computed from the last measurable concentration using linear 
trapezoidal rule. 
CLss/F apparent total body clearance at steady-state, calculated as: 
    
 ⁄  
    
    
 
Vz/Fobs apparent volume of distribution during the terminal phase 
 
 
4.5. Genotyping 
4.5.1. DNA Purification 
The cellular matter obtained in the sample preparation process outlined in 4.3.1 was 
kept in the EDTA tubes and stored at –20˚C until analysed. An aliquot volume of 
blood was transferred to a sterile 50 ml polypropylene centrifuge tube and diluted 
with 5-6 volumes of ice-cold Cell Lysis Buffer (1% Triton X-100, 320 mM sucrose, 5 
mM MgCl2, 10 mM Tros, pH 7.6) and mixed by 20-30 hand inversion. The tubes were 
centrifuged at 3000 rpm for 15 minute at 4˚C in an Eppendorf bench top centrifuge 
(Model 5810R). The cellular pellet obtained was re-suspend in 6 ml of Nuclei Lysis 
Buffer (400 mM NaCl, 10 mM Tris pH 8.2, 2 mM EDTA pH 8.2) with 1% sodium 
dodecyl sulphate (SDS) and 200 μg proteinase K enzyme solution (10 mg/ml) and 
incubated overnight at 37˚C. Two millilitre (2 ml) of saturated NaCl solution (>6 M) 
was added and gently hand mixed until it was homogeneity. It was then centrifuged 
at 4000 rpm for 30 minutes (4˚C) to a pellet of degraded proteins. The genomic DNA 
was precipitated from the supernatant by adding 2, 5 volumes of absolute ethanol 
(room temperature). Thereafter, the DNA was spooled out with a heat-sealed Pasteur 
pipette and was washed with 70% ethanol, heat dried for 15-20 minutes at 37˚C and 
re-dissolved in 800 μl of sterile 0.5 x TE (1 mM EDTA pH 8.0, 10 mM Tris pH 8.0) 
buffer for 16 hours at 4˚C. 
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4.5.2. DNA Concentration and Purity 
The quantification of purity nucleic acid solution was determined 
spectrophotometrically at 260 and 280 nanometres (nm), by measuring the 
absorbance of a diluted sample placed in a beam with a one centimetre path length. 
A solution of double stranded DNA with a concentration of 50 µg/ml has an A260 equal 
to one. The ratio of the 260 nm and 280 nm readings (A260/ A280), estimate the DNA 
purity in the solution, and are usually between 1.8 and 2.0, thus representing good 
deproteinisation of the samples. 
 
The integrity of the genomic DNA was assessed by agarose gel electrophoresis 
against a commercially supplied preparation of purified lambda DNA (Roche, USA). 
The DNA appeared as a single high molecular weight band, comparable in size and 
intensity to the lambda DNA band. 
 
4.5.3. Agarose Gel Electrophoresis 
Seakem ® LE agarose (BMA) gels were used for the electrophoresis of the DNA and 
evaluation of the PCR amplification products. The PCR product sizes were compared 
to commercially supplied DNA makers, 100 bp DNA ladder (Promega, USA). The 
gels were prepared in 0.5 x Tris-Borate-EDTA (TBE) buffer (45 mM Tris, 1 mM EDTA 
pH 8.0, 45 mM Borate) and set in a mini-gel electrophoresis apparatus (Omeg 
Scientific, South Africa) with gel dimensions of 100 mm x 65 mm x 3.5 mm. The DNA 
samples were mixed with a Blue/Orange DNA loading dye (Promega, USA), loaded 
on the gel, and electrophoresed at 15 volt. A 0.5 x TBE was used as the running 
buffer. The gels were then stained at room temperature for 20 minutes, in a solution 
of 0.5 x TBE containing the Gelstar® Nucleic Acid stain (BMA), diluted to a 1 x final 
concentration. The gels were visualized on the UV transilluminator (UVP, USA) and 
photographed using the Kodak electrophoresis Documentation and Analysis 120 
system (Kodak Digital Science, Eastman Kodak Co., USA) 
 
4.5.4. NAT1 
A 1492 bp domain of the NAT1 gene, spanning several genetic variations, including 
twenty-one single nucleotide polymorphisms (SNPs) and a number of inserted and/or 
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deleted sections within the 3’-UTR of the gene 
(http://www.louisville.edu/medschool/pharmacology/)h, was amplified using the gene-
specific primers: NAT1 fwd. (5’-117AGGATACCAGTTGG-3’) and NAT1 rev (5-
1585TTCGAAAATTACAACCAAATAACAA-3’). The amplification reaction was carried 
out in a total volume of 50 µl, using 0.92 units of Phusion® High-Fidelity DNA 
Polymerase (Finnzymes Oy, Finland). The reaction consisted out of 30 ng genomic 
DNA, 0.2 mM dNTP mixture (dATP, dGTP, dTTP and dCTP), 10 µl 5x of Phusion® 
High-Fidelity DNA Polymerase, 0.25 µM of forward and reverse primer, and 10 mM 
MgCl2. Amplification was performed in a Veriti 96-well Thermal Cycler (Applied 
Biosystems, USA). The temperature cycling conditions were as follow: initial 
denaturation at 98ºC for 1 minute; 35 cycles of alternating denaturation at 98ºC, for 
15 seconds; annealing at 60ºC for 20 seconds; polymerisation at 72ºC for 35 
seconds; and a final polymerisation of 72ºC for 10 minutes. 
 
Three micro litres of the PCR product was then assessed for specificity and efficiency 
using a submarine gel electrophoresis in 1% Seakem® LE agarose (BMA, USA) gel 
using 1x Sodium Borate (SB) buffer (5 mM Na2 B4O7.·10H2O), and a current of 250 
volts for 15 minutes in the Omeg mini-gel apparatus (Omeg Scientific,RSA). The 
electrophoresis results were visualised as described above in the ‘Agarose Gel 
Electrophoresis’ section. 
 
4.5.4.1. Direct sequencing 
The amplified NAT1 domain (PCR product) was assessed by direct sequencing at 
the Central Analytical Facility (CAF), Stellenbosch University. All sequencing results 
were quality controlled by the staff at CAF, and the sequence alignment analysis was 
performed using Sequencher, version 4.10.1 (http://www.genecodes.com), and the 
NAT1 reference sequence (http://www.ncbi.nlm.nih.gov/nuccore/14018355; Genbank 
Accession Number AJ307007). 
 
4.5.5. NAT2 
A fragment (1000 bp) of the NAT2 gene was amplified using the gene specific primer 
set, supplied by Integrated DNA Technologies (www.idtdna.com): HuNAT14 (5’-
                                                 
h
 This Human NAT1 and NAT2 alleles are listed by an international gene nomenclature committee 
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726GACATTGAAGCATATTTTGAAAG748-3’) and HuNAT16 (5’-
1724GATGAAAGTATTTGATGTTTAGG1702-3’). The PCR amplification was performed 
in a total volume of 100 µl, consisting out of 150 ng genomic DNA, 50 mM KCl. 20 
mM Tris buffer (pH 8.4), 0.2 mM dNTP mixture (dATP, dGTP, dTTP and dCTP), 2.5 
mM MgCl2, 0.25 µM of the primers, and one unit of Taq DNA Polymerase 1 (Gibco 
BRL Life Technologies, USA). The amplification was performed in the Gene Amp 
PCR system 2700 (Applied Biosystems, USA). The temperature cycling conditions 
were as follow: initial denaturation at 94ºC for 5 minute; 35 cycles of alternating 
denaturation at 94ºC, for 30 seconds; annealing at 56ºC for 40 seconds, 
polymerisation at 72ºC for 80 seconds, and an extended polymerisation at 72°C for 
10 minutes, where after the sample tubes were cooled and maintained at 4°C for 30 
minutes. 
Five micro litres of the PCR product (NAT2) was analysed for efficacy and specificity 
by submarine gel electrophoresis (Omeg mini gel apparatus) as described in the 
‘Agarose Gel Electrophoresis’ section. 
 
4.5.5.1. Restriction Endonuclease Analysis 
Restriction endonuclease analysis was used to determine the genetic 
variations/polymorphisms of NAT2 (NAT2*7; NAT2*6 and NAT2*14). The digestions 
were performed in accordance with the recommendations of the specific 
manufacturer. Fifteen micro litres of the PCR product was separately digested with 
the Bam HI, Dde I, Fok I, KpnI, MspI, and Taq I restriction endonucleases, 
respectively. The Bam HI, KpnI, and MspI restriction products were additional 
digested by PstI. These double digests generated fragment profiles possessing 
bands of less than 500 bp in size, which are specific for MspI, KpnI and BamHI, 
respectively. This provided the accurate resolution of these profiles on a non-
denaturing polyacrylamide gel electrophoresis.  
 
In comparison to the above, the amplified NAT2 gene sequence possesses several 
cutting sides for the Dde I, Fok I, and Taq restriction enzymes, which generated 
enzyme-specific profiles. 
 
The NAT2 profiles were analysed using a Mini-PROTEAN® II gel electrophoresis 
(BioRAd Laboratories, USA) and a 5% non-denaturing polyacrylamide gel. Gels were 
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run at 100 volts for 1 hour using 1 x TBE buffer. The DNA bands were then visualised 
and fixed by silver staining. The images were electronically scanned using Epson 
Scanner and supplied software (Siko Epsom, Japan) 
 
4.5.5.2. Allele – Specific PCR Analysis 
The NAT2*5 is specifically identified by the 341 T>C nucleotide change. The 
confronting primer PCR technique (CP-PCR) was used to assess this polymorphism. 
Two primer sets were used, allele-specific confronting primer set (341T:1045  
TTCTTCTGCAGGTGACCAT 1063 and 341C: 1081 ATGTAATTCCTGCCGTCAG 1063) 
and an outer-primer set (A: 894 CACATTGTAAGAAGAAACCGG 914 and B: 1368 
AAGATGTTGGAGACGTCTGC 1349). A total volume of 25 µl PCR reaction consisted 
out of 20 ng genomic DNA, 0.25 mM dNTP mixture (dATP, dGTP, dTTP and dCTP), 
2.5 µl 10 x PCR buffer (200 mM Tris, pH 8.4; 500 nM KCl) (Gibco BRL Life 
Technologies, USA), 2.5 mM MgCl2, 0.25 µM of the four primers, and 0.25 µl Taq 
DNA Polymerase 1 (Gibco BRL Life Technologies, USA). The amplification was 
performed in the Gene Amp PCR System 9700 (Applied Biosystem, USA). The 
temperature cycling conditions were as follow: initial denaturation at 94ºC for 5 
minute; 35 cycles of alternating denaturation at 94ºC, for 35 seconds; annealing at 
58ºC for 45 seconds, polymerisation at 72ºC for 60 seconds, extended 
polymerisation at 72ºC for 10 minutes and finally a cool down to 4ºC for 60 minutes. 
Two micro litres of PCR product were assessed by gel electrophoresis using 2% 
agarose gel (BMA, USA), and 0.5 x TBE running buffer. The gels were run at 220 
volts for 15 minutes, using Omeg gel apparatus and the RFLP bands were visual as 
previously described in the ‘Agarose Gel Electrophoresis’ section. 
 
4.5.6. Genetic categorising  
The genetic results were then used to categorise the subjects as either slow, fast or 
intermediate (one slow allele and one fast) acetylators for the NAT1 and NAT2 by 
using the available literature information.  
 
Louisville medical schoolh (http://www.louisville.edu/medschool/pharmacology/) 
summarised the known genetic variants of NAT1 and NAT2, and these were used as 
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a guideline. According to the summary of the Louisville medical school, the functional 
type of many of the NAT1 variations is in fact unknown. 
The genetic results were documented and the influence of NAT1 and NAT2 on the 
disposition of PAS was inspected by graphing the time-concentration profiles of each 
genotype against other genotypes combined. An interaction plot was generated to 
evaluate whether NAT1 and NAT2 have any interaction (described in ‘5.4.5 Effect of 
NAT1 and NAT2 polymorphisms’) 
 
4.6. Data analysis 
Since the aim of the study was to compare the once and twice-daily regimens and 
investigate the possible co-factors involved in the different pharmacokinetic profiles 
of PAS, both statistical and pharmacometric analysis was performed.  
 
4.6.1. Statistical analysis 
In study 1 the body weight, BMI and pharmacokinetic results of occasion 1 and 
occasion 2 were statistically compared. In the comparison of the two occasions, only 
the data of the subjects who had completed both occasions were used. 
 
In study 2, the body weight, BMI, pharmacokinetic results and tolerability (VAS 
scores) of once- and twice-daily regimens were compared by using cross-over 
statistical analysis. In this crossover comparison, only the data of the subjects who 
had completed both regimens were used. In addition, the pharmacokinetic profiles of 
the HIV positive and negative subjects of study 2 were compared.  
 
The data of both studies were documented in a dataset using Microsoft Excel 2010. 
The independent variables were age, gender, race, height, body weight, BMI, VAS 
scores, concomitant medications and the results of the pharmacokinetic analysis. 
The variables were summarised using standard summary statistics (descriptive 
statistics). The summary statistic results were presented in tables and graphs using 
Microsoft Excel 2010 and Graph Pad Prism version 6.00 (GramphPad software, Inc. 
San Diego, California). 
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Statistical analysis was performed using the statistical programs SAS 9.1.3 and 
STATISTICA version 10. The comparison between groups (prescribed ART vs. not 
on ART) was treated as an interindividual (between-subject) effect and the difference 
between the regimens and occasions as intraindividual (within-subject) effect. 
Normality of the subject characteristics, pharmacokinetic parameters and the VAS 
scores were analysed using the Sharpiro-Wilks normality tests. The significant 
difference was then established by mixed analysis of variance model (ANOVA), 
Wilcoxon rank sum test or Wilcoxon match pair test. A statistically significant 
difference was defined as p< 0.05.  
 
4.6.2. Population Pharmacokinetic analysis 
4.6.2.1. Datasets used in the model development 
The plasma concentration-time data of GSR-PAS administered as once- and twice-
daily came from rich sampling design. Available data were used for the population 
pharmacokinetic analysis. The aim of the study was to determine the 
pharmacokinetic profile for GSR-PAS given once-daily versus twice-daily. 
 
4.6.2.2. Population Pharmacokinetic Model 
Population pharmacokinetic models were built using a non-linear mixed-effects 
modelling approach. The first-order conditional maximum likelihood estimation in the 
NONMEM program (double precision, Version 7.2, ICON Development Solutions, 
Elliott City, MD) and NM-TRAN pre-processor were used. Models were run using the 
G-Fortran Compiler (GNU Compiler Collection) on a personal computer under the 
Microsoft Windows 7.0 operating system (Dell Optiplex 755). PerlSpeaksNONMEM 
3.5.5 (http://psn.sourceforge.net/) running activePerl 5.10.1 (ActiveState Software 
Inc., Vancouver, BC, Canada) were used to manage NONMEM batch files. The 
subroutines within NONMEM were linear mammillary models (ADVAN2 used with 
TRANS2 in the PREDPP library) to investigate a one-compartment, absorption 
model. The one-compartment open model with first order elimination with lag time 
provided the best fit to the dataset. The structural pharmacokinetic model for the two-
compartment model consists of the following parameters: absorption rate constant 
(Ka), oral clearance (CL), volume of the central compartment (V), and lag-time (Tlag). 
The relative bioavailability parameter F assumed the value of 1. All pharmacokinetic 
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parameters were assumed to be log-normally distributed, and exponential 
interindividual variability terms were included in the pharmacokinetic parameters in 
the model. Interoccasional variability (IOV) was introduced to the model using the 
general model for IOV (Equation 1). 
 
      ̃              Equation 1 
where: 
 
ηi and  ij to describe interindividual and interoccasion/ intraindividual (within an 
individual) variability are assumed to be independently, normally distributed 
parameters both with mean zero and variances   
  and   
 , respectively. 
 
The allometric scaling based on body weight (BW) was applied to the PK parameters 
CL and V, as described by Equation 2 
 
 
 
    ̃  (
  
     
)
  
 
Equation 2 
where: 
 ̃ is the parameter value for an individual body weight normalized to the ideal median 
body weight of the population of 70 kg and θ1 is the allometric scaling exponent. For 
V, the allometric scaling parameter θ1 was assumed to be 1.  
Once the base model was established, covariate screening was carried using 
stepwise covariate model in PerlSpeaksNONMEM. The continuous covariate tested 
includes the demographic variable age. The categorical covariates included HIV 
status, gender and race 
 
 
4.6.2.3. Covariate Analysis 
Covariate screening was accomplished using a stepwise covariate model (SCM) in 
PerlSpeaksNONMEM (PsN). The hypothesis testing was to discriminate among 
alternative hierarchical structural models based on the p-values for the forward 
inclusion and backward elimination at 0.05 and 0.01, respectively. The linear and 
power relationships were explored for continuous covariates and exponential 
relationship for categorical bivariate. The resulting model that included all significant 
covariates was considered the “final” population pharmacokinetic model. 
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The concomitant medications were categorized according to their effect on 
cytochrome P450 (major drug metabolic group of enzymes). The categories were as 
follows: CYP1A2 substrate, inhibitor; CYP3A substrate, inhibitor, inducer; CYP2B6 
substrate; CYP2C9 substrate, inhibitor; CYP2C19 substrate, inhibitor, inducer; 
CYP2D6 substrate, inhibitor; CYP2E1 inducer; CYP2C8 inducer; general inducer and 
inhibitor. Dummy variables consisting of 0 and 1 were introduced to each category for 
absence or presence of drug belonging to these categories, respectively. The 
influence of concomitant medications was evaluated using the SCM algorithm with 
the same forward inclusion and backward elimination probability values. Only 
exponential relationship was explored since these were categorical bivariates. 
 
4.6.2.4. Model Validation 
A degenerate visual predictive check was performed by the simulation of the 
parameter estimates of the final model to generate 1000 individual profiles. The 
median and 95% prediction intervals for the concentration at each time point were 
plotted and compared to the original data using R (v. 2.14.0). 
 
The accuracy and robustness of the final model were evaluated using a non-
parametric bootstrap procedure. The algorithm involves repeated random sampling 
of subjects available in the study, with replacement of the original dataset in each 
subsequent sampling to produce another dataset of the same size as the original, but 
with a different list of subjects. The re-sampling was repeated 500 times. The final 
population pharmacokinetic model was fitted to each of the bootstrap datasets and a 
set of model parameters were determined for each run. The median and 95% 
confidence intervals were computed and compared to the values from the original 
NONMEM analysis. The procedure was performed using PsN. 
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Chapter Five:  
 Results 
 
5.1. Study 1: Clinical Results 
5.1.1. Study Subjects  
The data of forty one subjects (n=41) with DR-TB were documented. Data of forty 
subjects (n=40) were available at the first occasion and thirty nine subjects’ (n=39) 
data were available at the second occasion. Thirty eight subjects (n=38) participated 
at both occasions and therefore their data were used in the comparison between the 
two occasions. The data of all the subjects (n=41) were used in the modelling and 
simulation analysis described in the population pharmacokinetic section. The 
demographic characteristics of all subjects are presented in Table 5.  
 
Twenty subjects (49%) were female. Four females (20%) had XDR-TB and ten (50%) 
were HIV positive. The mean age of the females was 31 years (median: 28 years). 
The mean height was 163.9 cm (median: 164.0 cm) and the mean weight was 50.6 
kg (median: 46.7 kg). 
 
Twenty-one subjects (51%) were male. Two males (10%) had XDR-TB and two (10%) 
were HIV positive. The mean age of the males was 36 years (median: 33 years). The 
mean height was 170.8 cm (median: 169.5 cm) and the mean weight was 59.6 kg 
(median: 59.5 kg). 
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Table 5 Demographic characteristics of the subjects in study 1 
Parameter All the subjects (n= 41) 
Gender (n, %)  
Female  20 (49%) 
Male 21 (51%) 
 
Race (n, %) 
 
Black 12 (29%) 
Coloured 29 (71%) 
 
Age (years) 
 
Mean  34 
SD 11 
CV% 34 
Range 18-62 
Median 31 
 
TB Diagnosis 
 
MDR-TB 35 (85%) 
XDR-TB 6 (15%) 
 
HIV status 
 
Positive 12 (29%) 
Negative 29 (71%) 
 
Height (cm) 
 
Mean  168.3 
SD 7.5 
CV% 4 
Range 149.0-183.0 
Median 168.0 
 
Weight (kg) 
 
Mean  55.6 
SD 12.0 
CV% 22 
Range 33.0-84.0 
Median 56.0 
SD standard deviation; CV coefficient of variation 
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5.1.2. Concomitant medication 
Six drugs of the standard XDR-TB regimen, including PAS were prescribed to the 
subjects in study 1. The anti-tuberculosis drugs and other antibiotics used are 
presented in Figure 8.  
The first-line drugs prescribed were ethambutol (93%), pyrazinamide (93%) and INH 
(59%). Two subjects (5%) received the injectable, kanamycin and thirty one subjects 
(76%) received an alternative injectable, capreomycin. The fluoroquinolones 
prescribed were ofloxacin (59%) and moxifloxacin (2%); and the second-line oral 
bacteriostatic agents were terizidone (98%) and ethionamide (85%). Additional 
antimicrobial agents were clarithromycin (7%) and dapsone (10%).  
All HIV positive subjects were on antiretroviral treatment. Figure 9 shows the 
concomitant antiretroviral drugs used by the HIV positive subjects. All HIV positive 
subjects were on lamivudine treatment. Eleven subjects (92%) received both 
efavirenz and stavudine. One subject (8%) was prescribed zidovudine (AZT), and 
one subject (8%) was prescribed lopinavir/ritonavir and lamivudine 
 
 
Figure 8 Anti-tuberculosis and antimicrobial drugs co-administered with GSR-PAS in 
study 1 
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Figure 9 Concomitant antiretroviral drugs 
administered to the HIV positive subjects (n=12) in 
study 1 
 
Sixteen subjects (39%) were prescribed pyridoxine (vitamin B6) and two (5%) 
subjects’ vitamin B complex as a supplement. Eight subjects (20%) received 
antidepressants: amitriptyline (20%), fluoxetine (2%), and fluphenazine (2%). One 
subject (2%) was prescribed orphenadrine, and insulin and metformin for his type 2 
diabetes. One subjects (2%) received eltroxin for hypothyroidism and two subjects 
(5%) ranitidine for peptic ulcer or heart burn. Figure 10 summarises the concomitant 
drugs used by the subjects in study 1.  
 
 
 
Figure 10 Other drugs co-administered with GSR-PAS in study 1 
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5.1.3. Comparison between first and second occasion  
Only the thirty eight subjects that participated in both PK blood sampling occasions 
were used in the comparison of the two occasions. The demographic characteristics 
of the group of subjects are summarised in Table 6 and the weight in Table 7. 
Eighteen females (47%) and 20 (53%) males participated in both occasions.  
 
Body weight and height measured on the PK sampling days were used for 
calculation of the BMI. Categories of BMI are as follows: underweight BMI<18.5 
kg/m2; normal weight 18.5-24.9 kg/m2; overweight 25.0-29.9 kg/m2 and obesity >30 
kg/m2. Six of the thirty eight subjects (16%) were underweight; thirty subjects (79%) 
had a normal weight; and one subject (3%) was obese. 
 
Seven subjects’ heights were not available; therefore the BMI of these subjects were 
not calculated. Mean body weight at the first occasion was 56.5 kg and 57.4 kg at the 
second occasion. Mean BMI was 20.5 kg/m2 and 20.8 kg/m2 at the first and second 
occasion, respectively.  
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Table 6 Demographic characteristics of subjects included in both occasions 
Parameter Both occasions (n=38) 
Gender (n, %)  
Female  18 (47%) 
Male 20 (53%) 
  
Race (n, %)  
Black 12 (32%) 
Coloured 26 (68%) 
  
Age (years)  
Mean 34 
SD 12 
CV% 35 
Range 18-62 
Median 32 
  
TB Diagnosis  
MDR 33 (87%) 
XDR 5 (13%) 
  
HIV status  
Positive 11 (29%) 
Negative 27 (71%) 
  
Height (cm)  
Mean 168.8 
SD 7.4 
CV% 4 
Range 149.0-183.0 
Median 169.0 
Missing values (n, %) 7 (18%) 
SD standard deviation; CV coefficient of variation 
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The weight and BMI were analysed for significant difference (Table 7). Body weight 
and BMI were considered as not normally distributed as verified by the Shapiro-Wilks 
normality test, therefore the Wilcoxon matched pairs test was used to assess 
whether there were any significant differences between the two occasions (level of 
significance set at p<0.05). 
 
Body weight (p=0.011) and BMI (p=0.007) were significantly higher at the second 
occasion; however the differences were only small and not clinically relevant. 
 
 
Table 7 Comparison between body weight and BMI of the same subjects recorded at the 
first and second occasion in study 1 
Parameter 
Occasion 1 
(n=38) 
Occasion 2 
(n=38) 
p-value* 
Body weight (kg) 
Mean 
SD 
56.5 
11.9 
57.4 
12.1 
0.011 
 
CV% 21 21  
Range 33.0-84.0 34.7-83.0  
Median 57 59.0  
Missing values (n, %) 0 (0%) 1 (3%)  
    
Body Mass Index (BMI=kg/m
2
) 
Mean 
SD 
20.5 
3.2 
20.8 
3.3 
0.007 
 
CV% 16 16  
Range 14.4-30.9 14.0-30.5  
Median 20.6 21.2  
Missing values (n, %) 7 (18%) 7 (18%)  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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5.2. Study 2: Clinical Results 
5.2.1. Study Subjects  
Thirty two subjects (n=32) were eligible for PK blood sampling in study 2. Twenty 
nine subjects (n=29) followed the once- and twice-daily regimens for two separate 
weeks (crossover) and therefore their data were used in the comparison between the 
two regimens (this group completed both regimens). The data of all the subjects 
(n=32) were used in the modelling and simulation analysis described in the 
population pharmacokinetic section. The demographic characteristics of the study 
subjects are presented in Table 8.  
 
Fourteen subjects (44%) were female. Two females (14%) had XDR-TB and three 
(21%) were HIV positive. The mean age of the females was 37 years (median: 36 
years) and mean height was 158.3 cm (median: 158.5 cm).  
 
Eighteen subjects (56%) were male. Six males (33%) had XDR-TB and six (33%) 
were HIV positive. The mean age of the males was 35 years (median: 34 years) and 
mean height was 171.0 cm (median: 170.0 cm). 
 
Serum creatinine, estimated glomerular filtration rate (eGFR) as determined by the 
Cockcroft & Gault formula99 and alanine aminotransferase (ALT) are presented in 
Table 9. Not all of the above mentioned clinical laboratory test results were available 
for each subject; the number of missing values is recorded in the table. 
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Table 8 Demographic characteristics of subjects in study 2 
Parameter All the subjects (n=32) 
Gender (n, %)  
Female  14 (44%) 
Male 18 (56%) 
  
Race (n, %)  
Black  5 (16%) 
Coloured 27 (84%) 
  
Age (years)  
Mean 36 
SD 11 
CV% 31 
Range 18-64 
Median 34 
  
HIV Status (n, %)  
Positive  9 (28%) 
Negative  23 (72%) 
  
TB Diagnosis (n, %)  
MDR 24 (75%) 
XDR 8 (25%) 
  
Height (cm)  
Mean 165.0 
SD 9.0 
CV% 5 
Range 150.0-183.0 
Median  167.0 
  
Weight (kg)  
Mean 56.1 
SD 10.0 
CV% 18 
Range 42.0-85.5 
Median  54.5 
 SD standard deviation; CV coefficient of variation 
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Table 9 Clinical laboratory results in study 2 
Parameter All the subjects (n=32) 
Serum creatinine (µmol/l)  
Mean  
SD 
81 
27 
CV% 33 
Range 44–152 
Median  73.0 
Missing values (n, %) 0 (0%) 
  
eGFR (ml/min)  
Mean  
SD 
92  
37 
CV% 41 
Range 37–206 
Median 88 
Missing values (n, %) 0 (0%) 
  
ALT (U/L)  
Mean 
SD 
17 
12 
CV% 71 
Range 5–57 
Median 16 
Missing values (n, %) 16 (47%) 
  SD standard deviation; CV coefficient of variation 
 
 
5.2.2. Concurrent diseases  
Three subjects (9%) were infected with Treponema pallidum (syphilis); two (67%) of 
these subjects were HIV positive. Four subjects (13%) suffered from diabetes 
mellitus (DM) and two subjects (6%) from hypothyroidism. Ten subjects (31%) had 
depression and two (6%) suffered from anxiety. Two subjects (6%) were diagnosed 
with a psychotic disorder, but were stable. 
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5.2.3. Concomitant medication  
Seven drugs of the standard XDR-TB regimen, including PAS were prescribed to the 
subjects in study 2. The anti-tuberculosis drugs and other antibiotics used are 
presented in Figure 11.  
 
The anti-TB drugs were capreomycin (88%), moxifloxacin (97%), ethionamide (88%), 
terizidone (97%), pyrazinamide (84%) ethambutol (84%), INH (47%), clofazimine 
(38%), dapsone (6%) and kanamycin (6%). Additional antimicrobial agents were 
clarithromycin (3%) and co-trimoxazole (6%).  
 
  
Figure 11 Anti-tuberculosis and antimicrobial drugs co-administered with GSR-PAS in study 2 
 
 
All HIV positive subjects were on antiretroviral treatment as shown in Figure 12. Eight 
subjects were prescribed lamivudine and efavirenz (89%). Seven of these subjects 
were also on stavudine (78%) and one was on zidovudine (11%). One subject was 
prescribed a lopinavir/ritonavir and lamivudine/zidovudine regimen.  
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Figure 12 Concomitant antiretroviral drugs administered to the 
HIV positive subjects (n=9) in study 2 
 
 
Four diabetic subjects (12.5%) were treated with metformin (50%), glibenclamide 
(25%), and insulin (actraphane 25% and humulin 50%) (See Figure 13). 
 
 
  
Figure 13 Concomitant diabetic drugs administered 
to the diabetic subjects (n=4) in study 2 
 
0
10
20
30
40
50
60
70
80
90
100
P
e
rc
e
n
ta
g
e
 (
%
) 
o
f 
H
IV
 p
o
s
it
iv
e
 
s
u
b
je
c
ts
 
Antiretroviral Drugs 
 Efavirenz
 Stavudine
 Lamivudine
 Zidovudine
 Lamivudine/zidovudine
 Lopinavir/ritonavir
0
10
20
30
40
50
60
70
80
90
100
P
e
rc
e
n
ta
g
e
 (
%
) 
o
f 
s
u
b
je
c
ts
 w
it
h
 
d
ia
b
e
te
s
 m
e
ll
it
u
s
 
Diabetic drugs 
 Metformin
 Glibenclamide
Actraphane
 Humulin
Stellenbosch University http://scholar.sun.ac.za
R e s u l t s  | 58 
 
 
Ten subjects (31%) were treated for depression with amitriptyline, and one subject 
was also prescribed fluoxetine. Two subjects (6.3%) suffered from anxiety and were 
prescribed lorazepam and diazepam, respectively. Two subjects (6.3%) had a 
psychotic disorder and were treated with haloperidol and chlorpromazine, 
respectively. These drugs are outlined in Figure 14. 
 
 
 
Figure 14 Anti-anxiety, anti-depressant and/or antipsychotic drugs co-
administered with GSR-PAS in study 2 
 
 
Other concomitant drugs and dietary supplements are shown in Figure 15. 
Pyridoxine (97%), vitamin B complex (47%), vitamin C (16%), potassium (6%), folic 
acid (3%) and magnesium (3%) were prescribed as dietary supplements. Other 
medications were eltroxin (6%), maxulon (31%), ranitidine (13%), orphenadrine (9%), 
codeine phosphate (9%), aspirin (3%), amlodipine (3%) and FeSO4 (3%). 
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Figure 15 Other drugs and dietary supplements co-administered with GSR-PAS in study 2 
 
 
5.2.4. Demographic data of subjects included in both cross-over periods 
Twenty nine (n=29) subjects were eligible for the cross-over comparison. On each 
PK sampling day the weight and height were measured with standard measuring 
instruments, and the BMI was calculated accordingly. The demographic 
characteristics and the weight are summarised in Table 10 and 11, respectively. 
Twelve subjects (41%) were female and 17 (59%) were male. Twenty four (83%) 
subjects were Coloured and five subjects (17%) were Black. The mean age was 36 
years (median 34 years). Nine subjects (31%) were HIV positive and seven subjects 
(24%) had XDR-TB. 
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Table 10 Demographic characteristics of subjects included in 
both cross-over periods 
Parameter Cross-over (n = 29) 
Gender no. (%)  
Female 12 (41%) 
Male 17 (59%) 
  
Race no. (%)  
Black 5 (17%) 
Coloured 24 (83%) 
  
Age (years)  
Mean 36 
SD 11 
CV% 31 
Range 18-64 
Median 34 
  
HIV Status  
Positive (n, %) 9 (31%) 
Negative (n, %) 20 (69%) 
  
TB Diagnosis  
MDR 22 (76%) 
XDR 7 (24%) 
  
Height (cm) 
Mean  165.9  
SD 8.3 
CV% 5 
Range 150.0-183.0 
Median 167.0 
SD standard deviation; CV coefficient of variation 
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Table 11 Comparison between body weight and BMI recorded at the start of both 
treatment regimens in study 2  
 Dosing Regimens of GSR- PAS  
Parameter 
Twice-daily  
(n=29) 
Once-daily  
(n=29) 
p-value* 
Body weight (kg)    
Mean 55.5  55.1 0.065 
SD 8.5 8.7  
CV% 15  16   
Range 42.0-73.0 40.0-71.5  
Median 56.0 56.0  
 
Body Mass Index (BMI= kg/m
2
) 
Mean  20.2 20.0 0.060 
SD 2.5 2.7  
CV% 12 13  
Range 16.0-25.6 15.1-25.2  
Median 19.9 19.8  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of 
variation 
 
 
The mean differences for body weight and BMI between the once-and twice-daily 
regimens was 0.4 kg and 0.2 kg/m2 which were not significantly different. Two 
subjects who started with the twice-daily regimen lost a remarkable amount of weight 
in a week (6.5 kg and 7.0 kg). 
 
5.3. Pharmacokinetic profiles and non-compartmental analysis 
Most of the blood samples in both studies were collected at the scheduled times. A 
time window of 10 minutes was allowed for each sample. In a few cases, it was not 
possible to obtain some of the samples at the scheduled times, due to intervening 
clinical events. The dosing and blood sampling times were accurately recorded and 
documented for each subject.  
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5.3.1. Study 1: Pharmacokinetic data  
A mean pharmacokinetic profile for PAS during administration of GSR-PAS at a dose 
of 4 g twice-daily was generated for each occasion to visually examine any 
differences between the two study days (occasions). Figure 16 depicts the 
pharmacokinetic profiles at the two occasions. Mean concentrations were higher at 
the first than at the second occasion. 
 
The individual pharmacokinetic results are available in Appendix J. The summary 
statistics of the pharmacokinetic parameters obtained after administration of 4 g 
GSR-PAS twice-daily at the two different occasions are presented in Table 12. The 
Wilcoxon matched pairs test was used to assess whether the parameters were 
significantly different between the two occasions (p<0.05). 
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Figure 16 Mean (standard deviation) plasma PAS concentration in subjects 
receiving 4 g twice-daily GSR-PAS dose on occasion 1 and occasion 2 
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Table 12 Summary statistics for the pharmacokinetic parameters of GSR-PAS (4 g twice-
daily, steady state conditions) at both occasions 
PK Parameter 
Occasion 1 
(N=38) 
Occasion 2 
 (N=38) 
P-value* 
Cmax (μg/ml)    
Mean  51.97  45.20  0.141 
SD 25.21 22.37  
CV% 49 49  
Range 13.35-119.00 11.25-119.00  
Median 44.63 40.20  
    
tmax (h)    
Mean  4.70 4.63 - 
SD 2.20 2.16  
CV% 49 47  
Range 0.00-8.00 0.00-8.00  
Median 5.00 4.02  
    
Cmin (μg/ml)    
Mean  14.82  10.29 0.078 
SD 14.80 12.38  
CV% 100 120  
Range 0.23-57.80 0.21-57.80  
Median 8.77 7.61  
    
C0 (μg/ml)    
Mean  20. 27  14.60  0.027 
SD 16.00 13.94  
CV% 79 95  
Range 1.19-57.80 0.21-57.80  
Median 20.10 11.25  
    
tmin (h)    
Mean  3.37 2.95 - 
SD 4.47 3.62  
CV% 133 123  
Range 0.00-12.00 0.00-12.00  
Median 1.50 2.00  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation
Stellenbosch University http://scholar.sun.ac.za
R e s u l t s  | 64 
 
 
Table 12 Summary statistics for the pharmacokinetic parameters of GSR-PAS (4 g twice-
daily, steady state conditions) at both occasions (continued) 
PK Parameter 
Occasion 1 
(N=38) 
Occasion 2 
 (N=38) 
P-value* 
AUClast    
Mean  305.48 242.41 0.028 
SD 181.56 147.26  
CV% 59 61  
Range 56.38-852.06 42.09-726.80  
Median 289.65 205.20  
 
Clast    
Mean 31.73  25.12  0.180 
SD 24.08 19.80  
CV% 76 79  
Range 1.80- 91.50 1.03-89.30  
Median 27.48 20.38  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation  
 
 
The mean maximum concentrations (Cmax) at the first and second occasion were 
51.97 μg/ml (median: 44.63 μg/ml) and 45.20 μg/ml (median: 40.20 μg/ml, 
respectively. The mean minimum concentration was 14.82 μg/ml (median: 8.77 μg/ml) 
at the first occasion and 10.29 μg/ml (median 7.61 μg/ml) at the second occasion.  
 
In two subjects the minimum concentrations were less than the MIC of 1 μg/ml at 
occasion 1 and were detected at 3 and 4 hours, respectively. In contrast to occasion 
1, minimum concentrations were below the MIC in eight subjects at occasion 2. 
Minimum concentrations were recorded at time zero in seven of the eight subjects. 
 
The mean concentration at time zero (p> 0.027) and the area under the curve from 
zero to the last concentration, was significantly (p> 0.028) higher at the first than at 
the second occasion. There was no significant difference between the first and 
second occasion for the maximum and minimum concentrations.  
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5.3.2. Study 2: Pharmacokinetic data 
The means of both pharmacokinetic profiles (4 g twice-daily and 8 g once-daily at 
steady state conditions) are presented in Figure 17. The twenty-four hour level of the 
profiles is connected with dashed lines, since no blood samples were obtained during 
the night. As expected, the 8 g once-daily regimen produced a much higher peak 
concentration than the 4 g twice-daily regimen. The peak concentration occurred 
later in the once-daily regimen.  
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Figure 17 Mean (standard deviation) plasma PAS concentration in subjects receiving 8 g 
once-daily or 4 g twice-daily GSR-PAS dose 
 
 
The individual parameters are available in Appendix K. Table 13 summarises the 
statistics for the pharmacokinetic parameters of both dosing regimens.  
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Once-daily regimen 
The Cmax and Cmin were 86.88 μg/ml (median: 80.00 μg/ml) and 3.42 μg/ml (median: 
0.93 μg/ml), respectively. The mean area under the curve to twelve hours (AUC12) 
was 665.55 μg.h/ml (median: 651.95 μg.h/ml). The estimated (oral) clearance and 
volume of distribution were 8.85 L/h (median: 7.53 L/h) and 35.32 L (median: 29.70 
L), respectively. 
 
The plasma concentrations of all subjects were maintained above the MIC of PAS (1 
μg/ml) from dosing to the twelve hour sample. The mean concentration at twelve (C12) 
hours was 56.63 μg/ml (median: 59.30 μg/ml).  
 
PAS concentrations were detected in the 24 hour samples of all subjects, except one. 
PAS plasma concentrations at 24 hour were above the MIC (range: 1.28-53.6 μg/ml) 
in eighteen subjects (62.1%). The mean concentrations at time zero (C0) and at 24 
hours (C24) (both pre-dose) were 4.39 μg/ml (median: 0.98 μg/ml) and 6.71 μg/ml 
(median: 1.36 μg/ml). The mean half-life of PAS was estimated to be 2.91 hours 
(median: 2.56 hours).  
 
Twice-daily regimen  
The mean Cmax and Cmin were 58.19 μg/ml (median: 60.70 μg/ml) and 19.66 μg/ml 
(median: 18.90 μg/ml), respectively. The mean AUC12 was 470.75 μg.h/ml (median: 
428.27 μg.h/ml). The estimated (oral) clearance and volume of distribution were 
10.96 L/h (median: 9.34 L/h) and 45.20 L (median: 37.71 L), respectively. 
 
PAS concentrations were maintained above the MIC (1 µg/ml) throughout the twice-
daily dosing interval. The mean C0 and C12 (both pre-dose) were 32.73 μg/ml (median: 
27.80 μg/ml) and 24.10 μg/ml (median: 21.40 μg/ml). The mean half-life of PAS was 
6.80 hours (median: 3.85 hours) 
 
Wilcoxon rank sum test was used to assess whether the parameters of the two 
regimens were significantly different (p<0.05). The mean C12, Cmax, AUC12 and the 
tmax were significantly higher in the once-daily regimen (p<0.0001, p<0.0004, p< 
0.009 and 0.004, respectively). In contrast, the mean Cmin, C0 and C24 were 
significantly higher for the twice-daily regimen (p<0.0001 for all three mean 
concentrations). There was no significant difference for the tmin, CLss/F and t½. 
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Table 13 Summary statistics for the pharmacokinetic parameters of GSR-PAS after steady 
state administration in 4 g twice-daily versus 8 g once-daily regimens 
 Dosing Regimens of GSR- PAS 
PK Parameter 
4 g twice-daily  
(N=29) 
8 g once-daily  
 (N=29) 
P-value* 
Cmax (μg/ml)    
Mean  
SD 
58.19 
24.58 
86.88  
29.12 
0.0004 
 
CV% 42 34  
Range 9.92-112.00 20.70-135.00  
Median 60.70 80.00  
 
tmax (h) 
   
Mean 
SD 
5.14  
3.52 
7.38 
2.97 
0.004 
 
CV% 68 40  
Range 0.00-12.00 3.00-12.05  
Median 4.03 8.00  
 
Cmin (μg/ml) 
   
Mean  
SD 
19.66  
16.02 
3.42 
6.86 
<0.0001 
 
CV% 82 201  
Range 0.80-63.20 0.00-28.60  
Median 18.90 0.93  
    
tmin (h)    
Mean  
SD 
7.89  
5.00 
6.97  
10.78 
0.709 
 
CV% 63 155  
Range 0.00-12.07 0.00-24.00  
Median 11.95 0.00  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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Table 13 Summary statistics for the pharmacokinetic parameters of GSR-PAS after steady 
state administration in 4 g twice-daily versus 8 g once-daily regimens (continued) 
 Dosing Regimens of GSR- PAS 
PK Parameter 
4 g twice-daily 
(N=29) 
8 g once-daily 
(N=29) 
P-value* 
C0 (μg/ml)    
Mean 32.73 4.39  <0.0001 
SD 25.30 7.73  
CV% 77 176  
Range 1.46-105.00 0.00-28.60  
Median 27.80 0.98  
    
C12 (μg/ml)    
Mean 24.10  56.63 <0.0001 
SD 18.02 27.67  
CV% 75 49  
Range 1.73-63.20 20.60-121.00  
Median 21.40 59.30  
    
C24 (μg/ml)    
Mean  29.71 6.71 <0.0001 
SD 20.36 12.87  
CV% 69 192  
Range 2.36-81.90 0.03-53.60  
Median 22.40 1.36  
    
AUC12 (μg.h/ml)    
Mean  470.75 665.55 0.009 
SD 232.47 268.81  
CV% 49 40  
Range 119.30-1022.49 161.09-1055.37  
Median 428.27 651.95  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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Table 13 Summary statistics for the pharmacokinetic parameters of GSR-PAS after steady 
state administration in 4 g twice-daily versus 8 g once-daily regimens (continued) 
 Dosing Regimens of GSR- PAS 
PK Parameter 
4 g twice-daily 
(N=29) 
8 g once-daily 
(N=29) 
P-value* 
t½ (h)    
Mean  6.80 2.91 0.058 
SD 10.43 1.34  
CV% 153* 46  
Range 1.36-47.06 1.42-6.77  
Median 3.85 2.56  
 
CLss/F (L/h) 
   
Mean 10.96  8.85  0.120 
SD 6.65 3.95  
CV% 61 45  
Range 3.91-33.53 4.23-19.39  
Median 9.34 7.53  
 
Vz/F (L) 
   
Mean 45.20  35.32  0.026 
SD 25.78 21.68  
CV% 57 61  
Range 19.47-119.71 11.61-112.72  
Median 37.71 29.70  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
 
 
5.3.3. Study 2: Pharmacokinetic data of subjects prescribed ART  
The nine HIV positive subjects were prescribed ART. The mean age of the HIV 
positive subjects was 35 years (median: 34 years) and the mean weight was 54.3 kg 
(median: 50.5 kg). The mean age and weight of the HIV negative subjects were 35.9 
years (median: 33.5 years) and 56.2 kg (median: 57.5 kg), respectively. 
Mean pharmacokinetic profiles were generated for both the HIV positive and negative 
subjects receiving the different regimens. Figure 18 depicts mean pharmacokinetic 
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profiles of the HIV positive and negative subjects’ on the twice-daily regimen and 
Figure 19 shows the once-daily regimen.  
The summary statistics of the pharmacokinetic parameters for the HIV positive and 
HIV negative subjects (4 g twice-daily and 8 g once-daily GSR-PAS doses at steady 
state conditions) are presented in Table 14. Since none of these parameters were 
normally distributed, the Wilcoxon rank sum test was used to assess whether the PK 
parameters for HIV positive and HIV negative subjects (p<0.05) were significantly 
different. 
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Figure 18 Mean (standard deviation) plasma PAS concentration in HIV positive and 
negative subjects receiving 4 g twice-daily GSR-PAS dose  
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Figure 19 Mean (standard deviation) plasma PAS concentration in HIV positive and negative 
subjects receiving 8 g once-daily GSR-PAS dose 
 
 
In both regimens PAS concentrations were remarkably lower for the HIV positive 
subjects. For the once-daily regimen, the mean AUC12 of the HIV negative subjects 
(mean: 727.26 µg/ml) was significantly (p-value: 0.043) larger than the HIV positive 
subjects (mean: 528.42 µg/ml). The significant higher mean AUC12 was only seen 
with once-daily dosing and not with twice-daily dosing.  
The mean Cmax of the HIV positive and negative subjects for the once-daily regimen 
was 72.56 µg/ml (median: 73.40 µg/ml) and 93.33 µg/ml (median: 98.40 µg/ml); and 
for the twice-daily regimen it was 49.64 µg/ml (median: 39.70 µg/ml) and 62.04 µg/ml 
(median: 61.80 µg/ml), respectively. There was a large variation of PAS plasma 
concentration at time zero and twenty four hours for both regimens. Only three of the 
nine (33.3%) HIV positive subjects’ PAS concentrations were maintained above the 
MIC throughout the once-daily dosing interval, while all but one subject’s minimum 
concentration (8 of 9, 89%) were above the MIC during the twice-daily dosing 
interval. Nine of the twenty (45%) HIV negative subjects’ minimum concentrations 
were above the MIC for the once-daily dosing interval, while all minimum 
concentrations were above the MIC during the twice-daily dosing interval.  
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Table 14 Summary statistics for the pharmacokinetic parameters of GSR-PAS in HIV positive and 
negative subjects (after steady state administration in 4 g twice-daily versus 8 g once-daily 
regimens) 
 Dosing Regimens of GSR- PAS 
 4 g twice-daily  8 g once-daily  
PK 
Parameter 
HIV Pos 
(n=9) 
HIV Neg 
 (n=20) 
P-
value* 
HIV Pos 
(n=9) 
HIV Neg 
(n=20) 
P-
value* 
Cmax (μg/ml)       
Mean 49.64  62.04 0.144 72.56 93.33  0.081 
SD 31.35 20.53  18.55 31.04  
CV% 64 33  26 33  
Range 9.92-105.00 27.60-112.00  47.80-111 20.70-135.00  
Median 39.70 61.80  73.40 98.40  
       
tmax (h)       
Mean 5.56 4.95 - 8.00 7.11 - 
SD 4.51 3.09  2.65 3.13  
CV% 81 62  33 44  
Range 0.00-12.00 0.00-11.98  0.25-28.60 3.00-12.05  
Median 6.00 4.02  0.77 8.00  
       
tmin (h)       
Mean 7.32 8.14  5.79 7.50 - 
SD 5.09 5.08  10.41 11.16  
CV%  69 62  180 149  
Range 0.00-12.00 0.00-12.07  0.00-24.00 0.00-24.00  
Median 7.97 11.95  0.00 0.00  
       
C0 (μg/ml)       
Mean 28.75 34.52 0.258 4.37 4.40 0.777 
SD 31.01 22.97  9.25 7.22  
CV% 108 67  211 164  
Range 1.46-105 3.79-100.00  0.33-28.60 0.00-21.30  
Median 19.80 32.00  0.77 1.15  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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Table 14 Summary statistics for the pharmacokinetic parameters of GSR-PAS in HIV positive and 
negative subjects (after steady state administration in 4 g twice-daily versus 8 g once-daily 
regimens) (continued) 
 Dosing Regimens of GSR- PAS 
 4 g twice-daily  8 g once-daily  
PK 
Parameter 
HIV Pos 
(n=9) 
HIV Ned 
(n=20) 
P-
value* 
HIV Pos 
(n=9) 
HIV Neg 
(n=20) 
P-
value* 
Cmin (μg/ml)       
Mean 16.87  20.9  0.239 4.06  3.10 0.888 
SD 18.73 15.0  9.25 5.80  
CV% 111 72  228 184  
Range 0.8-63.2 1.73-51.2  0.25-28.60 0.00-21.30  
Median 13.20 21.95  0.77 0.94  
       
C12 (μg/ml)       
Mean 21.73 25.17 0.850 43.28 62.65 0.099 
SD 17.05 18.77  19.73 29.02  
CV% 78 75  46 46  
Range 8.75-63.2 1.73-62.80  20.90-7.60 20.6-121.00  
Median 15.40 21.95  44.10 62.10  
C24 (μg/ml) 
     
Mean 22.15  33.11 0.090 8.59 5.86  0.925 
SD 19.25 20.38  17.69 10.48  
CV% 87 62  206 179  
Range 5.76-67.00 2.36-81.90  0.25-53.60 0.03-41.70  
Median 16.10 32.25  1.36 1.35  
       
AUC12 (μg.h/ml)      
Mean 410.35 500.96  0.205 528.42 727.25 0.043 
SD 292.20 201.97  208.16 274.46  
CV% 71 40  39 38  
Range 
119.30-
1022.49 
197.73-
934.09 
 252.31-888.22 
161.09-
1055.37 
 
Median 327.74 500.06  576.05 804.76  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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Table 14 Summary statistics for the pharmacokinetic parameters of GSR-PAS in HIV positive and 
negative subjects (after steady state administration in 4 g twice-daily versus 8 g once-daily 
regimens) (continued) 
 Dosing Regimens of GSR- PAS 
 4 g twice-daily 8 g once-daily 
PK 
Parameter 
HIV Pos 
(n=9) 
HIV Neg 
(n=20) 
P-
value* 
HIV Pos 
(n=9) 
HIV Neg 
(n=20) 
P-
value* 
AUC24 (μg.h/ml)      
Mean  647.99 592.95  0.930 859.10  1140.77  0.140 
SD 495.15 331.28  321.29 406.93  
CV% 76 56  37 36  
Range 256.34-
1627.17 
229.70-
1370.86 
 412.52-
1357.25 
533.79-
1892.72 
 
Median 492.66 541.35  889.57 1215.96  
 
t½ (h) 
      
Mean  13.14  3.87 0.161 2.62  3.03  0.764 
SD 17.41 2.76  0.89 1.50  
CV% 133 71  34 50  
Range 3.04-47.06 1.36-11.54  1.85-4.38 1.42-6.77  
Median 4.43 3.51  2.56 2.55  
       
CLss/F (L/h)       
Mean  14.12 9.37 0.2047 10.90  8.04 0.140 
SD 9.58 4.19  5.11 3.18  
CV% 68 45  47 40  
Range 3.91-33.53 4.28-20.23  5.89-19.36 4.23-14.99  
Median 12.20 8.00  9.00 6.58  
       
Vz/F (L)       
Mean 62.98  37.00  0.028 45.83  30.72  0.285 
SD 30.94 19.16  32.05 14.28  
CV% 49 52  70 46  
Range 35.13-119.71 19.47-94.88  19.74-112.72 11.61-58.59  
Median 58.67 36.74  34.07 29.67  
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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5.4. Genetic data 
Genetic analysis was performed in sixty one subjects. NAT1 variants were analysed 
in the first study, while both NAT1 and NAT2 were successfully determined in the 
second study. The individual genetic results of study 1 and 2 are presented in 
Appendix L and M.  
Since various genotypes were identified in a low sample size for genetics, the results 
of the two studies were combined. Table 15 summarises the NAT1 genotype 
distribution of all the subjects, including separation by their ethnic groups. Table 16 
summarises the NAT2 genotype distribution in study 2 and also includes the ethnic 
group separation.  
Sixteen subjects (26%) have the NAT 1*4/1*4 genotype, also known as the wild-type. 
The predominant alleles (haplotypes) were NAT1*4 and NAT1*10. The other alleles 
identified, were NAT1*4A, NAT1*27 and NAT1*3.  
One subject had a variation at nucleotide position 1088 and was a homozygote for 
this variation. Since this variation was not defined/ described in the NAT1 allele 
database, it was not classified. The functional type of NAT1*10, NAT1*3 and 
NAT1*4A is classified as unknown (according to the summary of Louisville medical 
school. 
Seven subjects (22%) of study 2 were identified to be wild-type or fast acetylators of 
NAT2, while eleven subjects (34%) were slow acetylators. Most of the coloured 
subjects had the intermediate genotype.  
To determine if the genetic variants had an effect on the concentrations of PAS, the 
results were analysed using pharmacometric methods described in the population PK 
section. 
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Table 15 NAT1 genotype distribution in all the subjects and separated by their ethnic groups 
Genotypes 
(haplotypes) 
Genotype distributions  
All subjects 
(n=61) 
Coloured subjects 
(n=48) 
Black subjects 
(n=13) 
 1*4/1*4 16 (26%) 13 (27%) 3 (23%) 
 1*10/1*10 10 (16%) 8 (17%) 2 (15%) 
 1*3/1*10 1 (2%) 1 (2%) 0 (0%) 
 1*3/1*3 1 (2%) 1 (2%) 0 (0%) 
 1*4/1*10 27 (44%) 19 (40%) 8 (62%) 
 1*4/1*27 2 (3%) 2 (4%) 0 (0%) 
 1*4/1*14A 2 (3%) 2 (4%) 0 (0%) 
 1*4/1*3 1 (2%) 1 (2%) 0 (0%) 
1088AA homozygote 1 (2%) 1 (2%) 0 (0%) 
 
 
 
 
Table 16 NAT2 genotype distribution in study 2 in all subjects and separated by their ethnic 
groups 
Genotypes 
(haplotypes) 
Genotype distributions  
All subjects  
(n= 32) 
Coloured subjects 
(n=27) 
Black subjects 
(n=5) 
 F/F (Fast) 7 (22%) 7 (26%) 0 (0%) 
 F/S (intermediate) 14 (44%) 12 (44%)  
2 (40%) 
 S/S (Slow) 11 (34%) 8 (30%) 
3 (60%) 
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5.5. Population Pharmacokinetics 
5.5.1. Excluded and Missing Data 
The available data of both studies were used, including the six subjects that were not 
included in the occasions and regimen comparisons described above. Therefore, 
forty-one subjects (n=41) from study 1 and thirty two subjects (n=32) from study 2 
were used in the modelling and simulation analysis.  
Exclusion criteria for data from the analysis were mainly for samples reported below 
the lower limit of quantification.  
 
5.5.2. Base Model 
A one-compartment open model with first-order absorption was fitted to the steady-
state concentration-time data of individuals administered 8 g once-daily or 4 g twice-
daily GSR-PAS. The structural pharmacokinetic model for the one-compartment 
model was parameterized on oral clearance (CL), volume of the central compartment 
(V), absorption rate constant (Ka), lag time (Tlag) and oral bioavailability (F) which was 
fixed at 1. The first twice-daily PAS profile from study 1 was designated as occasion 
1, and the second twice-daily profile as occasion 2. The twice-daily PAS profile 
obtained in study 2 was set as occasion 3 and the once-daily profile as occasion 4. 
   represents the approximate coefficient of variation for the interindividual variability 
and    is the approximate coefficient of variation for the interoccasion (intraindividual) 
variability within an individual. A combined proportional and additive residual error 
model was used. The pharmacokinetic estimates for each individual were 
subsequently obtained using Bayesian estimation. The final model parameters are 
shown in Table 17. 
The population mean for the volume of distribution (V) was approximately 66.6 L and 
clearance (CL) was 12.4 L/h. The absorption rate constant was 0.247 h-1 and the 
corresponding lag time was 1.55 h. The interindividual variability for both V and CL 
was approximately 40%. Interoccasion variability of the CL parameter was 
approximately 37%. The allometric exponent for the correlation between clearance 
and body weight was 0.321. 
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The model diagnostics are shown in Figure 20. There was a good agreement 
between model predictions and observations of PAS concentrations. The plots of the 
observed (OBS) concentrations vs. the model predicted (PRED) concentrations and 
OBS vs. individual predicted (IPRED) concentrations are shown in the top panel of 
Figure 20. The body weighted residuals (WRES) vs. time and WRES vs. PRED plots 
at the bottom panel of Figure 20 show that most of the data lie within 2 units from the 
zero-ordinate. Model stability was evaluated on the basis of 500 bootstrap replicates 
presented in Table 17. The 2.5th and 97.5th percentiles of the parameter estimates of 
the final model based on the bootstrap algorithm encompassed the mean population 
parameter estimates of the final model; the mean values were close to the bootstrap 
medians.  
 
 
Figure 20 Goodness-of-fit plots for the final GSR-PAS population pharmacokinetic model  
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Table 17: Population pharmacokinetic model parameters of the final model given no covariate 
relationship except for weight 
 Final Model  Bootstrap 
Parameter Mean 
Standard 
error 
 Median 
2.5
th
 – 97.5
th
 
Percentiles 
Structural model parameters      
Clearance (CL), L/h 12.4 1.14  12.8 10.9, 14.9 
Volume of central compartment (V), L 66.6 9.61  65.2 43.4, 89.5 
Absorption rate constant (Ka), h
-1
 0.247 0.041  0.240 0.171, 0.348 
Lag time (Tlag), h 1.55 0.07  1.56 1.43, 1.70 
 
Interindividual variability 
     
%CV of CL (ωCL) 38.3 4.8  36.9 26.5, 45.8 
%CV of V (ωV) 40.8 9.3  40.6 20.9, 71.2 
%CV of Ka (ωKa) 72.6 17.2  70.5 16.7, 104 
 
Interoccasion variability 
     
%CV of CL ( CL) 37.1 5.2  37.0 27.5, 48.4 
 
Residual variability 
     
Proportional residual error 0.294 0.078  0.300 0.16, 0.40 
Additive residual error, IU/dL 8.53 2.03  8.30 5.09, 11.8 
 
Covariates 
     
Allometric exponent for CL by 
weight
†
 
0.321 0.343  0.410 0.051, 1.01 
OFV 7834.83   7816.38 7462, 8165 
†
The covariate equations for CL and V by weight (BW) were:     ̃  (
  
     
)
  
. i for V is fixed 
to 1 
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5.5.3. Model Validation 
Prior to developing the visual predictive check, the distribution of the drug in the body 
was simulated assuming normal distribution with a mean value of 56 kg and 11 kg 
standard deviation, which were the distribution parameters of the body weights of the 
original subject population. The degenerate visual predictive check results are shown 
in Figures 21 and 22 for GSR-PAS. The results were generated from 1000 
simulations. The 95% prediction interval of the simulated results contained the 
individual concentration-time profiles by occasion relative to the time of their steady 
state dose. The simulated profiles were able to capture the majority of the observed 
data, supporting the validity of the model. These findings indicated that the 
population estimates in the final model were accurate and stable. 
 
The degenerate visual predictive check (Figure 21 and 22) show the median line in 
red; the observed drug concentration in black solid circles; and the 95% prediction 
interval in grey shade of the 1000 simulated profiles for subjects taking GSR-PAS. 
The top panels are for data in the linear scales and the lower panels are for data in 
semi-log scales. 
 
The profiles of occasion 1 and 2 are almost identical in the visual predictive check 
(Figure 21); however the 95% prediction interval (grey shade) is different given that 
the peak at occasion 2 is lower (flatter) than at occasion 1. 
 
In Figure 22, occasion 4 (once-daily regimen of study 2) has a higher peak than 
occasion 3 (twice-daily regimen of study 2). These results are similar to the results 
found in the classical statistical analysis previously presented. The semi-log of the 
prediction interval for occasion 4 falls below the MIC of 1 µg/ml.  
 
The simulated datasets were used to summarise the mean, median and 5th and 95th 
percentiles of the exposure parameters in Table 18. The parameters were 
determined by a non-compartmental method.  
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Figure 21 Degenerate visual predictive check results of occasion 1 and 2 (study 1) with 
weight as a covariate 
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Figure 22 Degenerate visual predictive check results of occasion 3 and 4 (study 2) with 
weight as a covariate 
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Table 18 Summary statistics for the pharmacokinetic parameters of GSR-PAS after steady 
state administration in 4 g twice-daily versus 8 g once-daily regimens in the simulated profiles 
consisting of 1000 subjects 
  Dosing Regimens of GSR- PAS 
PK 
Parameter 
Statistics 4 g twice-daily 
occasion 1/3 
(N=70) 
4 g twice-daily 
occasion 2 
 (N=39) 
8 g once-daily 
occasion 4 
 (N=32) 
Cmax 
(μg/ml) 
Mean  
Median 
44.8 
40.0 
44.0  
39.6 
67.7 
59.8 
 5
th
, 95
th
 percentile 19.0, 88.6 19.7, 82.0 29.3, 128.1 
 
Tmax 
(h) 
 
Mean  
Median 
 
4.9 
4 
 
4.93  
6 
 
5.74  
6 
 5
th
, 95
th
 percentile 3, 6 3, 6 3, 8 
 
Cmin 
(μg/ml) 
 
Mean  
Median 
 
22.0  
17.3 
 
21.8  
17.7 
 
9.8  
5.1 
 5
th
, 95
th
 percentile 2.2, 56.6 2.2, 57.1 0.04, 35.6 
 
C12 
(μg/ml) 
 
Mean 
Median 
 
24.9 
20.5 
 
24.0 
20.2 
 
35.6 
30.3 
 5
th
, 95
th
 percentile 3.73, 62.0 2.8, 61.6 6.1, 81.2 
 
C24 
(μg/ml) 
 
Mean 
Median 
 
NA  
NA 
 
NA  
NA 
 
10.7  
5.9 
 5
th
, 95
th
 percentile NA NA 0.06, 37.7 
 
AUC12 
(μg.h/ml) 
 
Mean 
Median 
 
407.4 
350.8 
 
401.7 
349.6 
 
NA  
NA 
 5
th
, 95
th
 percentile 149.7, 845.1 149.9, 846.2 NA 
 
AUC24 
(μg.h/ml) 
 
Mean  
Median 
 
NA  
NA 
 
NA  
NA 
 
788.8 
682.8 
 5
th
, 95
th
 percentile NA NA 295.2, 1679.2 
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5.5.4. Drug-drug interactions 
A relationship between CYP2B6 substrate and PAS was found during screening for 
covariates. Efavirenz (EFV) was categorised as the substrate for CYP2B6. EFV 
increased the clearance of PAS by 45% in subjects using this concomitant drug.  
 
The exponential coefficient for the effect of EFV on PAS CL was 0.37, which 
translates to 1.45 in the linear scale (Table 19). The increase in clearance is reflected 
in the generally lower drug concentrations of PAS in subjects who were prescribed 
EFV, represented by the filled red circles shown in Figures 23 and 24. The 
degenerate visual predictive check shows the median line in red; the observed drug 
concentration in black solid circles; and the 95% prediction interval in grey shade of 
1000 simulated profiles for subjects taking GSR-PAS. The top panels are for data in 
the linear scales and the lower panels are for data in semi-log scales. 
 
Using the simulated datasets, the mean, median and 5th and 95th percentiles of the 
exposure parameters are summarised in Table 20 and 21. Table 20 summarises the 
parameters of the subjects without concomitant EFV administration and Table 21 
those with the concomitant EFV. The parameters were determined by the non-
compartmental method. The exposure parameters of PAS without EFV were within 
the ballpark of those in the pooled dataset in Table 18. With EFV concomitant drugs, 
the PAS exposure, based on the simulated data, were lower than those without EFV. 
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Table 19 Population pharmacokinetic model parameters of the final model evaluating drug-
drug interaction 
 Final Model  Bootstrap 
Parameter Mean 
Standar
d error 
 Median 
2.5
th
 – 97.5
th
 
Percentiles 
Structural model parameters      
Clearance (CL), L/h 11.5 1.07  11.6 9.86, 14.03 
Volume of central compartment (V), L 39.5 5.81  40.01 29.42, 57.02 
Absorption rate constant (Ka), h
-1
 0.158 0.0118  0.159 0.136, 0.202 
Lag time (Tlag), h 1.60 0.0604  1.60 1.49, 1.71 
Interindividual variability      
%CV of CL (ωCL) 35.78 18.33  34.65 25.3, 43.5 
%CV of V (ωV) 66.03 49.90  85.67 39.5, 116.6 
%CV of Ka (ωKa) 17.78 19.24  19.73 10.7, 42.4 
Interoccasion variability      
%CV of CL ( CL) 36.19 18.81  35.69 26.4, 46.38 
Residual variability      
Proportional residual error 0.242 0.05  0.25 0.144, 0.375 
Additive residual error, IU/dL 9.89 1.25  9.62 6.12, 12.08 
Covariates      
Allometric exponent for CL by weight
†
 0.427 0.273  0.50 0.071, 1.02 
CYP2B6 substrate (efavirenz) on CL
‡
 0.37 131  0.347 0.12, 0.625 
OFV 7819.40   7820.18 7495, 8149 
†
The covariate equations for CL and V by weight (BW) were:    ̃  (
  
     
)
  
.i for V is fixed 
to 1 
‡
The covariate equation to describe the effect of efavirenz, a CYP2B6 substrate, on CL: 
    ̃               . 
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Figure 23 Degenerate visual predictive check results of occasion 1 and 2 (study 1) with 
weight and EFV drug-interaction as covariates 
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Figure 24 Degenerate visual predictive check results of occasion 3 and 4 (study 2) with 
weight and EFV drug-interaction as covariates 
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Table 20 Summary statistics for the pharmacokinetic parameters of GSR-PAS after steady state 
administration in 4 g twice-daily versus 8 g once-daily regimens in the simulated profiles 
consisting of 1000 subjects without concomitant efavirenz administration. 
  Dosing Regimens of GSR- PAS 
PK 
Parameter 
Statistics 
4 g twice-daily 
occasion 1/3 
(N=70) 
4 g twice-daily 
occasion 2 
 (N=39) 
8 g once-daily 
occasion 4 
 (N=32) 
Cmax 
(μg/ml) 
Mean  
Median 
47.5  
43.9 
45.9 
42.3 
68.1 
62.8 
 5
th
, 95
th
 percentile 20.1, 88.3 20.8, 86.9 31.0, 125.7 
 
Tmax 
(h) 
 
Mean 
Median 
 
5.0 
6 
 
5.0 
6 
 
5.8 
6 
 5
th
, 95
th
 percentile 3, 6 3, 6 3, 8 
 
Cmin 
(μg/ml) 
 
Mean 
Median 
 
24.6  
20.0 
 
23.5  
19.8 
 
10.4  
6.4 
 5
th
, 95
th
 percentile 6.5, 56.7 6.5, 53.0 1.2, 35.1 
 
C12 
(μg/ml) 
 
Mean 
Median 
 
27.2  
22.3 
 
24.0  
20.2 
 
40.1  
34.1 
 5
th
, 95
th
 percentile 7.7, 60.5 2.8, 61.6 12.8, 89.7 
 
C24h 
(μg/ml) 
 
Mean 
Median 
 
NA  
NA 
 
NA  
NA 
 
11.5 
 7.2 
 5
th
, 95
th
 percentile NA NA 1.4, 37.3 
 
AUC12 
(μg.h/ml) 
 
Mean 
Median 
 
442.0  
384.7 
 
427.0  
375.7 
 
NA 
NA 
 5
th
, 95
th
 percentile 168.8, 864.1 182.2, 847.3 NA 
 
AUC24 
(μg.h/ml) 
 
Mean 
Median 
 
NA  
NA 
 
NA  
NA 
 
841.6  
738.3 
 5
th
, 95
th
 percentile NA NA 345.7, 1694.7 
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Table 21 Summary statistics for the pharmacokinetic parameters of GSR-PAS after steady state 
administration in 4 g twice-daily versus 8 g once-daily regimens in the simulated profiles 
consisting of 1000 subjects with concomitant efavirenz administration. 
  Dosing Regimens of GSR- PAS 
PK Parameter Statistics 
4 g twice-daily  
occasion 1/3 
(N=70) 
4 g twice-daily 
occasion 2 
 (N=39) 
8 g once-daily 
occasion 4 
 (N=32) 
Cmax 
(μg/ml) 
Mean  
Median 
35.1 
31.4 
35.3  
30.7 
54.4  
47.5 
 5
th
, 95
th
 percentile 14.5, 70.4 14.8, 69.8 21.5, 109.6 
 
Tmax 
(h) 
 
Mean 
Median 
 
4.6  
4 
 
4.8 
4 
 
5.3  
6 
 5
th
 , 95
th
 percentile 3, 6 3, 6 3, 8 
 
Cmin 
(μg/ml) 
 
Mean  
Median 
 
16.1  
12.4 
 
16.5  
13.1 
 
6.0 
3.4 
 5
th
, 95
th
 percentile 3.7, 39.8 3.9, 43.0 0.74, 20.4 
 
C12 
(μg/ml) 
 
Mean  
Median 
 
18.0  
14.2 
 
18.4  
14.8 
 
26.9  
22.8 
 5
th
, 95
th
 percentile 4.5, 43.5 4.6, 46.7 8.6, 58.1 
 
C24 
(μg/ml) 
 
Mean 
Median 
 
NA  
NA 
 
NA  
NA 
 
6.7  
4.0 
 5
th
, 95
th
 percentile NA NA 0.89, 21.9 
 
AUC12 
(μg.h/ml) 
 
Mean  
Median 
 
311.3  
266.6 
 
316.4  
267.3 
 
NA  
NA 
 5
th
, 95
th
 percentile 137.3, 1004.5 138.7, 1067.8 NA 
 
AUC24 
(μg.h/ml) 
 
Mean  
Median 
 
NA  
NA 
 
NA  
NA 
 
602.6 
520.4 
 5
th
, 95
th
 percentile NA NA 244.1, 1165.9 
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5.5.5. Effect of NAT1 and NAT2 polymorphisms 
The influence of NAT1 and NAT2 gene variants on the disposition of PAS was 
initially inspected by plotting the time-concentration profiles of each genotype against 
other genotypes combined, as shown in Figures 25 - 27 and 29. These graphs were 
generated to depict if there are any associations between the concentrations and the 
different genotypes. The specific genotype is shown in red and the rest in black. 
There is a wide variation in the concentrations of the specific genotypes. The 
concentrations of the single 8 g dose were also plotted with the concentrations of the 
4 g dose. Therefore, in order to separate the two different doses, the mean PAS 
pharmacokinetic profiles of the different NAT1 genotypes for the 4 g were generated 
and depicted in Figure 28. Since only three subjects had the respective NAT1*3/1*3, 
NAT1*3/1*10 and NAT1*4/1*3 genotypes, these genotypes were not included in the 
graph. 
 
The NAT1*4/1*4 is the wild type and is considered as a fast acetylator. In theory the 
individuals with this genotype will have lower PAS plasma concentrations due to an 
increase in acetylating activity. The mean PAS plasma concentrations of the 
NAT1*4/1*4 are lower than the other genotypes (Figure 28); however this difference 
is only small. Two subjects had the NAT1*4/1*14A genotype and their mean PAS 
plasma concentrations were higher than the other genotypes. Although the 
concentrations of the NAT1*4/1*14A are higher, the sample size (two subjects) are 
too small to find any significance. The NAT1*10/1*10, NAT1*4/1*10, NAT1*4/1*4 and 
NAT1*4/1*27 had low concentrations. 
 
The individuals with the NAT1*4/1*4 genotype were designated as the baseline, the 
reference genotype to which the other genotypes were compared. No significance 
was found between the concentrations of the different genotypes (possibly due to 
small sample size), therefore to increase the size of the comparison, individuals with 
NAT1*4/1*10, NAT1*4/1*14A and NAT1*10/1*10 genotypes were grouped together, 
as a comparator to the wild-type. Due to their small sample size, the following 
genotypes were grouped with the wild-type group: NAT1*4/1*27, NAT1*3/1*3, 
NAT1*4/1*3 and NAT1*3/1*10. For the individuals whose NAT1 genotype was not 
determined, the patterns were similar to that for NAT1*4/1*4 and therefore were also 
grouped with the wild-type.  
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Dummy variable were introduced to the NAT1 categories. The wild-type group were 
designated as 0 whereas the group consisting of NAT1*4/1*10, NAT1*4/1*14A and 
NAT1*10/1*10 genotypes were designated as 1. The effect of the second group on 
PAS clearance was quantified as a decrease of approximately 20%, compared to the 
wild-type (Table 22).  
 
 
Figure 25 Visual diagnostics to inspect the influences of NAT1*4/1*4, NAT1*4/1*10, 
1*4/*14A and NAT1*10/1*10 on the disposition of PAS 
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Figure 26 Visual diagnostics to inspect the influences of NAT1*4/1*27, NAT1*3/1*3, 
NAT1*4/*3 and NAT1*3/1*10 on the disposition of PAS 
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Figure 27 Visual diagnostics to inspect the disposition of 
PAS in individuals who do not have their NAT1 genotype 
identified. 
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Figure 28 Mean PAS concentrations of the different NAT1 
genotypes after administration of 4 g GSR-PAS 
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Table 22 Population pharmacokinetic model parameters of the final model evaluating drug-drug 
interaction and NAT1 genotype influence. 
 Final Model  Bootstrap 
Parameter Mean Standard 
error 
 Median 2.5
th
 – 97.5
th
 
Percentiles 
Structural model parameters      
Clearance (CL) L/h 12.8 1.38  13.1 10.63, 16.63 
Volume of central compartment (V), L 39.5 6.07  40.9 29.26, 62.96 
Absorption rate constant (Ka), h
-1
 0.158 0.0127  0.160 0.140, 0.209 
Lag time (Tlag), h 1.60 0.0605  1.60 1.48, 1.71 
Interindividual variability      
%CV of CL (ωCL) 33.76 18.33  34.65 25.3, 43.5 
%CV of V (ωV) 85.73 49.90  85.67 39.5, 116.6 
%CV of Ka (ωKa) 18.14 19.24  19.73 10.7, 42.4 
Interoccasion variability      
%CV of CL ( CL) 36.47 18.81  35.69 26.4, 46.38 
Residual variability      
Proportional residual error 0.244 0.0516  0.244 0.147, 0.386 
Additive residual error, IU/dL 9.84 1.30  9.56 5.88, 12.22 
Covariates      
Allometric exponent for CL by 
weight
†
 
0.334 0.195  0.382 0.047, 0.935 
CYP2B6 substrate (efavirenz) on CL
‡
 0.323 0.135  0.312 0.026, 0.576 
NAT1 on CL
††
 0.199 0.0905  0.208 -0.022, 0.36 
OFV 7815.318   7798.47 7430, 8143 
†
The covariate equations for CL and V by weight (BW) were:     ̃  (
  
     
)
  
. i for V is fixed to 1 
‡
The covariate equation to describe the effect of efavirenz, a CYP2B6 substrate, on CL:    
 ̃               . 
††
The covariate equation to describe the effect of NAT1 genotype on CL:     ̃            . 
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The NAT2 genotypes and phenotypes could only be determined in subjects from the 
second study. Their influences on PAS disposition are presented graphically in 
Figure 29. 
 
 
Figure 29 Visual diagnostics to inspect the influences of NAT2 phenotypes on the disposition 
of PAS. 
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The NAT2 does not play a major role in PAS metabolism 17. However, several studies 
reported interaction between NAT1 and NAT2 polymorphisms 100. An interaction plot 
was generated to evaluate whether there is a trend that would suggest an interaction. 
In Figure 30, NAT1*4 heterozygous and NAT1*10 heterozygous in the fast-
intermediate NAT2 phenotypes had a relatively slower clearance than in the slow 
NAT2 phenotype. This interaction, however, was not statistically significant, 
suggesting that NAT2 phenotype has no effect on PAS disposition. 
 
 
 
Figure 30 Interaction plot evaluating the trend in NAT1 genotype and NAT2 phenotypes and 
their effect on clearance 
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5.6. Study 2: Tolerability and safety 
Tolerability and safety of the two different treatment regimens were monitored in 
study 2. All subjects completed the VAS forms which specifically recorded 
gastrointestinal adverse reactions. Mean scores of gastrointestinal intolerabilities for 
each day were calculated and summarised in Figures 31-35 and in Table 23.  
 
Abdominal pain and cramps 
According to the VAS scores, eleven subjects did not have any abdominal pains or 
cramps, while nine subjects only experienced such symptoms during the twice-daily 
regimen. Nine subjects reported abdominal pain and cramps during both regimens. 
Five of the nine subjects reported abdominal pain and cramps as worse during the 
once-daily regimen. The other four subjects gave a higher score for abdominal pain 
and cramps during the twice-daily regimen. On average, the VAS scores for 
abdominal pain and cramps were higher during the twice-daily regimen. Figure 31 
illustrates the mean VAS scores for abdominal pain and cramps experienced during 
the study.  
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Figure 31 Comparison of the mean VAS scores for 
abdominal pain and cramps (APC) over 8 days during 8 
g once- and 4 g twice-daily administration of GSR-PAS  
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Nausea 
According to the VAS scales only two subjects did not report nausea during the 
study. Four subjects reported nausea only during the once-daily regimen, six 
subjects during the twice-daily regimen, and seventeen subjects during both 
regimens. Ten of these latter subjects gave a higher score for nausea during the 
once-daily regimen and seven subjects during the twice-daily regimen. Figure 32 
illustrates the mean VAS scores for nausea in the study. Nausea varied on a daily 
base for the twice-daily regimen, while nausea for the once-daily regimen was more 
constant.  
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Figure 32 Comparison of the mean VAS scores for 
nausea over 8 days during 8 g once- and 4 g twice-
daily administration of GSR-PAS  
 
 
 
Vomiting 
According to the VAS scores fifteen of the subjects did not vomit during the study. 
Two subjects vomited during the once-daily regimen, four during the twice-daily 
regimen, and the remaining eight subjects during both regimens. Four of the former 
group experienced more vomiting during the once-daily regimen and three subjects 
during the twice-daily regimen. One subject vomited once during both regimens. On 
average, the VAS scores for vomiting were higher during the twice-daily regimen. 
Figure 33 illustrates the mean VAS scores for vomiting. Vomiting was similar for the 
once- and twice-daily regimens. The mean score on Day 3 for the once-daily regimen 
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was influenced by one subject who had an episode of severe vomiting in the 
morning, which cleared up later. 
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Figure 33 Comparison of the mean VAS scores for 
vomiting over 8 days during 8 g once- and 4 g twice-
daily administration of GSR-PAS  
 
 
 
Diarrhoea 
According to the VAS scores seven subjects did not have any diarrhoea during the 
study. One subject had diarrhoea only during the once-daily regimen, two subjects 
only during the twice-daily regimen and nineteen subjects during both regimens. 
Twelve of these latter subjects had more diarrhoea during the once-daily regimen 
and seven subjects during the twice-daily regimen. Figure 34 illustrates the mean 
VAS scores for diarrhoea during the study. On average, the VAS scores for diarrhoea 
were higher during the once-daily regimen. Diarrhoea was constant for the twice-
daily regimen throughout the 8 days.  
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Figure 34 Comparison of the mean VAS scores for 
diarrhoea over 8 days 8 g once- and 4 g twice-daily 
administration of GSR-PAS  
 
 
Bloatedness  
According to the VAS scores ten subjects did not report the symptom “bloatedness” 
in the study. Five subjects reported this symptom only during the twice-daily regimen, 
two subjects during the once-daily regimen and twelve subjects during both 
regimens. On average, the VAS scores for bloatedness were higher during the twice-
daily regimen. Figure 35 illustrates the mean VAS scores for bloatedness.  
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Figure 35 Comparison of the mean of the VAS scores 
for bloating over 8 days during 8 g once- and 4 g twice-
daily administration of GSR-PAS  
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The VAS scores for each day were analysed for significant differences using the 
Wilcoxon rank sum test. The results are summarised in Table 23.  
 
There were no significant differences between the once-daily and twice-daily regimen 
for tolerability, except for abdominal pain on Day 3 and diarrhoea on Day 1. It cannot 
be excluded that this may be a chance finding due to the high number of statistical 
tests performed. 
 
 
Table 23 Summary of gastrointestinal symptoms (abdominal pain and cramps, nausea) 
for the 8 g once-daily vs. 4 g twice-daily regimens 
Gastrointestinal 
Symptoms 
Once-daily 
Mean; SD 
Twice-daily 
Mean; SD 
p-value 
Abdominal Pain and Cramps 
Day 1 0.3; 1.37 0.68; 1.52 0.327 
Day 2 0.25; 0.93 0.42; 1.27 0.683 
Day 3 0.35; 1.32 0.53; 0.98 0.035 
Day 4 0.12; 0.31 0.83; 2.10 0.187 
Day 5 0.09; 0.31 0.37; 1.06 0.337 
Day 6 0.19; 0.59 0.35; 1.02 0.559 
Day 7 0.19; 0.63 0.36; 1.12 0.280 
Day 8 0.19; 0.61 0.17; 0.66 0.598 
 
Nausea 
Day 1 0.87; 1.95 0.38; 0.90 0.288 
Day 2 0.81; 1.80 1.08; 1.93 0.768 
Day 3 1.25; 2.14 0.43; 0.91 0.085 
Day 4 0.76; 1.69 1.51; 2.58 0.146 
Day 5 0.78; 1.74 0.69; 1.22 0.666 
Day 6 0.52; 0.94 0.83; 1.56 0.493 
Day 7 1.02; 1.88 1.01; 1.98 0.866 
Day 8 0.33; 0.64 0.60; 1.20 0.314 
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
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Table 23 Summary of gastrointestinal symptoms (vomiting, diarrhoea and bloatedness) 
for the 8 g once-daily vs. 4 g twice-daily regimens (continued) 
Gastrointestinal 
Symptoms 
Once-daily 
Mean; SD 
Twice-daily 
Mean; SD 
p-value 
Vomiting    
Day 1 0.07; 0.26 0.07; 0.26 0.921 
Day 2 0.10; 0.31 0.03; 0.19 0.400 
Day 3 0.38; 1.12 0.10; 0.31 0.134 
Day 4 0.07; 0.26 0.10; 0.31 0.665 
Day 5 0.03; 0.19 0.14; 0.35 0.142 
Day 6 0.17; 0.38 0.17; 0.47 0.913 
Day 7 0.07; 0.26 0.14; 0.44 0.617 
Day 8 0.04; 0.19 0.04; 0.19 1.000 
 
Diarrhoea 
   
Day 1 1.55; 2.67 0.72; 1.83 0.048 
Day 2 1.24; 2.33 0.75; 1.37 0.246 
Day 3 1.85; 3.02 0.71; 1.16 0.317 
Day 4 0.83; 1.77 0.82; 1.89 0.508 
Day 5 0.74; 1.72 0.55; 1.04 0.471 
Day 6 0.76; 1.47 1.11; 2.42 0.336 
Day 7 0.97; 1.93 1.12; 2.42 0.852 
Day 8 0.53; 0.88 0.92; 1.61 0.579 
 
Bloatedness 
Day 1 0.67; 2.15 0.33; 1.00 0.979 
Day 2 0.67; 1.93 0.41; 1.09 0.482 
Day 3 0.35; 1.20 0.88; 1.86 0.377 
Day 4 0.22; 0.63 0.63; 1.77 0.688 
Day 5 0.35; 1.06 0.62; 1.66 0.776 
Day 6 0.22; 0.46 0.33; 1.01 0.726 
Day 7 0.07; 0.28 0.26; 0.73 0.505 
Day 8 0.22; 0.51 0.29; 0.98 0.380 
* Indicates significance (p < 0.05); SD standard deviation; CV coefficient of variation 
 
Stellenbosch University http://scholar.sun.ac.za
R e s u l t s  | 103 
 
 
VAS scores were compared for individuals with low and high Cmax values of PAS to 
investigate if any of these symptoms were concentration-related. Table 24 
summarises the mean VAS scores for patients with low and high Cmax values. 
Concentrations above 80 µg/ml were considered as high. The maximum 
concentrations were sub-categorised as below or above 80, 90 and 100 µg/ml. 
 
Scores for abdominal pains and diarrhoea were higher in subjects with maximum 
concentrations below 80 and 90 µg/ml, while the subjects with maximum 
concentrations above 80 and 90 µg/ml gave a higher score to vomiting, nausea and 
bloatedness. The scores of all the gastrointestinal intolerance except for vomiting 
were higher for the subjects with maximum concentrations below 100 µg/ml. This 
mixed depiction does not show definite trends and is thus not suggestive of dose-
related toxicity. 
 
 
Table 24 Summary of the gastrointestinal tolerability of individuals with low and high maximum 
PAS concentrations 
Gastrointestinal Symptoms Mean VAS scores 
 ≥80 (n=20) <80 (n=38) 
Abdominal pain and cramps 0,272 0,369 
Nausea 0,822 0,790 
Vomiting 0,119 0,106 
Diarrhoea 0,692 1,082 
Bloated 0,470 0,371 
   
 
≥90 (n=16) <90 (n=42) 
Abdominal pain and cramps 0,230 0,376 
Nausea 0,852 0,782 
Vomiting 0,148 0,097 
Diarrhoea 0,549 1,099 
Bloated 0,549 0,351 
   
 
≥100 (n=13) <100 (n=45) 
Abdominal pain and cramps 0,071 0,412 
Nausea 0,677 0,837 
Vomiting 0,135 0,104 
Diarrhoea 0,573 1,050 
Bloated 0,278 0,442 
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The VAS scales documented the gastrointestinal intolerances generally associated 
with PAS. Other reported side effects were documented separately. Reported side 
effects were loss of appetite (5 of 29, 17%) and tiredness (8 of 29, 28%).  
 
5.7. Study 2: Post-study interview 
After the study, a short interview was held with each subject to discuss their 
experiences. Table 25 summarises the subjects’ experience and preference. Thirteen 
subjects (45%) believed that there was no difference between the two regimens, but 
ten of them (77%) preferred the twice-daily regimen. The reason provided by the 
subjects was the bulkiness of the drug when given as a single daily dose in the 
morning after which they did not have any appetite for breakfast afterwards. Sixteen 
subjects (55%) claimed that they did not like the once-daily regimen, because of 
diarrhoea and vomiting. Three subjects (10%) preferred the once-daily 
administration. According to two subjects, they felt healthier and had more energy. 
One subject asked if the once-daily regimen could be continued after the study. 
 
5.8. Study 2: Follow-up 
Five subjects (16%) were discharged from the hospital. Four subjects (13%) were 
non-compliant to their TB treatment and failed treatment. One XDR-TB subject (3%) 
developed hypothyroidism, approximately a month after the study and two subjects 
(6%) developed renal impairment approximately one to two week after the study. 
One subject (3%) developed soft tissue inflammation and one subject died (reported 
as serious adverse events not associated with the study). The other subjects (56%) 
were in a good condition.  
 
5.9. Study 2: Serious adverse events 
One HIV negative subject with XDR-TB completed the study but died with acute renal 
failure (creatinine level of 1255 µmol/L) two weeks after completion. No abnormalities 
were reported during and at the follow-up, a week after the study.  
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Table 25 Summary of the subjects experience and preference of the two regimens in 
study 2 
 Worse Experience Preferred Regimen 
Subjects 
No 
difference 
Once- 
daily 
Twice-
daily 
Once- 
daily 
Twice-
daily 
1 X    X 
2 X    X 
3 X    X 
4 X    X 
5  X   X 
6  X   X 
7  X   X 
8  X   X 
9  X   X 
10 X   X  
11  X   X 
12 X    X 
13 X    X 
14  X   X 
15  X   X 
16 X   X  
17  X   X 
18  X   X 
19 X    X 
20  X   X 
21 X    X 
22  X   X 
23  X   X 
24  X   X 
25  X   X 
26  X   X 
27 X   X  
28 X    X 
29 X    X 
Total 13 (45%) 16 (55%) 0 (0%) 3 (10%) 26 (90%) 
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Chapter Six:  
Discussion 
 
PAS is an old drug and has been formulated in a new granular slow release form i.e. 
GSR-PAS. Although the benefit of this drug is limited, it is still used as part of a 
treatment regimen for M/XDR-TB. Since only a few Mycobacterium isolates have 
developed resistance to PAS, it is valuable in preventing resistance to other 
susceptible drugs.  
Even though newer anti-TB agents (e.g. bedaquiline and PA-824 101,102) for MDR-TB 
have been developed in the last few years, PAS may be still useful in preventing the 
development of resistance to these drugs and may be important in future regimens. 
However, little is known about its drug interactions, pharmacogenetics and 
pharmacokinetics. 
The recommended dose for PAS is 12 g in divided doses, but 4 g twice-daily has 
been evaluated and was found to provide adequate concentration for bacteriostasis 
81. However, an ideal treatment regimen in a non-compliant and resource-poor 
setting is one in which medication is taken only once daily. 
Not only has once-daily PAS dose been reported to be clinically as effective 82 as 
divided daily doses but it also has the potential for early bactericidal activity with a 
single high dose 103. These studies, however, used PAS salt formulations, rather than 
the free PAS encapsulated in granules. Peloquin et al. 81,104 was the only group that 
has investigated the pharmacokinetics of GSR-PAS and the only group thus far that 
compared once- and twice-daily GSR-PAS regimens in adults, while Liwa et al 78, 98 
specifically focused on children.  
The present study provided a comprehensive overview of the pharmacokinetics of 
PAS in a DR-TB population, in which some subjects were also co-infected with 
HIV/AIDS. The study focused on several aspects of the clinical pharmacology of PAS 
including dosing, potential drug interactions and genetic variants. Several unique and 
novel findings were described for GSR-PAS. Not only did the results indicate that a 
single 8 g GSR-PAS dose can sustain the PAS plasma concentrations above the 
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MIC, but also that ART, possibly due to EFV interactions, increases the PAS 
clearance by 45%. 
The additional unpublished data served as a baseline for the study and was therefore 
incorporated in the analysis and model development. Pharmacometric analysis 
(population pharmacokinetics) was a supportive tool to explore the data and predict 
future results. The analysis estimated the population PK parameters and assessed 
covariates that may change the parameters of the PAS profiles. 
 
Pharmacokinetics 
Serial blood samples provided high-quality pharmacokinetic profiles. Wide inter- and 
intraindividual pharmacokinetic variability was noted in both studies. Several factors 
can contribute to these variations such as intestinal motility, gastric pH, gastric 
emptying time, different foods, intestinal metabolism, concomitant drugs, genetic 
factors, presence of gastrointestinal disease; and prolonged period of absorption that 
overlaps distribution and excretion 69, 78,104.  
The twice-daily regimen of both studies had mean concentrations ranging between 
20-60 μg/ml and was thus within the range previously reported for adults also 
receiving the GSR-PAS formulation 11, 78, 81,104.  
The mean PAS concentrations of the twice-daily regimen in study 2 were much 
higher than the concentrations detected in study 1. The subjects in study 2 received 
a 12-hourly GSR-PAS dose, while most of the subjects in study 1 received a GSR-
PAS dose 15 hours before the next dose. Subsequently, lower PAS plasma 
concentrations were detected in the pre-dose samples (C0) of study 1 (Table 12). The 
PAS concentration detected in the C0 is the starting concentration of the following 
dose and therefore a high C0 can increase the PAS plasma concentration as noted in 
study 2 (Table 13). In addition, interindividual variability could also have contributed 
to this finding. 
 
Study 1: Two occasions (4 g twice-daily) 
PAS plasma concentrations in study 1 were significant lower during the second than 
during the first occasion. The same finding had been reported by Liwa 98. This 
tendency for the subjects to have lower PAS concentration levels in occasion 2 (2-4 
weeks after the first occasion) can be due to the significant increase in body weight, 
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which is associated with a decrease in plasma concentrations. However, the mean 
body weight between the two occasions would only explain a difference in 
concentrations of 2%.  
PAS PK profiles are highly variable and as mentioned various factors as well as the 
change in disease state, concomitant drugs and different diets between the two 
occasions (2-4 weeks apart), can contribute to these variations. 
The median lines (red lines) in the visual predictive graphs of the two occasions 
(Figure 21) were almost identical, indicating that the difference between the mean PK 
graphs may be due to larger or smaller outlier values. The 95% predictive interval for 
occasion 2 was lower than occasion 1. However, when the parameters for twice-daily 
regimens of 1000 subjects were compared, the results showed only a small value 
difference.  
 
Study 2: Once vs. Twice-daily 
As expected, dose proportionality was seen between the single 8 g daily dose and 
the 4 g twice-daily dose (Figure 17). The 8 g daily dose generated a mean AUC12 
that was larger and, a mean Cmax that was much higher and later than the 4 g dose. 
Not only did the 8 g dose have a significant higher Cmax and later peak, but also an 
earlier start. The same pattern was reported by Liwa et al 78 in children receiving a 
single dose of 150 mg/kg and a twice-daily dose of 75 mg/kg. The difference 
between the mean maximum concentrations of the 150 mg/kg and 75 mg/kg doses 
was however, much smaller in the children’s study. The earlier start for the single 
high dose (8 g for adults and 150 mg/kg for children) could be due to the release and 
absorption of PAS from the granules in the stomach.  
PAS is mainly released and absorbed in the more alkaline intestines12. Small 
amounts however, can also be absorbed in the stomach if the free PAS is 
unprotected by enteric coating. The free PAS can be released from the granules if 
the pH of the stomach is increased due to consumption of more alkaline food or 
beverages shortly after PAS administration 12. The free PAS can also be exposed if 
the granules are chewed, which was often noticed in the higher dose. In addition, 
more granules (higher dose) are exposed for potential absorption through the 
intestines, which will result in an earlier rise in concentration. 
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A tmax of GSR-PAS normally ranges between 4-8 hours 
11. Although the later peak 
seems to be normal, the tmax of the once-daily regimen was clearly later compared to 
the twice-daily regimen. The later peak seen in the once-daily regimen can be outlier 
values. However, the mean tmax of the once-daily regimen (Table 13) is less than the 
median, which indicates that most of the maximum concentrations were at a later 
period.  
A later peak was also visible in the simulated profiles (Table 18) of the two regimens, 
but in contrast to the original data, the difference was much smaller. With the 
predicted simulated profiles, the tmax of the once-daily regimen had a 90% Cl of (3, 8), 
indicating that once-daily regimen will have patients with a peak that is two hours 
later than the twice-daily regimen which has a 90% CI of (3, 6).  
The later peak observed for the once-daily regimen is unusual, since the once-daily 
regimen had an earlier start with a much lower starting concentration (C0) than the 
twice-daily regimen. GSR-PAS formula is specifically designed to slowly release the 
PAS from the granules and may therefore be involved in the later peak observed for 
the higher dose. Walter and Heilmeyer105 described that the later Cmax is dose 
related; therefore, as the dose increases, the time will also increase.  
With a bacteriostatic agent the aim is to maximise the time the drug concentration is 
above the MIC. Since PAS is thought to be mainly a bacteriostatic agent, the aim 
was to investigate if the different regimens could maintain the PAS plasma 
concentrations above the MIC. In both doses the PAS plasma concentrations were 
well maintained throughout the 12-hour interval, with the once-daily dose’s C12 and 
Cmax being significantly higher (more than double the concentration). 
The C12 was the last sample (Clast ) of the twice-daily regimen (before the next dose), 
while the Clast  of the once-daily regimen was the C24.  
In theory the difference between the pre-doses, C0 and the Clast, is relatively small. 
However, in the study wide inter- and intraindividual variation in the concentrations 
was observed. As mention above, several factors can contribute to these variations, 
including pre-sample day dosing. In the study it was preferred to use the 24-hour 
sample concentrations since these samples were taken exactly 24 hours after the 
previous dose.  
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In the once- and twice-daily GSR-PAS study done by Peloquin81, no PAS 
concentrations were detected in the 24-hour samples for the once-daily regimen. In 
contrast to their findings, PAS plasma concentrations in more than half of our study 
subjects were maintained above the MIC at the 24-hour sample. The remaining 
subjects were just below the MIC with some exceptions. It is however, important to 
note that Peloquin used a single 4 g dose, while an 8 g dose was used in this study. 
Since the mean C12 for the once-daily was relatively high and PAS was still present in 
the C24 samples of those subjects with concentrations below the MIC, the once-daily 
dose probably maintained the PAS plasma concentrations above the MIC for the 
majority of the time between 12 and 24 hours. 
With the simulated data of 1000 subjects (Table 18), predictions were made that the 
C12 and C24 of the simulated subjects that are using the once-daily regimen will have 
a 90% CI of (6.1, 81.2) and (0.06, 37.7), respectively. This indicates that most 
subjects’ 24-hour concentration will fall below the MIC. However, the results were 
based on the first model with weight as the only covariate (Table 17). 
 
Drug-drug interactions  
Although only a few significant differences were found between the HIV positive and 
negative subjects, a significant difference was seen between their concentration 
profiles and statistics. The PAS plasma concentration and AUC12 of the HIV positive 
subjects was significantly lower than the HIV negative subjects. This observation can 
be associated with the disease state as well as the concomitant ARVs taken by the 
HIV positive subjects. The CYP2B6 substrate, EFV was identified as a covariate that 
increases the clearance of PAS by 45%. An interaction between PAS and EFV has 
so far not been reported in the literature.  
EFV is predominantly metabolised by the CYP2B6, but is also a substrate for the 
CYP2A6, CYP3A4 and UGT2B7 enzymes 106. As mentioned, a drug such as EFV 
can decrease or increase the clearance of other drugs by inhibiting or inducing the 
enzyme activity affecting those drugs. EFV is known to influence the enzyme activity 
of CYP3A4, CYP2B6, CYP2C9, CYP2C19, UGT2B7 and UGT 3A4 UGT 107,108,109. 
Since several drugs are substrates for the CYP group, especially the CYP3A4, the 
drug interactions for EFV have been studied extensively.  
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PAS is not a substrate for any of the CYP enzymes; therefore, it is highly unlikely that 
the low PAS concentration is a result of induction of any of the CYP enzymes. 
Although PAS is predominantly acetylated by NAT1, it can also be glucuronidated by 
UGT1A9. As mentioned above EFV has an inducing and inhibiting effect on the UGT 
enzymes, including UGT1A9 109. Our observation could, therefore be a result of an 
inducing effect of EFV on the glucuronidation of PAS.  
However, it is important to note that lamivudine and stavudine were also co-
administered with EFV. During the screening for covariates, the concomitant 
medications were categorised according to their effect on the CYP enzymes, 
therefore the drugs that are metabolised by other enzymes were not screened.  
Stavudine and lamivudine are classified as nucleoside reverse transcriptase 
inhibitors (NRTIs) and are predominately phosphorylated to their active metabolites. 
According to Coyne14 interactions between the NRTIs and PAS are highly unlikely.  
Since only a few HIV positive subjects were prescribed a regimen without EFV, it is 
difficult to conclude if the clearance is increased only by EFV or all the other ARVs. 
However, the increase in PAS clearance is not due to the disease state (HIV), since 
some HIV positive subjects that were not compliant to their ART had higher PAS 
concentrations. 
The discovery of the effect of EFV on PAS clearance provided a new perspective and 
approach to the pharmacokinetic modelling. The 90% CI for the subjects taking EFV 
was much lower than those not taking EFV, for instance the C24 (once daily) of those 
taking EFV (Table 21) has a 90% CI of (0.89, 21.9), while those not taking EFV had a 
90% CI of (1.4, 37.3) (Table 20). This indicates that most of the subjects receiving 
EFV with a single 8 g GSR-PAS dose will fall below the MIC, while fewer subjects will 
have concentrations below the MIC if they are not taking EFV.  
In the simulated data (Table 21) for the subjects taking EFV (once-daily), the C12 90% 
CI was (8.6, 58.1). Those not taking EFV had a 90% CI of (12.8, 89.7). This indicates 
that more subjects who are taking the EFV will have concentrations below the MIC 
between 12 and 24 hours than those not taking EFV. 
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Genetic variants and gene-gene interactions 
Although no significant difference was found between the genotypes, the mean PK 
profiles of the different genotypes (Figure 28) indicate that NAT1*4/1*4 (wild type), 
NAT1*4/NAT1*27, NAT1*4/1*10 and NAT1*10/*10 are fast acetylators. The mean 
PAS PK profiles of the two subjects with the NAT1*4/NAT1*14A genotype were much 
higher than the other genotypes, indicating that these subjects are slow acetylators. 
The results of the profiles are consistent with the literature 20,100.  
With the grouping, the NAT1*4 heterozygous and NAT1*10 homozygous individuals 
(NAT1*4/1*10, NAT1*4/1*14A and NAT1*10/1*10) had an approximate 20% 
decrease in PAS clearance, compared to the wild type (NAT 1*4 homozygous). This 
decrease may be due to the higher concentrations of the NAT1*14A and not the 
NAT1*10 alleles. However, the NAT1*10 alleles also have higher PAS concentrations 
than the wild type (Figure 28)  
Although a relatively slower clearance was seen with the NAT1*4 and NAT1*10 
heterozygous and fast-intermediate NAT2 phenotype, no statistical significance was 
found.  
Due to the small sample size, these results cannot conclusively indicate that there is 
a NAT1 effect on the PAS disposition. 
 
Tolerability and Safety  
The measurement of the tolerability depended on the subject’s understanding of the 
VAS forms and their ability to recall. Although the scales were thoroughly explained 
on each occasion, potential misinterpretation could still have occurred. For this 
reason, a short interview was conducted before the subjects completed the VAS 
scales. The interview provided a verification of the tolerability scores of the subjects.  
There was a wide variation in the intolerability, but no significant differences were 
found between the two regimens. However, there were some noteworthy differences. 
According to the VAS scores, the subjects had more abdominal pain and cramps with 
the twice-daily regimen, while the subjects had more diarrhoea with the once-daily 
regimen. Diarrhoea is one of the symptoms related to gastrointestinal intolerance 
which the GSR-PAS formulation could not decrease 110.  
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It is important to note that most of the concomitant drugs prescribed to the subjects 
such as ethionamide, moxifloxacin, dapsone, ethambutol, INH and kanamycin, are 
also known to cause gastrointestinal intolerance 110. The subjects were asked 
whether they had nausea before or after the administration of the concomitant drugs. 
The majority of the subjects indicated that they had nausea after receiving the 
concomitant drugs. The nausea could therefore either be due to the concomitant 
drugs or be a combined effect of PAS and the other drugs.  
 
Intolerance is often caused by high drug plasma concentrations and since no 
distinctive difference could be found between the two regimens, the association 
between the Cmax and gastrointestinal intolerance was investigated (Table 24). 
Diarrhoea and abdominal pain and cramps were associated with low concentrations, 
while nausea, vomiting and bloatedness were associated with higher concentrations. 
However, lower scores for the gastrointestinal intolerance (except vomiting) were 
given by the subjects with concentrations above 100 µg/ml. These results indicate 
that PAS adverse events are not necessarily related to the higher PAS plasma 
concentrations seen with the once-daily regimen. 
 
In the post-study interview, more subjects claimed that the once-daily regimen was 
worse than the twice-daily regimen, which indicated that the subjects misinterpreted 
the scales or did not complete it with their full intent. However, there was consistency 
between the daily interview and VAS scoring.  
 
Apart from gastrointestinal intolerance, other side effects observed were tiredness 
and loss of appetite. PAS reduces the thyroxin synthesis, which can be related to the 
tiredness. The drug may also cause drug-induced hepatitis which is also related to 
lack of energy/fatigue and the development of anorexia. Since the drug-induced 
hepatitis has symptoms (nausea, loss of appetite, diarrhoea and nausea) that are the 
same as the side effects of PAS, it was difficult to differentiate between the two. 
Therefore, rashes and fevers were used as a guide. However, no rashes or fevers 
were reported.  
 
Clinical usefulness and considerations 
In the comparison between the two regimens, the twice-daily regimen seems to be 
the preferable dose, as it is well tolerated and results in PAS concentrations well 
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above the MIC. However, since the once-daily regimen has proven that it can sustain 
PAS plasma concentrations above the MIC or for the majority of time after 12 hours, 
the once-daily dosing may be useful in some cases. 
 
Since the PAS concentrations and AUC12 of the HIV positive subjects receiving ARVs 
such as EFV were significantly lower, the once-daily GSR-PAS regimen may be less 
suitable in these patients. The patients co-administrating ARVs and PAS need to be 
encouraged to be compliant to the PAS and ART to avoid developing drug 
resistance. 
 
Although PAS is a bacteriostatic agent, its potential to have an early bactericidal 
activity (EBA) with a single high dose of 15 g has been evaluated by Jindani et al.103. 
Even though the EBA 2-14 was low at 0.076, a moderate EBA 0-2 of 0.259 was 
reported for PAS. Unfortunately Jindani et al103 did not measure PAS plasma 
concentrations after a single 15 g dose, but according to Walter and Heilmeyer 111 a 
15-17 g dose can produce concentrations between 100-200 µg/ml.  
 
The single high GSR-PAS dose used in the present study produced high 
concentrations that were in some cases above 100 µg/ml. However, EBA tests were 
not preformed, therefore the study was not able to confirm if the high concentrations 
have any early bactericidal effects. If it is possible to confirm that a concentration 
more than 100 µg/ml will result in an early bactericidal affect, a higher GSR-PAS 
dose could provide a combination of a bacteriostatic and bactericidal activity. More 
clinical data is required to confirm if once-daily dosing will be effective. 
 
Jindani et al103 studied PAS as monotherapy, while in this study various other 
concomitant drugs were used, including a high dose of INH, which may be beneficial 
or harmful (i.e. neurotoxicity a result of increase INH levels). In addition, most of the 
concomitant drugs and PAS are metabolised by the liver and excreted by the 
kidneys, therefore increasing the risk for hepatotoxicity and renal failure. The two 
subjects, who developed renal impairment after the study were on capreomycin 
(known to cause renal failure) for a long period, thus the study cannot conclude that 
the impairment was caused by the high GSR-PAS dose. Prospective studies are 
needed to determine the safety of the once-daily dose for a longer period than in the 
present study.  
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Study limitations and future work  
Design  
Although several interesting and clinically important outcomes were provided by the 
study, there were some limitations. It would have been ideal to include a washout 
period for the crossover design. This was unfortunately not possible, since the 
subjects were receiving the investigated drugs as part of their treatment regimen. It 
will be worth doing parallel trials or a 3-4 week cross-over trial, with a week in 
between the once- and twice-daily regimens. The extra week will then serve as the 
washout period and will assist in determining the intolerance of the different 
regimens. 
 
The two week PK study was only able to determine the short term effect of the once-
daily regimen; therefore an extensive study is needed to assess the safety and 
efficacy of the 8 g dose over a longer period. Addition clinical tests and culturing will 
be required for these assessments. 
 
Clinical approaches 
The subjects complained of not having an appetite in the morning after taking the 
single 8 g dose, therefore a future investigation could assess administration of PAS 
several hours after breakfast. Later administration may not only increase the 
tolerability, but may increase the PAS absorption, since PAS absorption is increased 
by food intake 40.  
 
Although the VAS form is a standard approach to determine tolerability, more 
methods need to be considered in prospective studies. Interviews or observations 
could be more feasible than VAS, but with a few adjustments to the VAS it could still 
be a valuable tool. 
 
Furthermore, other side effects need to be determined for the single daily dose. 
Interviews and physical examinations will be a good approach to determine the other 
side effects.  
 
Only a small group of subjects participated in the study, and therefore future work is 
needed to determine the safety and tolerability of the once-daily regimen, especially 
when prescribed in combination with other drugs that have the same toxic effect and 
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those that can reach toxic levels due to PAS interactions, such as INH.  
 
Drug-drug interactions 
The interactions between the ARVs and PAS need to be confirmed in a larger study, 
where both drugs are analysed to determine if PAS also has an effect on the ARVs. 
Prospective work will be to analyse other concomitant drugs with PAS and 
investigate potential interactions of PAS with the older and newer TB and ARV drugs. 
 
Genetic factors 
In order to describe all the different genetic variants and phenotypic activity in the 
population, a larger sample size is required. A feasible approach to genetics will be to 
analyse the other genes that may be directly or indirectly involved in the ADME of 
PAS. The investigation of genetic factors affecting the metabolism of concomitant 
drugs such as EFV and INH will be a valuable approach to predict the clearance of 
PAS and development of toxicity. 
 
Minimum Bactericidal Concentration 
Furthermore, in vitro and in vivo bactericidal testing is required to determine if PAS 
has early bactericidal activities with high concentrations. 
 
Pharmacometric evaluations 
A next step in the pharmacometric evaluation of the outcome of the present study 
could be the development of pharmacokinetic and pharmacodynamic models that 
correlate the relationship between the subjects’ characteristics, PAS plasma 
concentrations, other drugs, M. tuberculosis cultures and tolerability. 
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Chapter Seven:  
Conclusion 
 
The study provided information about the pharmacokinetics of PAS in adults with 
M/XDR-TB. It showed that a single 8 g dose of GSR-PAS leads to significantly higher 
PAS plasma concentrations than a 4 g dose given twice-daily. This higher dose is 
able to sustain the PAS plasma concentrations above the MIC of 1 µg/ml throughout 
the dosing interval of 24 hours in a high proportion of non-HIV infected adult patients 
with M/XDR-TB. A single dose can therefore not only provide a prolonged 
bacteriostatic effect, but possibly increase the bactericidal effect of GSR-PAS. 
 
Therefore, the 8 g once-daily dose can be considered for future regimens when 
outpatient-based, supervised treatment is needed. Both regimens are reasonably 
well tolerated on the background of a cocktail of accompanying anti-tuberculosis 
agents. Due to lower exposure the once-daily regimen will be less suitable for HIV-
infected subjects on ARV-drugs. PAS and ARV interactions need to be clarified 
before the 8 g once-daily dose can be recommended for the HIV co-infected patients 
on ART. 
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Appendices 
 
Appendix A: Package Insert of Granules delayed-release PAS (PASER)  
PASER - aminosalicylic acid granule, delayed release 
Jacobus Pharmaceutical Company, Inc. 
 
4 grams 
Caution: Federal, law prohibits dispensing without prescription. 
JACOBUS PHARMACEUTICAL COMPANY, INC. 
Princeton, NJ 08540 
2A JULY, 1996 
PASER® GRANULES 
(aminosalicylic acid granules) 
 
DESCRIPTION 
PASER granules are a delayed release granule preparation of aminosalicylic acid (p-
aminosalicylic acid; 4-aminosalicylic acid) for use with other anti-tuberculosis drugs 
for the treatment of all forms of active tuberculosis due to susceptible strains of 
tubercle bacilli. The granules are designed for gradual release to avoid high peak 
levels not useful (and perhaps toxic) with bacteriostatic drugs. 
Aminosalicylic acid is rapidly degraded in acid media; the protective acid-resistant 
outer coating is rapidly dissolved in neutral media so a mildly acidic food such as 
orange, apple or tomato juice, yogurt or apple sauce should be used. 
Aminosalicylic acid (p-aminosalicylic acid) is 4-Amino-2-hydroxybenzoic acid. PASER 
granules are the free base of aminosalicylic acid and do NOT contain sodium or a 
sugar. The molecular formula is C7H7NO3 with a molecular weight of 153.14. With 
heat p-aminosalicylic acid is decarboxylated to produce CO2 and m-aminophenol. If 
the airtight packets are swollen, storage has been improper. DO NOT USE if packets 
are swollen or the granules have lost their tan color and are dark brown or purple. 
The structural formula is: 
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PASER granules are supplied as off-white tan colored granules with an average 
diameter of 1.5 mm and an average content of 60% aminosalicylic acid by weight. 
The acid resistant outer coating will be completely removed by a few minutes at a 
neutral pH. The inert ingredients are: 
 
colloidal silicon dioxide 
 
dibutyl sebacate 
 
hydroxypropyl methyl cellulose 
 
methacrylic acid copolymer 
 
microcrystalline cellulose 
 
talc 
 
 
The packets contain 4 grams of aminosalicylic acid for oral administration three times 
a day by sprinkling on apple sauce or yogurt to be eaten without chewing. 
Suspension in an acidic fruit drink such as orange juice or tomato juice will protect 
the coating for at least 2 hours. Swirling the juice in the glass will help resuspend the 
granules if they sink. 
 
CLINICAL PHARMACOLOGY 
 
Mechanism of Action: Aminosalicylic acid is bacteriostatic against Mycobacterium 
tuberculosis. It inhibits the onset of bacterial resistance to streptomycin and isoniazid. 
The mechanism of action has been postulated to be inhibition of folic acid synthesis 
(but without potentiation with antifolic compounds) and/or inhibition of synthesis of 
the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis. 
 
Characteristics: The two major considerations in the clinical pharmacology of 
aminosalicylic acid are the prompt production of a toxic inactive metabolite under 
acid conditions and the short serum half-life of one hour for the free drug. Both are 
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discussed below. After two hours in simulated gastric fluid, 10% of unprotected 
aminosalicylic acid is decarboxylated to form meta-aminophenol, a known 
hepatotoxin. The acid-resistant coating of the PASER granules protects against 
degradation in the stomach. The small granules are designed to escape the usual 
restriction on gastric emptying of large particles. Under neutral conditions such as are 
found in the small intestine or in neutral foods, the acid-resistant coating is dissolved 
within one minute. Care must be taken in the administration of these granules to 
protect the acid-resistant coating by maintaining the granules in an acidic food during 
dosage administration. Patients who have neutralized gastric acid with antacids will 
not need to protect the acid resistant coating with an acidic food since no acid is 
present to spoil the drug. Antacids may influence the absorption of other medications 
and are not necessary for PASER consumed with an acidic food. 
 
Because PASER granules are protected by an enteric coating absorption does not 
commence until they leave the stomach; the soft skeletons of the granules remain 
and may be seen in the stool. 
Absorption and excretion: In a single 4 gram pharmacokinetic study with food in 
normal volunteers the initial time to a 2 µg/ml serum level of aminosalicylic acid was 
2 hours with a range of 45 minutes to 24 hours; the median time to peak was 6 hours 
with a range of 1.5 to 24 hours; the mean peak level was 20 µg/ml with a range of 9 
to 35 µg/ml; a level of 2 µg/ml was maintained for an average of 7.9 hours with a 
range of 5 to 9; a level of 1 µg/ml was maintained for an average of 8.8 hours with a 
range of 6 to 11.5 hours. The recommended schedule is 4 grams every 8 hours. 80% 
of aminosalicylic acid is excreted in the urine, with 50% or more of the dosage 
excreted in acetylated form. The acetylation process is not genetically determined as 
is the case for isoniazid. Aminosalicylic acid is excreted by glomerular filtration; 
although previously reported otherwise, probenecid, a tubular blocking agent, does 
not enhance plasma concentration. In a 1954 study thyroxine synthesis but not iodide 
uptake was reported reduced about 40% when the sodium salt (not PASER 
granules) of aminosalicylic acid was administered one hour before radio-iodine; the 
sodium salt typically produces a serum level over 120 µg/ml at one hour lasting one 
hour. Occasional goiter development can be prevented by the administration of 
thyroxine but not iodide. Penetration into the cerebrospinal fluid occurs only if the 
meminges are inflamed. Approximately 50-60% of aminosalicylic acid is protein 
bound; binding is reported to be reduced 50% in kwashiorkor. Microbiology: The 
aminosalicylic acid MIC for M. tuberculosis in 7H11 agar was less than 1.0 µg/ml for 
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nine strains including three multidrug resistant strains, but 4 and 8 µg/ml for two other 
multidrug resistant strains. The 90% inhibition in 7H12 broth (Bactec) showed little 
dose response but was interpreted as being less than or equal to 0.12-0.25 µg/ml for 
eight strains of which three were multi-resistant, 0.50 µg/ml for one resistant strain, 
questionable for four non-resistant strains and greater than 1µg/ml for one non-
resistant and three resistant strains. Aminosalicylic acid is not active in vitro against 
M. avium. 
 
INDICATIONS AND USAGE 
PASER is indicated for the treatment of tuberculosis in combination with other active 
agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) 
or in situations when therapy with isoniazid and rifampin is not possible due to a 
combination of resistance and/or intolerance. When PASER is added to the 
treatment regimen in patients proven or suspected drug resistance, it should be 
accompanied by at least one and preferably two other new agents to which the 
patient's organism is known or expected to be susceptible. 
 
CONTRAINDICATIONS 
Hypersensitivity to any component of this medication. 
Severe renal disease. 
Patients with severe renal disease will accumulate aminosalicylic acid and its acetyl 
metabolite but will continue to acetylate, thus leading exclusively to the inactive 
acetylated form; deacetylation, if any, is not significant. 
The half-life of free aminosalicylic acid in renal disease is 30.8 minutes in comparison 
to 26.4 minutes in normal volunteers, but the half-life of the inactive metabolite is 309 
minutes in uremic patients in comparison to 51 minutes in normal volunteers. 
Although aminosalicylic acid passes dialysis membranes, the frequency of dialysis 
usually is not comparable to the half-life of 50 minutes for the free acid. Patients with 
end stage renal disease should not receive aminosalicylic acid. 
 
WARNINGS 
 
Liver Function 
In one retrospective study of 7492 patients on rapidly absorbed aminosalicylic acid 
preparations, drug-induced hepatitis occurred in 38 patients (0.5%); in these 38 the 
first symptom usually appeared within three months of the start of therapy with a rash 
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as the most common event followed by fever and much less frequently by GI 
disturbances of anorexia, nausea or diarrhea. Only one patient was diagnosed on 
routine biochemistry. 
Premonitory symptoms in 90% of these 38 patients preceded jaundice by a few days 
to several weeks with the mean time of onset 33 days with a range of 7-90 days. Half 
of the adverse reactions occurred during the third, fourth or fifth weeks. When 
aminosalicylic acid-induced hepatitis was diagnosed, hepatomegaly was invariably 
present with lymphadenopathy in 46%, leucocytosis in 79%, and eosinophilia in 55%. 
Prompt recognition with discontinuation led to the recovery of all 38 patients. If 
recognized in the premonitory stage, the reaction is reported to “settle” in 24 hours 
and no jaundice ensues. From other reported studies failure to recognize thereaction 
can result in a mortality of up to 21%. The patient must be monitored carefully during 
the first three months of therapy and treatment must be discontinued immediately at 
the first sign of a rash, fever or other premonitory signs of intolerance. 
 
PRECAUTIONS 
 
(1) General: 
 
All drugs should be stopped at the first sign suggesting a hypersensitivity reaction. 
They may be restarted one at a time in very small but gradually increasing doses to 
determine whether the manifestations are drug-induced and, if so, which drug is 
responsible. Desensitization has been accomplished successfully in 15 of 17 patients 
starting with 10 mg aminosalicylic acid given as a single dose. The dosage is 
doubled every 2 days until reaching a total of 1 gram after which the dosage is 
divided to follow the regular schedule of administration. If a mild temperature rise or 
skin reaction develops, the increment is to be dropped back one level or the 
progression held for one cycle. Reactions are rare after a total dosage of 1.5 grams. 
Patients with hepatic disease may not tolerate aminosalicylic acid as well as normal 
patients, even though the metabolism in patients with hepatic disease has been 
reported to be comparable to that in normal volunteers. 
 
(2) Information for Patients: 
 
The patient should be advised that the first signs of hypersensitivity include a rash, 
often followed by fever, and much less frequently, GI disturbances of anorexia, 
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nausea or diarrhea. If such symptoms develop, the patient should immediately cease 
taking the medication and arrange for a prompt clinical visit. Patients should be 
advised that poor compliance in taking anti-TB medication often leads to treatment 
failure, and, not infrequently, to the development of resistance of the organisms in the 
individual patient.Patients should be advised that the skeleton of the granules may be 
seen in the stool. 
The coating to protect the PASER granules dissolves promptly under neutral 
conditions; the granules therefore should be administered by sprinkling on acidic 
foods such as apple sauce or yogurt or by suspension in a fruit drink which will 
protect the coating, but the granules sink and will have to be swirled. The coating will 
last at least 2 hours in either system. All juices tested to date have been satisfactory; 
tested are: tomato, orange, grapefruit, grape, cranberry, apple, “fruit punch”. 
Patients should be advised to store PASER in a refrigerator or freezer. PASER 
packets may be stored at room temperature for short periods of time. 
Patients should be advised NOT to use if the packets are swollen or the granules 
have lost their tan color and are dark brown or purple. The patient should inform the 
pharmacist or physician immediately and return the medication. 
 
3) Laboratory Tests: 
 
Aminosalicylic acid has been reported to interfere technically with the serum 
determinations of albumin by dye-binding, SGOT by the azoene dye method and with 
qualitative urine tests for ketones, bilirubin, urobilinogen or porphobilinogen. 
 
(4) Drug Interactions: 
 
Aminosalicylic acid at a dosage of 12 grams in a rapidly available form has been 
reported to produce a 20 percent reduction in the acetylation of isoniazid, especially 
in patients who are rapid acetylators; INH serum levels, half-lives and excretions in 
fast acetylators still remain half of the levels seen in slow acetylators with or without 
p-aminosalicylic acid. The effect is dose related and, while it has not been studied 
with the current delayed release preparation, the lower serum levels with this 
preparation will result in a reduced effect on the acetylation of INH. 
 
Aminosalicylic acid has previously been reported to block the absorption of rifampin. 
A subsequent report has shown that this blockade was due to an excipient not 
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included in PASER granules. Oral administration of a solution containing both 
aminosalicylic acid and rifampin showed full absorption of each product. 
 
As a result of competition, Vitamin B12 absorption has been reduced 55% by 5 
grams of aminosalicylic acid with clinically significant erythrocyte abnormalities 
developing after depletion; patients on therapy of more than one month should be 
considered for maintenance B12. 
A malabsorption syndrome can develop in patients on aminosalicylic acid but is 
usually not complete. The complete syndrome includes steatorrhea, an abnormal 
small bowel pattern on x-ray, villus atrophy, depressed cholesterol, reduced D-xylose 
and ironabsorption. Triglyceride absorption always is normal. In one literature report 
8 hours after the last dosage of aminosalicylic acid at 2 gm qid serum digoxin levels 
were reduced 40% in two of ten patients but not changed in the remaining eight. 
 
(5) Carcinogenesis, mutagenesis, impairment of fertility: 
 
Sodium aminosalicylate produced an occipital bone defect, probably with a dose 
response, when administered to ten pregnant Wistar rats at five doses from 3.85 to 
385 mg/kg from days 6 to 14. There were no significant changes from controls in any 
group in corpora lutea, early resorptions, total resorptions, fetal death, litter size, or 
hematomas. For all except the 77 mg/kg group, fetal weights were significantly 
greater than controls. Chinchilla rabbits on 5 mg/kg from days 7 to 14 did not show 
any significant differences as compared to controls for the same parameters studied. 
Sodium aminosalicylic acid was not mutagenic in Ames tester strain TA 100. In 
human lymphocyte cultures in-vitro clastogenic effects of achromatic, chromatid, 
isochromatic breaks or chromatid translocations were not seen at 153 or 600 µg/ml. 
At 1500 and 3000 µg/ml there was a dose related increase in chromatid aberrations. 
Patients on isoniazid and aminosalicylic acid have been reported to have an 
increased number of chromosomal aberrations as compared to controls. 
 
(6) Pregnancy: Pregnancy Category C: 
 
Aminosalicylic acid has been reported to produce occipital malformations in rats 
when given at doses within the human dose range.Although there probably is a dose 
response, the frequency of abnormalities was comparable to controls at the highest 
level tested (two times the human dosage). When administered to rabbits at 5 mg/kg, 
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throughout all three trimesters, no teratologic or embryocidal effects were seen. 
Literature reports on aminosalicylic acid in pregnant women always report 
coadministration of other medications. 
 
Because there are no adequate and well controlled studies of aminosalicylic acid in 
humans, PASER granules should be given to a pregnant woman only if clearly 
needed. 
 
(8) Nursing mothers: 
 
After administration of a different preparation of aminosalicylic acid to one patient, the 
-life of 2.5 
hours; the maximum maternal plasma concentration was 70 µg/ml at two hours. 
 
ADVERSE EFFECTS 
The most common side effect is gastrointestinal intolerance manifested by nausea, 
vomiting, diarrhea, and abdominal pain. Hypersensitivity reactions: Fever, skin 
eruptions of various types, including exfoliative dermatitis, infectious mononucleosis-
like, or lymphoma-like syndrome, leucopenia, agranulocytosis, thrombocytopenia, 
Coombs' positive hemolytic anemia, jaundice, hepatitis, pericarditis, hypoglycemia, 
optic neuritis, encephalopathy, Leoffler's syndrome, vasculitis and a reduction in 
prothrombin. Crystalluria may be prevented by the maintenance of urine at a neutral 
or an alkaline pH. 
 
OVERDOSAGE 
 
Overdosage has not been reported. 
 
DOSAGE AND ADMINISTRATION 
PASER granules should be administered with other drugs to which the organism is 
known or expected to be susceptible. It is most commonly administered to patients 
with Multi-drug Resistant TB (MDR-TB) or in other situations in which therapy with 
isoniazid or rifampin is not possible due to a combination of resistance and/or 
intolerance. The adult dosage of four grams (one packet) three times per day or 
correspondingly smaller doses in children should be given by sprinkling on apple 
sauce or yogurt or by swirling in the glass to suspend the granules in an acidic drink 
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such as tomato or orange juice. 
DO NOT USE if packet is swollen or the granules have lost their tan color, turning 
dark brown or purple. 
 
HOW SUPPLIED 
Carton of 30 PASER packets (NDC 49938-107-04). 
Each packet contains four grams aminosalicylic acid. 
PASER granules are supplied in packets containing 4 grams of aminosalicylic acid 
for administration three times a day by suspension in an acidic drink or food with a 
pH less than 5. Examples include apple sauce, yogurt, tomato or orange juice. 
Distributors and Pharmacists: Store below 59°F (15°C) (in a refrigerator or freezer). 
Patients are urged to store PASER in a refrigerator or freezer. PASER packets may 
be stored at room temperature for short periods of 
time. AVOID EXCESSIVE HEAT. DO NOT USE if packet is swollen or the granules 
have lost their tan color, turning dark brown or purple. 
 
JACOBUS PHARMACEUTICAL CO. INC. 
P.O. Box 5290 
Princeton, NJ 08540 
2A JULY, 1996 
 
PRINCIPAL DISPLAY PANEL 
Principal Display Panel – 4g Carton Label 
NDC 49938-107-04 
PASER® Aminosalicylic Acid 
Delayed-release Granules 
4 Grams 
30 Unit Dose Packets 
STORE BELOW 59°F (15°C) 
ALTERNATIVELY STORE IN A 
REFRIGERATOR OR FREEZER 
AVOID EXCESSIVE HEAT 
Caution: Federal law prohibits dispensing without prescription 
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Appendix B: Protocol of Study 1 
 
 
 
Clinical Pharmacology of Second-line Antituberculosis Drugs. 
 
RESEARCH PROTOCOL 
 
Investigators: 
 
 
Anthony Liwa, MD, BSc (Hons) 1 
Bernd Rosenkranz, MD, PhD, FFPM1 
Patrick Bouic, PhD2 
Simon Schaaf, MBChB3 
Peter Donald, MBChB3 
 
Division of Pharmacology (1) 
Synexa Group, South Africa (2) 
Department of Paediatrics (3) 
 
Address of correspondence: 
Prof. Bernd Rosenkranz 
Professor and Head 
Division of Pharmacology 
[Faculty of Health Sciences, Department of Medicine, Division of Pharmacology, PO 
Box 19063, Tygerberg, 7505, Cape Town, South Africa 
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Department of Medicine 
University of Stellenbosch 
PO Box 19063 
Tygerberg, Cape Town, 7505 
South Africa 
Phone: +27-21-938 9331 
Mobile: +27-82-955 0017 
Fax: +27-21-932 6958 
Mail: Rosenkranz@sun.ac.za 
 
Preface 
In the current protocol we propose to study: 
1. The in vivo pharmacokinetics (PK) of the second-line antituberculosis drugs 
terizidone and para aminosalycylic acid (PAS) in children  
2. The pharmacokinetics (PK) of the second-line antituberculosis drug para-
aminosalycylic acid (PAS) in adults 
3. The pharmacogenetics of genes relevant for drug elimination such as N-
acetyltransferase among patients treated with PAS for treatment of drug 
resistant tuberculosis. 
4. The in vitro metabolism of the second-line anti tuberculosis drugs 
determination using liver microsomes. 
The primary objective of the protocol is to evaluate the PK profile of terizidone and 
PAS in children by single dose study under strictly managed conditions following a 
defined protocol at set time points after dosing in children and adults. In parallel, we 
plan to assess the pharmacogenetics of PAS, the in vitro metabolic stablility and the 
effect of ethionamide, terizidone and PAS on different metabolizing enzymes by 
using standardized methodology. 
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Research protocol  
Title: Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
 
Protocol synopsis 
Tuberculosis continues to cause an unacceptably high toll of disease and death 
among children worldwide. Available data has suggested an exponential rise in the 
proportion of the tuberculosis case load caused by children as the incidence of 
tuberculosis rises so that children may constitute nearly 40 per cent of the case load 
in certain high incidence communities. Until now no trials have been done in children 
to establish optimum antituberculosis treatment regimens and current treatment 
guidelines are largely inferred from adult data. This is despite the fact that 
pharmacokinetics in children and especially very young children are likely to be 
different from that in adults. Furthermore resistance to frontline therapeutics has 
resulted in treatment of patients with “second line“ agents that are considered more 
toxic, and the experience of these drugs with children is even more limited. 
Tuberculosis management in children therefore presents particularly difficult 
challenges, and advances in paediatric tuberculosis research could provide insights 
and opportunities for tuberculosis control.  
In the proposed protocol we aim to conduct the pharmacokinetic study of second line 
anti tuberculosis drugs terizidone and PAS in childhood TB across the range of 
dosages and ages in order to determine the validity of the currently suggested dose 
based on adult data. 
We will also conduct the in vitro study of the susceptibility and stability of the second 
line anti TB drugs (ETH, terizidone and PAS) to biotransformation when subjected to 
metabolic enzymes. These drugs will also be incubated with the substrates of major 
enzymes/isoenzymes i.e. cytochrome P450 enzymes (CYPs), flavin containing 
monooxygenases (FMO) and uridine glucoronosyl transferases (UGT) to determine 
whether they have any effects on these enzymes. 
 
Research hypothesis 
1. Because of developmental changes, the pharmacokinetics of terizidone and 
PAS and resulting serum levels may differ in children of different age groups. 
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2. Young children require a higher body weight adjusted dosage of the “second-
line” antituberculosis agents, terizidone and PAS than adults to achieve 
equivalent serum concentrations. 
3. Because of the genetic variations of the metabolizing enzymes (N-
acetyltransferase) the serum concentrations may differ in different individuals. 
4. The drugs under investigation are metabolically unstable and we therefore will 
investigate their in vitro metabolism and potential for drug-drug interactions. 
 
Aim of this study 
1. To document the descriptive pharmacokinetics of the second-line 
antituberculosis    agents terizidone and PAS in children, in an attempt to 
provide an insight to the dosing rationale of these compounds; these data will 
be compared to the results obtained in adult patients as a reference group. 
2.  To investigate the genetic variation of NAT1and NAT2 in patients with 
tuberculosis treated by PAS.  
3. To evaluate the stability and susceptibility to biotransformation of the second-
line antituberculosis drugs (ETH, terizidone and PAS) when subjected to 
metabolic enzymes 
4. To generate baseline data and methodology for the future in vitro metabolic 
analysis of new compounds at the Division of Pharmacology. 
 
Study methodology 
The proposed study is a prospective longitudinal clinical as well as laboratory study; 
We plan to recruit children 13 years or younger and a group of adults 18 years or 
older with probable or confirmed drug resistant tuberculosis admitted to Brooklyn 
Hospital for Chest Diseases (BHCD) and In this explorative study, up to 40 children 
(for both drugs) and up to 40 adults will be enrolled. 
We plan to measure the serum concentrations at different set points after dosing in 
different age groups. The methodology requires 1 ml of blood for each assay and 
blood will be drawn during each assessment via an indwelling catheter that will be 
inserted on the morning of the evaluation. The indwelling catheter will be used to 
minimize the number of venipunctures required throughout the investigation. The 
serum concentrations will be determined by an established high performance liquid 
chromatography/mass spectrometry method (HPLC-MS). 
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Methodology for the in-vitro study will involve the incubation of the test compound at 
concentrations with the enzyme source (Human liver microsomes (HLM)), and S9 
fractions) with appropriate positive and negative controls. The time spacing and 
replicate number will be according to standardized procedures. The amount of parent 
drug remaining in the incubation media will be analyzed by HPLC/MS detection. The 
current procedure will also involve the incubation of substrates for specific 
isoenzymes with the test compounds using HLM to determine the effects of these 
drugs on different metabolizing enzymes. 
Microsoft excel will be used to capture the data and STATISTICA version 8 (StatSoft 
Inc. (2008) STATISTICA (data analysis software system) will be used to analyse the 
data. Summary statistics will be used to describe the variables. Distribution of 
variables will be presented as histograms and or as frequency tables. Medians or 
means will be used as the measures of central location for ordinal and continuous 
responses and standard deviations and quartiles as indicators of spread. 
 
Time plan 
We have planned to submit the protocol between August-September 2009 and have 
full Ethics approval for the study to start shortly thereafter. The aim is to collect data 
according to the protocol within a year. Data analysis and writing of the manuscript 
could be completed in 2 months. It would be possible to aim at the final manuscript at 
the end of year 2010 for the final master’s thesis presentation and graduation. At the 
time of the submission of this amendment, the clinical project is ongoing (paediatric 
population).  
The in vitro study will have a specific timeline, its implementation will commence after 
the approval from the ethical committee and the arrival of the required study 
materials. At the time of submission of this amendment, the laboratory work is being 
initiated.  
 
Conclusion 
The data generated in this study will be used as guidance for future studies involving 
much larger populations. We plan to present the data at congresses and to write this 
up for publications. 
Funding and budget 
Partial funding from the departmental funds is readily available. In addition, funding is 
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available from NRF grants provided to Prof. P. Donald.  
 
Introduction 
Tuberculosis continues to cause an unacceptably high toll of disease and death 
among children worldwide. (Newton et al., 2008) Approximately 8.3million new TB 
cases were diagnosed globally in 2000. It is estimated that 884,019 (11%) cases 
occurred among children, with the highest burden noted in areas of endemicity. A 
survey conducted in Cape Town, South Africa, indicated that 13% of cases entered 
into the register were found among children < 13 years of age. (Marais et al., 2004) 
Children are particularly vulnerable to severe disease and death following infection. 
Few trials have been done in children to establish optimum antituberculosis treatment 
regimens and current treatment guidelines are largely inferred from adult data. 
(Newton et al., 2008) Resistance to frontline therapeutics, most notably, isoniazid 
(INH) and rifampicin, results in treatment of patients with “second-line” agents that 
are less effective and/or more toxic. Among the second tier drugs for the treatment of 
multidrug-resistant tuberculosis, ethionamide (ETH), (Vanneli et al., 2002) and 
terizidone or cycloserine (CS) are generally used first because of efficacy, side effect 
profile, and historical use in tuberculosis (Murkherjee et al., 2004). Dosages for 
children are based on weight and extrapolated from data from studies with adults, yet 
pharmacokinetics for children, especially very young children, is likely to be different 
than for adults. Studies of ethambutol and pyrazinamide have found lower plasma 
drug levels and shorter half-lives in children than in adults using the same dosages. 
(Graham et al., 2006) Similar conclusions were drawn from a study of isoniazid 
pharmacokinetics in South African children. (Schaaf et al., 2005) 
In the light of the above remarks we conclude that tuberculosis management in 
children presents particularly difficult challenges, and that advances in paediatric 
tuberculosis research could provide wider insights and opportunities for tuberculosis 
control.  
In the proposed protocol we aim to study the pharmacokinetics of second-line anti 
tuberculosis drugs terizidone and PAS in childhood TB across the range of dosages 
and ages in order to determine the validity of the currently suggested doses based on 
adult target concentrations as well as pharmacokinetic data obtained in a reference 
group of adult patients in the present study..  
We also aim to conduct the in vitro evaluation of susceptibility and stability of the 
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  B :  P r o t o c o l  o f  S t u d y  1  | 146 
 
 
second line anti TB drugs (ETH, terizidone and PAS) to biotransformation when 
subjected to metabolic enzymes. These drugs will also be incubated with the 
substrates of major enzymes/isoenzymes i.e. cytochrome P450 enzymes (CYPs), 
flavin containing monooxygenases (FMO) and uridine glucoronosyl transferases to 
determine whether they have any inhibitory effects on these enzymes. 
 
Background information and literature review 
Burden of TB 
Tuberculosis (TB) is a highly contagious chronic granulomatous bacterial infection, 
and is still a leading killer worldwide. TB has returned with a new face and the global 
scourge of multi-drug resistant TB (MDR TB) is reaching epidemic proportions. Rates 
of HIV infection among TB patients are correspondingly high, exceeding 60% in 
South Africa, Botswana, Zambia, and Zimbabwe. (Du Toit et al., 2006) It is 
estimated that one third of the world’s population is infected with mycobacterium 
tuberculosis, and that each year, about 9 million people develop TB, of whom about 2 
million die. Of the 9 million annual TB cases, about 1 million (11%) occur in children. 
Of these childhood cases, 75% occur annually in 22 high burden countries. (WHO 
Guidelines., 2006) TB in the Western Cape Province was 520/100,000 in 1998 and 
678/100,000 in 2003. (Cape Town TB Control Progress report 1997-2003) 
 
Tuberculosis in children 
Children are mainly infected by adult pulmonary TB source cases and childhood TB 
therefore reflects the intensity of ongoing transmission of Mycobacterium tuberculosis 
within a community. (Schaaf et al., 2005) Since most children acquire the organisms 
from adults in their surroundings, the epidemiology of childhood tuberculosis follows 
that in adults. Tuberculosis case load represented by children suggest an exponential 
rise in the proportion of the tuberculosis case load caused by children as the 
tuberculosis rises, nearly 40 per cent of the case load in certain high incidence 
communities. (Donald PR., 2002) In Cape Town, South Africa, childrensuffer 
considerable morbidity: 207/439 (47.1%) had disease manifestations other than 
uncomplicated lymph node disease, while 26/439 (5.9%) were diagnosed with 
disseminated (miliary) disease and/or tuberculous meningitis (TBM). (Marais et al., 
2004) 
 
Pediatric pharmacology: Consequences of immaturity 
Developmental changes are responsible for differences in drug disposition seen 
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throughout childhood, therefore the weight-adjusted drug dose may not be the same 
for different age groups. During a period of latent or rapid growth, some drugs that 
may cause severe or protracted toxicity can alter the final mature expression of a 
system.. These concepts of drug effects on host effect on drug need to be 
appreciated for appropriate use of drugs in children. (Pradhan et al., 1986) Age-
related differences in PK, in addition to those of body size, can be used to guide 
calculations. Altered absorption, distribution, and elimination are most marked in the 
newborn, but for many drugs, disposition process may equal or exceed the adult 
capacity by late infancy and /or childhood. (Pradhan et al., 1986) 
 
Drug-resistant Tuberculosis 
The treatment and control of TB is more complex when the organism is resistant to 
the action of antituberculosis drugs. MDR-TB are associated with mortality as high as 
43–93% in adults, despite limited information in children,  resistance patterns in 
children have generally been found to be similar to those of adults from the same 
areas and similar backgrounds. (Nelson et al., 2004) Traditionally, patients with 
drug-resistant tuberculosis are classified as having acquired or primary drug 
resistance on the basis of a history of previous treatment. In the survey in 35 
countries, the median prevalence of primary resistance to any antituberculous drug 
was 9·9% (range 2-41) and that of acquired resistance was 36%. (Van Rie et al,. 
2000). In a study conducted at Tygerberg Children Hospital (TCH). Among 313 
children (range 2 weeks -/12.9 years) in whom drug susceptibility test (DST) results 
were available, 40 (12.8%) and 17 (5.4%) were infected with strains resistant to 
isoniazid and rifampicin, respectively. All who had rifampicin-resistant strains had co-
existent resistance to isoniazid (MDR TB). Only 1/40 (2.5%) children with resistance 
to isoniazid and/or rifampicin was also resistant to ethambutol. (Schaaf et al., 2007) 
Extensively drug resistant tuberculosis has now been reported from 45 countries, 
though this almost certainly underestimates its true extent as many countries lack 
laboratory facilities to detect resistance to second line drugs. The outbreak in South 
Africa was particularly alarming because, most patients with extensively drug 
resistant tuberculosis had no history of tuberculosis treatment, implying person to 
person transmission of extensively drug resistant tuberculosis, and because of 
evidence of transmission in healthcare settings. (Grant et al., 2008)  
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Second-line anti-tuberculosis drugs 
Terizidone 
Terizidone (a derivative of cycloserine) It has a bacteriostatic effect at the usual dose, 
is used in combination with other second-line agents in the treatment of MDR-TB, as 
it does not share cross resistance with other anti TB drugs.  It is believed to have 
lower incidence of side effects than cycloserine. (WHO, Geneva., 2002. SAMF 8th 
Ed, 2008) 
 
Para-aminosalicylic acid (PAS) 
PAS is bacteriostatic drug, in-vitro, most strains of the mycobacterium tuberculosis 
are sensitive to a concentration of 1µg/ml. It is administered orally in a daily dose of 
10 to 12g. (Goodman and Gilman., 2006) PAS is used primarily as a second-line 
drug to treat MDR TB. (Mathys et al., 2009) 
 
Hypothesis 
1. Because of developmental changes, the pharmacokinetics of terizidone and 
PAS and resulting serum levels may differ in children of different age groups. 
2. Young children require a higher body weight adjusted dosage of the “second-
line” antituberculosis agents, terizidone and PAS than adults to achieve 
equivalent serum concentrations. 
3. Because of the genetic variations of the metabolizing enzyme (N-
acetyltransferase) the serum concentrations may differ in different individuals. 
4. The drugs under investigation are metabolically unstable and have a potential 
for drug-drug interactions.  
 
Rationale 
Children in endemic settings are highly susceptible to TB infection and disease. 
Because of the rising rates of MDR TB and because children are at a higher risk of 
developing disseminated forms of tuberculosis, information on drug dosing for 
second line drugs in this patient population is urgently needed. 
 
Aim of study 
1. To document the descriptive pharmacokinetics of the second-line 
antituberculosis agents terizidone and PAS in children, in an attempt to 
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provide an insight to the dosing rationale of these compounds; these data will 
be compared to the results obtained in adult patients as a reference group. 
2. Investigate the genetic variation of NAT1and NAT2 in patients with 
tuberculosis treated by PAS. 
3. To evaluate the susceptibility and stability of the second line anti TB drugs 
(ETH, terizidone and PAS) to biotransformation when subjected to metabolic 
enzymes. 
4. To generate baseline data and methodology for the future applicationif in-vitro 
metabolism studies at the Division of Pharmacology. 
 
Study methodology 
Study design 
1. A prospective, longitudinal, hospital based clinical pharmacokinetic study.  
2. An in-vitro laboratory based analytical study 
 
Study setting and study population 
The study recruitment sites will be Tygerberg Children's Hospital (TCH) and Brooklyn 
Chest Hospital (BCH) both associated with the Stellenbosch University and situated 
in the district of Cape Town. TCH is a tertiary level hospital and serves as referral 
hospital for complicated TB cases from the surrounding high-burden communities.  
BHC is a specialized TB hospital, focusing on the long-term treatment of complicated 
and drug-resistant TB. 
Subjects and sites 
Children with probable or confirmed drug-resistant tuberculosis admitted to the above 
mentioned hospitals, who are on treatment with terizidone and/or PAS.  
Sample size considerations  
In this explorative study a valid estimation of number of cases needed for statistical 
significance cannot be made as there is neither data on terizidone, PAS serum levels 
nor on standard deviations in children of different age groups. For reasons of 
practicability and according to the incidence of a therapy regimen containing 
terizidone and PAS in childhood tuberculosis, we plan to enrole up to 30 children for 
terizidone, up to 10 children for PAS and up to 40 adults for PAS, however this 
relatively small sample size may have less statistical power. 
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Inclusion criteria  
Children between 2 month and 13 years of age and adults older than 18 years who 
require treatment with second line anti-TB drugs terizidone and PAS and are 
admitted to one of the participating hospitals, who are medically stable and 
accompanied by a parent or legal guardian who has given written, informed consent 
for the participation of the child in the study. Patients included in another study 
(Schaaf et al) involving PK of ethionamide may also be included in the present 
protocol 
Exclusion criteria  
Children who are medically unstable such as those with severe anaemia, severe 
malnutrition, diarrhea and dehydration or other medical condition such as to make 
the drawing of blood inadvisable, or whose parents or legal guardian are unwilling to 
give permission for their children to participate in the study.  
 
Procedure for in-vivo study 
The serum concentration of terizidone will be determined at time 0, -1, -2, -3, -4-, -6, -  
and 24 hours after dosing in groups of up to 10 children from each age group, in 
children 3 months -<2 years, 2-<6 years, and 6-12 years of age receiving the 
currently recomended dosage. This methodology requires 1 ml of blood for each 
assay and a total of 7 ml of blood will thus be drawn during each assessment. 
The serum concentrations of PAS will be determined at time 0, - 2, - 4, - 6, - 8, - and 
12 or 24 hours in one group of up to 10 children aged between 3 months and 13 
years after receiving a single dose per day. In adults, blood sampling times will be 0, 
-2, -3, -4, -5, -6, -8 and 12 or 24 hours. Blood sampling will be repeated after 2 to 4 
weeks after receiving a multiple dose per day (twice-daily). The dose will be kept 
refrigerated and will be given with an orange juice under observation from the 
researcher. This methodology requires 1 ml of blood for each assay and a total of 
12 ml of blood will thus be drawn for both assessments in children and a total of 20 
ml in adults.  
These amounts does not exceed the allowable sample volume of 9.6, 36, 96 ml for 
the full term neonates, children (3 years) and children (12 years), respectively 
(Abdel-Rahman et al., 2007). However, considerations will be given to patients with 
diarrhea, severe anaemia, severe malnutrition or any other medical conditions that 
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restrict blood sampling. 
In the paediatric population, an anesthetic patch will be applied for 45 minutes before 
inserting an indwelling catheter that will be used so that venipunctures are reduced 
throughout the investigation. 
Serum concentrations will be determined by an established high performance liquid 
chromatography with mass spectrometry (HPLC-MS) methodology. 
Procedure for in-vitro metabolism  
The test compound will be incubated at concentrations with the enzyme source 
(Human liver microsomes (HLM), and S9 fractions) with appropriate positive and 
negative controls. At varying time intervals, the reactions will be terminated. The time 
spacing and replicate number will be according to the standardized procedures. The 
amount of parent drug remaining in the incubation media will be analyzed by HPLC-
MS.  
The current procedure will involve the incubation of substrates for specific 
isoenzymes with the test compounds and the enzyme source (Human liver 
microsomes) to determine the effects of these drugs to different metabolizing 
enzymes. 
 
Procedure for pharmacogenetics assays 
The blood cell pellet obtained from blood samples taken for pharmacokinetic assays 
will be stored frozen at -40oC or below. In an initial stage it is planned to determine 
the genotype for both types of N-acetyl-transferase (NAT-1 and NAT-2). Samples 
may also be analysed for other proteins involved in drug elimination (such as P-
glycoprotein) at a later stage.  
 
Data management and Statistical analysis  
Microsoft Excel will be used to capture the data and STATISTICA version 8 (StatSoft 
Inc. (2008) STATISTICA (data analysis software systems. will be used to analyse the 
data. Data will be collected on case report forms (CRF) and study flowcharts and 
then entered into an Access or SPSS database.  
Summary statistics will be used to describe the variables. Distribution of variables will 
be presented as histograms and or as frequency tables. Medians or means will be 
used as the measures of central location for ordinal and continuous responses and 
standard deviations and quartiles as indicators of spread. The relationship between 
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continuous response variables and nominal input variables will be analysed using 
appropriate analysis of variance (ANOVA). When ordinal response variables are 
compared versus a nominal input variable, non-parametric ANOVA methods will be 
used. For completely randomized designs the Mann-Whitney test or the Kruskal-
Wallis test will be used and for repeated measures the Wilcoxon- or Friedman tests 
will be used. 
A population pharmacokinetic analysis will also be conducted to determine the 
pharmacokinetic effects of different covariates and to quantify the covariates 
contributing to the studied drugs’ clearance and volume of distribution population 
parameters including variability in order to establish an initial estimate of the major 
covariates required for dosing predictions.  
Ethical consideration  
The study will be conducted according to the principles of Good Clinical Practice, 
South African and internationally accepted ethical standards taking into account the 
Declaration of Helsinki and International Conference on Harmonisation (ICH) 
guidelines. 
All patients referred to the hospital for treatment might participate if they are eligible 
and a written informed consent (for children: by parents or legal guardians) is given. 
Before enrolment, children older than 7 years will be asked to assent after being fully 
informed about the rationale, procedure, data management as well as potential 
benefits and risks of the study.  
The patients participating in the study will not directly benefit from the study; 
however, the study will provide important information for the optimal treatment and 
the use of terizidone and PAS in childhood tuberculosis. 
This study is in the interest of improving medical care for children with tuberculosis in 
need of the second line drugs, terizidone and PAS. No alteration in the prescribed 
treatment of the children will be made other than that prescribed by the attending 
physicians. 
The consent form will be available in English, Afrikaans and isiXhosa, the parents will 
be informed of the possibility to revoke informed consent even though it was made in 
writing. There will be no financial incentive offered for study participation. 
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Blood samples for measurements of serum levels and additional parameters will be 
collected through a permanent angiocatheter that will be inserted at the beginning of 
each study day to minimize the number of necessary venipunctures. 
Obtained data will be collected in a database using a unique anonymous subject 
code for each patient. Identified information linked to the study code will be recorded 
separately. The confidentiality of all information of a personal nature will be 
maintained and ensured at all times. Only the researcher and authorized officials 
affiliated to control bodies will be allowed access to personal information. 
It is the intention of the researcher to present and publish the findings of the study in 
an appropriate medical journal without, as indicated, divulging any information of a 
personal nature. 
Risks associated with participation in the study 
The participants will be treated as usual by their attending physician. The 
investigators will not in any way alter their drug therapy. The risks are therefore those 
associated with venipuncture. These include pain, bruising and bleeding at the site of 
IV cannula insertion.  
To minimize these risks, an indwelling IV cannula will be inserted so that repeat 
venipuncture is minimized and a topical anaesthetic gel will be used. These 
symptoms usually resolve spontaneously or may require the application of gentle 
pressure to the area for a few minutes after cannula removal.   
A further risk is the drawing of blood in children who are anaemic or dehydrated. To 
prevent this, children who are medically unstable such as those with severe anaemia, 
severe malnutrition, diarrhea and dehydration or other medical condition such as to 
make the drawing of blood inadvisable will be excluded from the study.   
Furthermore, the amount of blood drawn will be limited to 8ml in total, which is less 
than the upper limit recommended in guidelines (Abdel-Rahman et al., 2007).  
Feasibility of the study  
The participating hospitals admit good number of children per year (approximately 
120-130) of whom great majority have either drug-resistant tuberculosis and require 
second line anti tuberculosis agents. It should therefore be possible to enroll the 
proposed number of patients at these facilities within a time a year. Furthermore, the 
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Division of Pharmacology has a long standing and extensive experience in 
conducting pharmacokinetic studies in childhood tuberculosis. It has previously been 
involved in studies which characterized the pharmacokinetic disposition of isoniazid 
in children and has produced refined the methodology for determining the serum 
concentrations of several antituberculosis agents. 
For the in vitro study we are collaborating with experts from Synexa group, South 
Africa, who have considerable experience in such kind of laboratory work; the 
reagents for the in vitro study are readily available commercially. 
 
Conclusion 
The data generated in this study will be used as guidance for future studies involving 
much larger populations. We plan to present the data at congresses and to write this 
up for publications. 
 
Time plan 
We have planned to submit the protocol between August-September 2009 and have 
full Ethics approval for the study to start shortly thereafter. The aim is to collect data 
according to the protocol within a year. Data entry analysis and writing of the 
manuscript could be completed in 2 months. It would be possible to aim at the final 
manuscript at the end of year 2010 for the final master’s thesis presentation. At the 
time of the submission of this amendment, the clinical project is ongoing (paediatric 
population).  
The in vitro study will have a specific timeline, its implementation will commence after 
the approval from the ethical committee and the arrival of the required study 
materials. 
 
Funding and budget: 
Partial funding from the departmental funds is readily available. In addition, funding 
requests/ applications have been submitted to Medical Research Council and Harry 
Crossley Foundation and we await for feedback and possible approval. The budget 
summary is as indicated in the chart below: 
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Table 1: Budget 
 
 Unit cost 
(R) 
No. of 
units 
Sub-total 
(R) 
Consumables    
 Blood collection and specimens     75  180 13 500  
 Micro centrifuge polypyrolene tubes   950      1     950  
Reagents    
 Liver microsomes 1660    25 41 500  
S9 fractions   650   20 13 000  
Co-factors (NADPH, UDPGA)     9 000  
Other reagents (DMSO, Phosphate buffer, 
Methanol, Acetonitrile) 
    4 000  
Substrates    20 000 
Laboratory analyses    
 Development and Validation of assays     10 000  
 Analysis of specimens   800  180 144 000  
Travel    
 Parents/ caregivers to and from the hospital   100   30   3 000  
 Cost for courier services - -   8 000  
Total 266 950 
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Appendix   
Terms and definitions relating to tuberculosis and drug resistance  
 Drug resistant tuberculosis-Tuberculosis that is resistant to any first line 
antituberculosis drug  
 Multidrug resistant tuberculosis (MDR-TB)-Tuberculosis that is resistant to 
at least isoniazid and rifampicin 
 Extensively drug resistant tuberculosis (XDR-TB)-Tuberculosis that is 
resistant to at least isoniazid and rifampicin and also to a fluoroquinolone and 
a second line injectable agent (amikacin, capreomycin, or kanamycin) 
 Drug resistance in new tuberculosis cases (primary drug resistance)-
Drug resistant tuberculosis in a person with no history of tuberculosis 
treatment, implying they were infected with a resistant organism. This reflects 
person to person transmission of drug resistant tuberculosis 
 Drug resistance among previously treated cases ("acquired" drug 
resistance)-Drug resistant tuberculosis in a person with a history of 
tuberculosis treatment. This reflects drug resistance acquired during 
tuberculosis treatment but may also reflect infection or reinfection with a 
resistant organism (Grant et al., 2008)  
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The standardized regimen for treatment of multidrug-resistant TB in South Africa is 
as shown in the table below: 
Standardized Regimen for Treatment of Multidrug-Resistant TB(MDR-TB) in SA 
Treatment should be started in a referral centre and be adjusted according to a 
patient weight 
Pre-
treatment 
body 
weight 
Intensive phase: 4 months 
Doses given daily 
Kanamycin Ethionamide   PZA Ofloxacin   Ethambutol or 
terizidone 
< 50 kg 
   50-65 
≥ 65 
750 mg 
1000 mg 
1000 mg 
500 mg 
750 mg 
750 mg 
1000 
mg 
1500 
mg 
2000 
mg 
600 mg 
600 mg 
800 mg 
800mg 
1200mg 
1200 
mg 
750 mg 
750 mg 
750 mg 
 Pre-
treatment 
body 
weight 
Continuation phase 12-18 months depending on culture conversion 
Doses give daily 
       Ethionamide          Ofloxacin Ethambutol or 
terizidone 
< 50 kg 
   50-65 
kg 
≥ 65 kg 
500 mg 
750 mg 
750 mg 
60 mg 
600 mg 
800 mg 
800 mg 
1200 mg 
1200 mg 
500 mg 
750 mg 
750 mg 
Ethambutol is used if strain still susceptible. Terizidone is used if strain resistant to 
ethambutol. Reduce terizidone dose to 500 mg if weight ≤ 35 kg. Pyridoxine (Vit B6) 
150 mg to be given to patients on terizidone. Some provinces may be using 
cycloserine instead of terizidone. (Begley, 2007)  
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Appendix C: Protocol of Study 2 
PHARMACOKINETICS OF TWICE DAILY VS. 
ONCE DAILY DOSING WITH GRANULAR SLOW-
RELEASE PARA-AMINOSALICYLIC ACID IN 
ADULTS ON SECOND-LINE ANTI-
TUBERCULOSIS AND ANTIRETROVIRAL 
TREATMENT 
 
PLACE OF RESEARCH: 
Division of Pharmacology, Faculty of Health Science, University of Stellenbosch, Tygerberg 
 
INVESTIGATOR 
Lizanne de Kock1 
 
CO-INVESTIGATORS: 
Prof AH Diacon3 
Prof PR Donald MD2 
Dr K Prescott MFPM1 
Dr HI Seifart PhD 1 
Prof B Rosenkranz MD PhD FFPM 1 
Dr C Werely 
 
 
1Division of Pharmacology, Department of Medicine, Faculty of Health Science 
2 Department of Paediatrics and Child Health and Desmond Tutu TB Centre 
3Department of Molecular Biology and Human Genetics, and the MRC Centre for Molecular 
and Cellular Biology, DST/NRF Centre of Excellence for Biomedical TB research 
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1. PROTOCOL SYNOPSIS 
Title 
Pharmacokinetics of twice daily vs. once daily dosing with granular slow-release 
para-aminosalicylic acid in adults on second-line anti-tuberculosis and antiretroviral 
treatment 
Introduction  
Extensive drug resistant tuberculosis (XDR-TB) is difficult to treat and a high mortality 
rate has been reported. These patients may require second-line treatment which 
includes para-aminosalicylic acid (PAS). Despite being the oldest effective TB drug, 
little is known about the pharmacokinetics of PAS and interactions with other drugs, 
particularly in the face of antiretroviral drug regimens and using the new granular 
slow-release PAS (GSR-PAS). Although, interactions have not been reported, the pill 
burden prescribed to multi-drug resistant tuberculosis (MDR-TB) and XDR 
tuberculosis patients with HIV may increase the potential for interactions. Several 
efforts are underway not only to improve the management of MDR-TB cases co-
infected with HIV, but also to reduce the daily drug regimen, pill burden and duration 
of therapy. In the face of large pill burden due to multiple drugs being used to treat 
both TB and AIDS, and a treatment programme that relies on directly observed 
treatment (DOT), a once-daily dosing regimen for PAS is preferable rather than the 
twice-daily regimen being used at present. As PAS is increasingly being used in the 
second-line treatment of TB, this study aims to add to our understanding of the 
pharmacokinetic profile of PAS in adults on multiple drug regimens, including patients 
who are also on antiretroviral drug regimens and those who are not.  
Primary objective is to investigate the pharmacokinetics of PAS given once daily vs. 
twice daily and to establish whether once daily dosing will result in concentrations 
above the MIC of M tuberculosis for a period comparable to twice daily dosing in 
adult MDR/XDR-TB patients.  
Secondary objectives: To investigate the safety and tolerability of PAS when given 
once daily vs. twice daily; to investigate the pharmacokinetics of PAS in patients on 
antiretroviral treatment and those not on antiretroviral treatment; and to investigate 
the pharmacokinetic effects of genetic variations of the genes involved in PAS 
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metabolism (NAT 1 and NAT 2)  
Study design and methodology 
This is a randomized, two-period, open-label cross-over study which will investigate 
and compare the pharmacokinetics and tolerability of the two different methods of 
PAS dosing, once-daily vs. twice-daily, in adult patients with MDR- or XDR-TB. The 
proposed study can be completed only in a population with high prevalence of drug 
resistant disease and HIV. Therefore, the study will utilize a hospital-based strategy 
to recruit adults routinely screened for drug resistant tuberculosis and treated for the 
disease. Forty eight adults (aged ≥ 18) at Brooklyn Hospital for Chest Diseases 
and/or D.P. Marais Hospital, Cape Town, South Africa will be enrolled in the study. 
These patients will be equally divided into two groups: Those on antiretroviral 
treatment (ART) and those not on ART (24 patients in each group). Patients in each 
group will be randomized to receive either 2x 4g GSR-PAS (n = 2x12) or 1x8g GSR-
PAS (n =2x12) for 8 days. Samples will be collected for pharmacokinetic analysis 
over a 24 hour period on Day 8. Thereafter, the regimens will be crossed over and 
these regimens will be followed for another 8 days (Days 9 to 15). Blood samples will 
again be taken over a 24 hour period on Day 16. The duration of the study for an 
individual subject will be 31 days. Dosage regimens, dosing time and blood sampling 
times will be recorded for each patient. Three millilitre blood specimens will be 
collected through a catheter inserted into a forearm vein, pre-dose and at t0, 1, 2, 3, 
4, 6, 8, 10, 12 (pre-dose) and 24 hours after dosing. Therefore, 30 ml blood will 
collected for each pharmacokinetic sampling day. An additional blood sample (3 ml) 
will be collected in an EDTA tube for genetic analysis. If not already known, blood for 
HIV testing will also be obtained. 
Sample Analysis 
Samples will be analysed for PAS by a high-performance liquid chromatography 
(HPLC) MS/MS assay using binary HPLC (Agilent Series 1100 HPLC, Agilent 
Technologies, Waldbronn, Germany) equipped with an Agilent Zorbax analytical 
column (150mm x 2.1 mm, 3.5 µm particle size. 
Safety monitoring 
Safety and tolerability will be assessed by health assessments including physical 
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examinations, Visual analogue scales (VAS), clinical laboratory results, reporting of 
adverse events and vital signs. Subjects will be interviewed at the beginning and at 
the end of the study and monitored throughout the study. If clinically indicated, 
additional tests will be conducted as required. 
Risks and Benefits 
The participants will be treated as usual by the attending physician. The investigators 
will not alter their drug therapy, except for the PAS dosing regimen during the study 
period. The patients may experience pain, bruising and/or bleeding at the side of 20-
gauge angiocatheter insertion. In addition, there is a risk that unexpected side-affects 
may occur and that the once-daily dosage may not be as effective as the standard 
dosage. However, it has never been demonstrated in any trial that twice or thrice 
daily dosing gives better results than once daily dosing. It is thought that the plasma 
concentration must be continuously above known minimum inhibitory concentrations 
(MIC= 1μg/ml) to be effective.  Therefore, the side-affects will be monitored and the 
patient will be made aware of the risks of the study. 
Ethical Considerations 
The project will be conducted accordingly to South African laws and regulations 
including South African GCP and to the Declaration of Helsinki. Blood samples will 
be collected through an indwelling catheter which will be inserted at the beginning of 
each pharmacokinetic study day to minimise the number of necessary punctures. A 
qualified research nurse will insert the catheter and the patients may experience 
minor pain or bruising at the site. The data and information of each patient will be 
concealed by the use of a unique subject code and identified information linked to 
study code will be recorded separately. The confidentiality will be maintained at all 
times. Only the researcher and authorized officials affiliated to control bodies will be 
allowed access to personal information. 
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2. LITERATURE REVIEW 
Multi-drug resistant tuberculosis (MDR-TB) caused by strains of M. tuberculosis 
resistant to first-line tuberculosis (TB) drugs, rifampicin and isoniazid, has emerged 
as an increasing threat world-wide 1, 2. Extensively drug-resistant (XDR) isolates are 
in addition, resistant to second-line drugs, i.e. fluoroquinolones and injectable 
second-line drugs such as kanamycin (KM), amikacin (AM) and capreomycin (CM) 1, 
3.  The emergence of these drug-resistant (DR) strains largely results from 
deficiencies in TB case- and program-management 1.  
XDR-TB is difficult to treat and a high mortality rate has been reported. According to 
the South African  MDR-TB Guidelines (2011), depending on the resistance pattern 
of the isolates, these patients may require  treatment with the following second-line 
drugs: capreomycin, moxifloxacin, ethionamide, terizidone, pyrazinamide, clofazimine 
and para-aminosalicylic acid (PAS). These second-line drugs are less effective, more 
toxic and more costly than drug-susceptible TB treatment 2. Little is known about the 
pharmacodynamics and pharmacokinetics of these drugs, but especially the new 
slow-release preparation of PAS.  
PAS 
PAS was used to treat tuberculosis for the first time in 1944 4 and formed part of the 
standard treatment for TB for several decades until more effective first-line drugs for 
example, rifampicin were introduced. In 1992, PAS was re-introduced in the USA for 
management of MDR-TB and later for XDR-TB 5 and is increasingly used in South 
Africa for treatment of DR-TB. 
PAS is a bacteriostatic agent valuable in preventing resistance to other drugs 6. It 
has been described as less tolerable than the other second-line drugs and has a 
short half-life. After re-introduction as a treatment for MDR-TB, a granular slow-
release formulation (GSR-PAS) was developed, which demonstrated an improved 
gastrointestinal tolerance and a longer half-life than the immediate-release sodium 
PAS tablet 7. The maximum serum concentration is reached after 6 hours following 
GSR-PAS administration 8 
Despite the above reservations about once daily dosing it is of interest that several 
early studies comparing once daily and intermittent daily GSR-PAS dosing found that 
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adult patients tolerated once daily dosing better than multiple doses.  9, 10, 11 It was 
also reported that a single daily GSR-PAS dose was clinically as effective as divided 
daily doses of GSR-PAS, both in TB patients 9 and experimental animals.12 When 
the early bactericidal activity of GSR-PAS in a single daily dose of 15 g over the first 
two days of treatment was evaluated in a small group of pulmonary TB patients it 
was second only to that of isoniazid suggesting significant early bactericidal activity 
at higher concentrations.13  
Peloquin et al. conducted a study with GSR-PAS (Paser; Jacobus Pharmaceuticals, 
Princeton, NJ) in a small number of patients and reported that serum concentrations 
in excess of the MIC were achieved throughout the dosing interval of the granules 7. 
After the 22nd dose, a median serum concentration of nearly 3 times higher than the 
initial concentration was reported, which indicated an accumulation of GSR-PAS. 
In another study by Peloquin et al., once daily dosing in comparison to a twice daily 
dosing regimen of GSR-PAS was investigated, and concentrations above improved 
minimum inhibitory concentrations (MIC= 1μg/ml) were reported to be longer for the 
4g twice daily than the 4g once daily regimen8. The granules were generally well 
tolerated in this study; however a few patients reported nausea and gastrointestinal 
discomfort, which can be ascribed to the high serum concentrations (80-90µg/ml).  
Higher pH in the patient’s stomach can increase the rate of release of PAS from 
granules which can cause an increased serum concentration, but also a more rapid 
elimination of PAS. The higher pH is possibly due to the basic food or beverages 
patients consumed near their dosing time. Although twice daily dosing is associated 
with a longer period above MIC, multiple daily doses are not practical in all settings 
especially not in resource-limited settings with notably poor patient compliance and a 
need for directly observed treatment (DOT). Peloquin’s studies were also carried out 
on MDR-TB treated patients and did not include those treated with anti-retroviral 
treatment (ART) and other anti-tuberculosis agents. 
Despite being the oldest effective TB drug, little is known about the pharmacokinetics 
of PAS and interactions with other drugs, but especially other anti-tuberculosis and 
antiretroviral treatments. Although, interactions have not been reported, the pill 
burden prescribed to MDR and XDR tuberculosis patients with HIV may increase the 
potential for interactions.  
In addition to drug interactions, genetic variations may influence an individual’s ability 
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to utilize and tolerate different treatments. Gene variations involved in absorption, 
distribution and metabolism of drugs are often studied in this regard. Variants in N-
acetyltransferase 2 (NAT2) have long been recognized to modulate toxicity produced 
by the anti-tuberculosis drug isoniazid (INH) 14. PAS is metabolised by acetylation, 
where more than 50% of the drug is acetylated 15. N-acetyltransferase 1 (NAT 1) is 
responsible for the acetylation of PAS. NAT 1 is also known to be polymorphic but is 
usually thought to have a relatively minor effect on PAS pharmacokinetics 16. 
This is a randomized, two-period, open-label cross-over study which will investigate 
and compare the pharmacokinetics and tolerability of the two different methods of 
PAS dosing, once-daily vs. twice-daily, in adult patients with MDR- or XDR-TB, 
including patients who are also on ART and those who are not, in order to investigate 
the possible interactions with commonly used ARV regimens. 
3. RATIONALE FOR STUDY DESIGN 
Little is known about the pharmacokinetics of PAS in treatment of adults requiring 
second-line tuberculosis treatment, particularly in the face of antiretroviral drug 
regimens and using the new slow-release preparation. Several efforts are underway 
not only to improve the management of MDR-TB cases co-infected with HIV, but also 
to reduce the daily drug regimen, pill burden and duration of therapy. In the face of 
large pill burden due to multiple drugs being used to treat both TB and AIDS, and a 
treatment programme that relies on DOT, a once-daily dosing regimen for PAS is 
preferable rather than the twice-daily regimen being used at present. As PAS is 
increasingly being used in the second-line treatment of TB, this study aims to add to 
our understanding of the pharmacokinetic profile of PAS in adults on multiple drug 
regimens, including patients who are also on antiretroviral drug regimens and those 
who are not.  
Genetic variations 
Significant individual variations in the tolerability and effects of PAS have been 
reported. This may be due to genetic factors. N-acetyltransferase (NAT) is 
responsible for the metabolism of PAS and will therefore be investigated in the study. 
Formal evaluation by genotyping of the effects of NAT1 and NAT2 enzymes on the 
pharmacokinetics of PAS has never been undertaken. 
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4. OBJECTIVES 
4.1. Primary objective is to investigate the pharmacokinetics of PAS given once 
daily vs. twice daily and to establish whether once daily dosing will result in 
concentrations above the MIC of M tuberculosis for a period comparable to twice 
daily dosing in adult MDR/XDR-TB patients.  
4.2. Secondary objectives: 
– To investigate the safety and tolerability of PAS when given once daily vs. 
twice daily 
– To investigate the pharmacokinetics of PAS in patients on antiretroviral 
treatment and those not on antiretroviral treatment 
– To investigate the pharmacokinetic effects of genetic variations of the genes 
involved in PAS metabolism (NAT 1 and NAT 2)  
5. STUDY DESIGN AND METHODS  
This is a randomized, two-period, open-label cross-over study which will investigate 
and compare the pharmacokinetics and tolerability of the two different methods of 
PAS dosing, once-daily vs. twice-daily, in adult patients with MDR- or XDR-TB. The 
proposed study can be completed only in a population with high prevalence of DR 
disease and HIV. Therefore, the study will utilize a hospital-based strategy to recruit 
adults routinely screened for DR-TB and treated for the disease.  
Forty eight adults (aged≥ 18) at Brooklyn Hospital for Chest Diseases and/or D.P. 
Marais Hospital, Cape Town, South Africa will be enrolled in the study. These 
patients will be equally divided into two groups: Those on ART and those not on ART 
(24 patients in each group). Patients in each group will be randomized to receive 
either 2x 4g GSR-PAS (n = 2x12) or 1x 8g GSR-PAS (n =2x12) for 8 days. Balanced 
allocation will mean that 12 patients on ART and 12 patients not on ART will receive 
each regimen in both Treatment Periods 1 and 2.  
Samples will be collected for pharmacokinetic analysis over a 24 hour period on Day 
8. Thereafter, the regimens will be crossed over, with those who received 2x4g GSR-
PAS, then receiving 1x 8g GSR-PAS and those who received 1x 8g GSR-PAS then 
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receiving 2x 4g GSR-PAS. These regimens will be followed for another 8 days (Days 
9 to 16). Blood samples will again be taken over a 24 hour period on Day 16. The 
duration of the study for an individual subject will be 31 days. Day -7 to -1: Screening 
and baseline measurements; Day 0: Subjects will be officially enrolled on Day 0 and 
will be randomised to one of the treatment regimens; Day 1-8: Continue the dosing 
for 8 days; Day 8: Pharmacokinetic samples will be taken; Day 9: Cross-over; Days 
8-16: continue the dosing; Day 16: Pharmacokinetic samples will be taken; Day 23: 
follow- up. Figure 1 is a schematic illustration of the study and table 1 shows the 
study events. 
Figure 1 Schematic illustration 
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Table 1 Events table 
Test -7 to -
1 
1 to 7 8 9 10 to 
15 
16 17 to 
22 
23 
Screening X        
Randomisation  X       
PAS routine X      X X 
GSR-PAS 
2x4g* 
 X X (X) (X) (X)   
GSR-PAS 
1x8g* 
 (X) (X) X X X   
PK sampling   X   X   
Cross over*    X     
Follow up        X 
* Patients will be randomized to start with either treatment and be switched to the 
alternative treatment at cross over day.  
5.1. Sample size 
The sample size chosen for this study was based on precedent set by other 
pharmacokinetic studies of similar nature and not on statistical considerations. 
However, the sample size is more than twice the sample size used in other 
pharmacokinetic studies in order to account for known variability in the 
pharmacokinetics of PAS, and the potential for patients to drop out. 
5.2. Subject criteria 
Eligible: Adults routinely screened for MDR-TB and XDR and treated for disease (N= 
48) at Brooklyn Hospital for Chest Diseases and/or D.P. Marais Hospital, Cape 
Town, South Africa, the following will be eligible for enrolment. 
5.2.1. Inclusion criteria 
The following criteria must be met to participate in this study: 
 Males and females, aged ≥18 years 
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 Written informed consent; if patients agree to take part in the genetic sub-
study, a separate informed consent must be obtained for this sub-study  
 Known HIV status or willingness to undergo HIV testing in the presence of 
unknown status. A negative test result will be accepted up to 4 weeks 
 Participants must have been clinically stable on an unchanged regimen 
including PAS as part of their routine treatment for 14 days or more 
 The subjects must assent for all aspects of the study and be able to give 
written informed consent for participation in the study before enrolment 
5.2.2. Exclusion criteria 
Subjects will not be included in the study if they meet any of the following criteria: 
 Informed consent for participation or consent for HIV testing not obtained if no 
HIV test is available  
 Any concomitant illness that according to the investigator makes participation 
inadvisable because of potential interference with study variables or increase 
risk to the patient 
 Planned change in TB or HIV related treatment during the study period 
5.3. Study procedures 
5.3.1. Informed Consent 
Before enrolment into the study and any study procedures will be performed, the 
participant has to give written informed consent for the study. (See appendices for 
consent forms) 
5.3.2. Baseline Procedures  
The following measures and data will be obtained from the patients at baseline 
(enrolment): HIV status and HIV-associated immunity, TB disease status and disease 
spectrum and chest radiograph (CXR), mycobacterial culture and drug susceptibility 
test DST pattern, concurrent illness, concomitant medication, age, Body Mass Index 
(BMI), blood pressure, liver function, renal function, thyroid function, haematology, 
race and gender. 
Note: Race is an important aspect, as drug response is different among different 
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ethnic groups. Local race categories will include African, Indian, Caucasian and 
South African Coloured (mixed ethnicity). Gender will be categorized as male or 
female. 
5.3.3. Physical Examination 
Physical examination will take place at screening and on Days 7 and 15 during the 
study, as well as a follow-up physical examination. 
5.3.4. Treatment Procedures 
The patients will follow their current drug regimens for their tuberculosis treatment; 
and the drugs and dosage will be carefully recorded. All HIV-infected patients will be 
on ARVs. An hour before eating, PAS will be given to all patients with 250 ml of 
orange juice and observed to ensure that they drink all of the juice at the time of 
dosing 
The patients will already be on PAS (≥2 weeks TB treatment), therefore only the daily 
regimen for this drug will change, which they must follow for seven days before the 
first pharmacokinetic sampling will take place. The regimens (once or twice daily) will 
be allocated to the subjects according to an agreed randomisation schedule. 
Adherence to PAS and other medicines will be well controlled and recorded. 
5.3.5. Dosage and Administration 
2x4g GSR-PAS: Twice Daily dosing- Patients will receive a 12-hourly dose (4g) oral 
PAS (PASER® granules) regimen with other already prescribed medicines (See 
appendices for package insert: 
1x8g GSR-PAS: Once Daily dosing- Patients will receive a single (8g) oral PAS 
(PASER® granules) dose once daily along with other already prescribed medicines 
(ARVs and other anti-TB drugs) according to the usual dosing schedule. 
An hour prior to food, PAS will be given with yoghurt or a glass of orange juice under 
direct observation. The acidic beverage prevents early release of the drug in the 
stomach 8.  
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5.3.6. Pharmacokinetic (PK) sampling 
The following pharmacokinetic parameters of PAS will be determined by using non-
compartmental analysis: Maximum observed concentration (Cmax); time at which 
Cmax occurred (Tmax); area under the plasma concentration-time curve (AUC); 
Minimum observed concentration Cmin. 
The blood samples for the PK assessments will be taken at the following time points: 
pre-dose (t0), 1, 2, 3, 4, 6, 8, 10, 12 (pre-dose) and 24 hours. 
5.3.7. Sample collection 
Dosage regimens, dosing time and blood sampling times will be recorded for each 
patient. Three millilitre blood specimens will be collected through a catheter inserted 
into a forearm vein, pre-dose and at t0, 1, 2, 3, 4, 6, 8, 10, 12 (pre-dose) and 24 
hours after dosing. Therefore, 30 ml blood will collected for each pharmacokinetic 
sampling day. The blood will also be used for genetic analysis and informed consent 
will be obtained separately for genotyping. If not already known, blood for HIV testing 
will also be obtained. 
5.3.8. Safety monitoring 
Safety and tolerability will be assessed by health assessment including physical 
examinations, self-rating Visual Analogue Scales (VAS), clinical laboratory results, 
reporting of adverse events and vital signs. Subjects will be interviewed at the 
beginning and at the end of the study and monitored throughout the study. If clinically 
indicated, additional tests will be conducted as required. 
Concurrent illness  
Concurrent illnesses which may have an impact on evaluation of toxicity will be 
documented before and during the study, such as viral hepatitis, central nervous 
system disease, HIV-related target organ disease (particularly renal and hepatic 
impairment) and others. 
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Concomitant medication  
All concomitant medications will be documented, including-but not limited co-
trimoxazole (TMP/SMX); multivitamin supplementation, analgesics, antifungals, 
anthelmintics, antiretroviral treatment, anti-tuberculosis treatment and other 
antibiotics. Should anti-nausea or anti-diarrhoeal medications are required during the 
study; these will also be recorded and included in the adverse event reporting where 
appropriate. 
Self-rating scales 
The most common adverse drug reactions reported for PAS are gastrointestinal 
intolerance manifested by vomiting, diarrhoea, nausea, and abdominal pain. These 
adverse events will be rated by the participant with self-rating Visual Analogue 
Scales (VAS). VAS scales are well validated for assessment of symptoms in 
gastrointestinal conditions 17. The VAS scales will be used to rate the 
gastrointestinal discomfort using scales for: bloating, vomiting, nausea, diarrhoea and 
abdominal pain. The scales will be 10-point scales, with the far left indicating no 
symptoms and far right as severe symptoms. The participants will be asked to 
complete the self-rating VAS scales on a daily basis during the study period. (See 
appendices for VAS scales. 
Clinical laboratory results 
Biochemical parameters for liver, renal, and thyroid function, and haematological 
parameters will be tested at baseline. Thyroid function will be measured at the end of 
the study.  
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Table 2 Clinical Laboratory Tests 
Haematology Plasma Chemistry Urinalysis 
MCV ALT  pH 
MCHC Alkaline phosphatase Specific gravity 
Red blood cells AST Ketones 
White blood cells Bilirubin, total and direct Protein 
Differential white cell count Creatinine Glucose 
Hemoglobin Urea Blood 
Haematocrit Creatine kinase  
Platelets Potassium  
 Sodium  
 
Glucose 
TSH 
 
6. SAMPLE ANALYSIS 
Samples will be analysed for PAS by a high-performance liquid chromatography 
(HPLC) MS/MS assay using binary HPLC (Agilent Series 1100 HPLC, Agilent 
Technologies, Waldbronn, Germany) equipped with an Agilent Zorbax analytical 
column (150mm x 2.1 mm, 3.5 µm particle size 
7. GENETIC ANALYSIS 
DNA will be extracted from the blood sample obtained for genetic analysis. Variations 
in the N-acetyltransferase (NAT1 and NAT2) will be determined through polymerase 
chain reaction (PCR) and sequencing procedure.  
8. PHARMACOKINETIC ANALYSIS 
Descriptive statistics (number of subjects, mean, CV%, SD, percent co-efficient of 
variation, 25th percentile median, 75th percentile, minimum, and maximum) will be 
used to summarize the plasma concentrations of PAS at each scheduled time-point. 
Linear and semi-logarithmic plots of the mean and individual plasma concentration-
time curves of the analytes on Day 1 and Day 5 will be provided. Individual subject 
plasma concentration data will be listed. 
Actual post-dose sampling times, rather than scheduled sampling times will be used 
in the derivation of plasma PK parameters. For ease of presentation, scheduled 
sampling times will be used to present results in tables, listings and figures. 
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The following PK parameters will be determined for each subject: 
AUC (0-24): Area under the concentration-time curve from time 0 to 24 hours post-
dose on Days 8 and 16 
Cmax:  Maximum observed plasma concentration from time 0 to 12 hours post 
dose on Days 8 and 16 
Cmin: Minimum observed plasma concentration just prior to dosing on Days 8 
and 16 
Tmax: Time to reach Cmax on Days 8 and 16 
9. STATISTICAL ANALYSIS 
The sample size chosen for this study was based on precedent set by other 
pharmacokinetic studies of similar nature and not on statistical considerations, as 
very little data is known.  
Subjects will receive a subject number at the time of signing the informed consent 
form and will be randomized according to the numbers to receive 2x 4g GSR-PAS or 
1x 8g GSR-PAS. The subject numbers will be used in all study documentations. 
Subject numbers will not be re-used if a subject withdraws. The statistician will draw 
up a randomisation schedule using blocks of 4 to balance the baseline to ensure that 
equal numbers of patients on ART and those who are not on ART are allocated to 
each Regimen. 
Each variable will be summarised using standard summary statistics, according to 
the regimen sequence. AUC, Cmin and Cmax will be analysed, after log 
transformation, using an analysis of variance model (ANOVA), fitting for the effects of 
subject, period and regimen (once-daily vs. twice daily) as a random effect. The 
results of analysis will be presented in terms of the geometric least squares means 
for each regimen, the ratio of the geometric least squares means and the 
corresponding 95% confidence interval. 
The median difference between each treatment in Tmax will be assessed non-
parametrically on untransformed data; the difference between the 2 being analysed 
by use of a Wilcoxon signed rank test. All safety and tolerability data will be 
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presented with descriptive statistics. 
10. TIME PLAN 
Jan 
2012 
Feb 
2012 
March 
2012 
Apr 
2012 
May 
2012 
Jun 
2012 
Jul 
2012 
Aug 
2012 
Sept 
2012 
Oct 2012 
Nov 
2012 
Ethic approval Start Study 
Data analysis and writing 
up 
Prepare for 
submission 
Submit 
thesis 
 
11. ETHICAL CONSIDERATIONS 
The project will be conducted accordingly to South African laws and regulations 
including South African GCP and to the Declaration of Helsinki.  
The consent forms will be available in English, Afrikaans and isiXhosa. Participants 
will be compensation for inconvenience (R150 per visit).  
Blood samples will be collected through an indwelling catheter which will be inserted 
at the beginning of each pharmacokinetic study day to minimise the number of 
necessary punctures. A qualified research nurse will insert the catheter and the 
patients may experience minor pain or bruising at the site. 
The data and information of each patient will be concealed by the use of a unique 
subject code and identified information linked to study code will be recorded 
separately. The confidentiality will be maintained at all times. Only the researcher 
and authorized officials affiliated to control bodies will be allowed access to personal 
information. 
 12. RISKS AND BENEFITS 
The participants will be treated as usual by the attending physician. The investigators 
will not alter their drug therapy, except for the PAS dosing regimen during the study 
period. The patients may experience pain, bruising and/or bleeding at the side of 20-
gauge angiocatheter insertion. In addition, there is a risk that unexpected side-affects 
may occur and that the once-daily dosage may not be as effective as the standard 
dosage. However, it has never been demonstrated in any trial that twice or thrice 
daily dosing gives better results than once daily dosing. It is thought that the plasma 
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concentration must be continuously above known minimum inhibitory concentrations 
(MIC= 1μg/ml) to be effective.  Therefore, the side-affects will be monitored and the 
patient will be made aware of the risks of the study.  
Patients in the study will not directly benefit from the study; however the study will 
provide important information for the optimal dose regimen for future patients. 
13. STRENGTHS AND LIMITATIONS 
This is a cross-over study; therefore each participant will be his/her own control. The 
limitation of the study will be the relatively small number of participants in the study, 
and also that no sampling will take place during the night. PK samples will be 
collected pre-dose and up to 12 hours, with a final sample collected at 24 hours, 
which will be set as the endpoint. 
14. REPORTING AND RESULTS  
The results of the study will be presented at congresses/forums and included in 
scientific articles and a student thesis, without revealing the identity of the study 
participants.  
15. RESOURCES AVAILABLE  
The Brooklyn Hospital for Chest Diseases and/or D.P. Marais Hospital, Cape Town, 
South Africa hospital will be available for the study. A clinical research team will 
follow the pharmacokinetic study protocol accordingly.  
 16. FUNDING  
Departmental funds will be available. In addition, funding will be available from NRF 
grants provided to Prof PR Donald. 
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17. BUDGET  
BUDGET AND FUNDING 
 UNIT COST (R) NO OF UNITS SUB-TOTAL 
Analysis    
Bio-analysis    R   288 000.00  
    
CONSULTING SERVICES       
Statistical services    R       3 000.00  
    
CLINICAL WORK       
 
R  1 428.57  
per participant  R 1,428.57X 8  R      68571.43 
PERSONNEL    
Research nurse 150/hr. R150X2X150 R     45 000.00 
COMPENSATION       
Participant   R150 per visit    R 150 X 2 X 48   R     14 400.00  
    
OTHER DIRECT COST 
Printing and copying    R       1 000.00  
    
TOTAL EXPENDITURES      R    419971.43  
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Appendix D: Informed consent of Study 1 
STELLENBOSCH UNIVERSITY 
Participant information leaflet and consent form for use by parents/legal 
guardians 
Title; Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
Reference number: 
Principal Investigator:  Prof Bernd Rosenkranz 
Address: Department of Medicine, Division of Pharmacology, 7th Floor Clinical 
Building, Faculty of Health Sciences, Stellenbosch University, Francie van Zijl Drive, 
Tygerberg, 7505 
Contact Numbers: Office phone; +27 21 938 9331 
                                Mobile phone; +27-82-9550017 
  
Your child is being invited to take part in a research project. Please take some time to 
read the information presented here, which will explain the details of this project.  
Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand. It is very important that you are fully satisfied that you 
clearly understand what this research entails and how your child could be involved. 
Also, your child’s participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you or your child negatively in any way 
whatsoever. You are also free to withdraw him/her from the study at any point, even 
if you do initially agree to let him/her take part. 
This study has been approved by the Committee for Human Research at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines 
for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
Introduction 
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Tuberculosis (TB) is a very important health problem in South Africa and is often 
complicated by resistance to the commonly used medicines. When resistance is 
present other medicines (second-line medicines) must be used. These are not as 
effective as the medicines usually given for tuberculosis and they often have 
complications.  The medicines used to treat drug resistant tuberculosis include para-
ethionamide (ETH), terizidone /cycloserine (CS) and para-aminosalicylic acid (PAS). 
All of the second-line drugs are not very effective and it is important that they be 
given in the best possible dosage. There is no information regarding the amount of 
these medicines that get into the blood of children. Such information would make it 
possible for doctors to give much more accurate dosages of these medicines than is 
possible at present. This study aims to determine the amount of terizidone and PAS 
that gets into the blood of children of different ages following different doses of 
terizidone and PAS.   
Before you decide if you want your child to be a part of this study, we want you to 
know about the study. You may choose not to be part of this study. No health care 
will be withheld for your child should you choose not to be part of the study. Your 
child will still receive the standard treatment for drug-resistant tuberculosis used at 
this hospital.  
This is a consent form. It gives you information about this study. The study staff will 
talk with you about this information. You are free to ask questions about this study at 
any time. If you agree to allow your child to take part in this study, you will be asked 
to sign this consent form. You will get a copy to keep. 
Why is this study being done? 
The purpose of this study is to evaluate the absorption of the antituberculosis 
medicines, terizidone and PAS when given in different doses in children of different 
ages with drug-resistant tuberculosis. To date, the dosage used is based on studies 
done in adults and we do not have reliable data for children. 
What will happen to my child and what will I have to do if my child is in this 
study? 
If you decide to allow your child to take part in this study a number of investigations 
will be done. The absorption of the medicines will be studied by placing a needle in a 
vein. This needle will then be removed and a soft plastic tube will be left in your 
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child’s arm for 8 hours. A small amount of blood will be taken from this tube a total of 
5 times in eight hours. No further pricking is required during this period. After 8 hours, 
the plastic tube will be removed. The next morning, another single blood sample will 
be taken. The amount of the medicine in the blood will then be measured. All of the 
above investigations (all 6 blood draws in total) will mean taking less than 2 
teaspoonfuls (less than 10ml) of blood from your child. 
How many children will take part in the study? 
About 30 children will be enrolled in the study. 
How long will your child be in the study? 
The investigations on your child will be completed as soon after being admitted to 
Brooklyn Hospital or Tygerberg Children’s Hospital as is possible and the 
examination of your child by the doctor and the blood investigations should be 
completed within 24 hours. 
Why might the doctor not admit my child / baby to this study? 
The study doctor may decide that your child is too sick to take part in the study.  The 
study might also be cancelled by the site’s Ethics Committee (the committee that 
watches over the safety and rights of research subjects). 
What are the risks of the study? 
Adverse reactions to second-line medicines needed to treat drug-resitant TB 
medicine can occur and your child will be carefully observed for these. Your 
child/baby’s participation in this study will not increase the risk that your child might 
be affected by any of the tuberculosis medicines, but will increase the chance that 
such reactions will be detected early.  
There is a risk of pain and bleeding at the site of insertion of the IV cannula (blood 
drawing needle), but this will soon heal. A gentle application of pressure for a few 
minutes may be required for bleeding after the cannula has been removed.  
Are there benefits to taking part in this study? 
It is likely that your child/baby may derive no benefit from being in this study. 
Information from this study may, however, help experts decide what dosage of 
Terizidone and PAS should be recommended for use in other children in future. The 
study will therefore only show benefit at a leter stage. 
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  D :  I n f o r m e d  c o n s e n t  o f  S t u d y  1  | 186 
 
 
What other choices does my child/baby have besides this study? 
Should you decide that you do not want your child/baby to take part in this study your 
child’s/baby’s treatment will be unaffected and will continue as usual.  Please talk to 
your doctor about the study if you should be uncertain as to whether your child 
should take part in the study.   
What about confidentiality? 
Every effort will be made to keep your child’s/baby’s personal information 
confidential, however we cannot guarantee absolute confidentiality. Your 
child’s/baby’s personal information may be disclosed if required by law. On our study 
record we will use codes instead of your child’s/baby’s name. Only the study staff will 
know these codes. The study workers will not give out any information about your 
child/baby without written consent from you. Your family’s privacy will be respected. 
The public health authorities will be notified as usual if your child/baby has TB. Any 
publication of this study will not use your child’s/baby’s name or identify your 
child/baby personally. 
Your child’s/baby’s study records may be inspected by the South African Department 
of Health, study staff or study monitors. The study records will be kept separate from 
the normal medical records. 
What are the costs to me? 
There is no extra cost to you resulting from your child’s/baby’s participation in the 
study.   
 
Will I receive any payment? 
We will re-imburse you transportation money to enable you to attend the hospital 
should you wish to be with your child on the day that the study is undertaken. 
What happens if my child/baby is injured? 
If your child/baby is injured as a result of being in this study, your child/baby will be 
given immediate treatment for his/her injuries at no cost to you. 
What are my rights and my child's rights as a research subject? 
Participation in this study is completely voluntary. You may choose not to allow your 
child/baby to take part in this study or take your child/baby out of the study at any 
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  D :  I n f o r m e d  c o n s e n t  o f  S t u d y  1  | 187 
 
 
time. Your child/baby will be treated the same no matter what you decide, there will 
be no penalty. 
We will tell you about new information from this or other studies that may affect your 
child’s/baby’s health, welfare or willingness to stay in this study. 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact: Prof Bernd 
Rosenkranz with above address or the person who gave you this form. 
You can contact the committee for Human Research at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your child’s 
study doctor. 
You will receive a copy of this information and consent form for your own 
records. 
Declaration by parent/legal guardian 
 
By signing below, I (name of parent/legal guardian) ……………………………...……. 
agree to allow my child (name of child) ………………………………….… who is 
………. years old, to take part in a research study entitled: Pharmacokinetics and 
dosing rationale of terizidone and/or PAS in Children. 
 
I declare that: 
 
 I have read or had read to me this information and consent form and that it is 
written in a language with which I am fluent and comfortable. 
 If my child is older than 7 years, he/she must agree to take part in the study 
and his/her ASSENT must be recorded on this form. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to let my child take part. 
 I may choose to withdraw my child from the study at any time and my child will 
not be penalised or prejudiced in any way. 
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 My child may be asked to leave the study before it has finished if the study 
doctor or researcher feels it is in my child’s best interests, or if my child does 
not follow the study plan as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
 
 
 ...................................................................   .................................................................  
Signature of parent/legal guardian Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understand all aspects of the research, 
as discussed above 
 I did/did not use an interpreter (if an interpreter is used, then the interpreter 
must sign the declaration below). 
 
Signed at (place) ......................…........…………….. On (date) …………....………..  
 
 
 
 
 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………….…………………………. to 
explain the information in this document to (name of parent/legal guardian) 
……...………………………... using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the parent/legal guardian fully understands the content of 
this informed consent document and has had all his/her questions 
satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....………..  
 
 
 ...................................................................   .................................................................  
Signature of interpreter Signature of witness 
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Title; Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
 
We want to ask you to take part in a study about one of the tablets (terizidone or 
PAS) that you are taking as part of your TB treatment. In the study we measure the 
amount of this tablet that goes into your blood and in this way we can see whether 
we are giving too much, too little or just enough of this specific medicine. To do this, 
we have to draw a small amount of blood from you. We will apply some ointment to 
your arm so that the needle prick will be less painful.  
 
A few minutes later we will use a needle to put a soft plastic tube in your arm. The 
needle will then be taken out and the plastic tube will stay in.  
From this plastic tube we will then take small amounts of blood 5 times in a few 
hours. We only have to prick you once in this time because we can take blood from 
the soft tube without pricking you again. We will then measure the amount of the 
medicine in your blood. The soft plastic tube will be taken out. The next morning we 
will take one more little bit of blood.  
You can decide if you want to be part the study or not. You do not have to take part if 
you don’t want to. You can decide at any time to stop being a part of the study if you 
are unhappy. 
Assent of minor 
I (Name of Child/Minor)……………………………………………. have been invited to 
take part in the above research project.  
 The study doctor/nurse and my parents have explained the details of the 
study to me and I understand what they have said to me. 
 They have also explained that this study will involve.  
 I also know that I am free to withdraw from the study at any time if I am 
unhappy. 
 By writing my name below, I voluntary agree to take part in this research 
project.  I confirm that I have not been forced either by my parents or doctor 
to take part. 
 
 
 ...................................................................   .................................................................  
Name of child Independent witness 
(To be written by the child if possible) 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
TITLE OF RESEARCH PROJECT: “Pharmacokinetics and dosing rationale of 
terizidone and para-aminosalicyclic acid (PAS) in children and in-vitro 
metabolism of ethionamide, terizidone and PAS.” 
 
REFERENCE NUMBER: N09/08/212 
 
PRINCIPAL INVESTIGATOR:  Prof Bernd Rosenkranz 
 
ADDRESS: Department of Pharmacology 
          7th Floor, Clinical Building 
          Stellenbosch University 
          Tygerberg Campus 
          7505 
CONTACT NUMBER: 021 938 9331/ 0829550017 
 
We would like to invite your child to participate in a research study that involves 
genetic analysis and possible long-term storage of blood or tissue specimens.  
Please take some time to read the information presented here which will explain the 
details of this project.  Please ask the study staff or doctor any questions about any 
part of this project that you do not fully understand.  It is very important that you are 
fully satisfied that you clearly understand what this research entails and how your 
child could be involved.  Also, your participation is entirely voluntary and you are 
free to decline to participate.  If you say no, this will not affect your child negatively in 
any way whatsoever.  You are also free to withdraw your child from the study at any 
point, even if you do agree to take part initially.  
 
If you do not wish your child to participate in this genetic analysis part of the study, 
they can still be part of the main study of antituberculosis drug levels in the blood. 
The genetic analysis will then not be performed on your child’s blood. 
 
This research study has been approved by the ethics Committee for Human 
Research at Stellenbosch University and it will be conducted according to 
international and locally accepted ethical guidelines for research, namely the 
Declaration of Helsinki, and the SA Department of Health’s 2004 Guidelines: Ethics 
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in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
 
Genetic material, also called DNA or RNA, is usually obtained from a small blood 
sample.   Genes are found in every cell in the human body.  Our genes determine 
what we look like and sometimes what kind of diseases we may be susceptible to.  
Worldwide, researchers in the field of genetics are continuously discovering new 
information that may be of great benefit to future generations and also that may 
benefit people today, who suffer from particular diseases or conditions. 
 
What does this particular research study involve? 
In the main part of the study in which your child is involved, the amount of 
antituberculosis drug in the blood will be measured at various time points. A number 
of factors can affect the amount of drug in a patient’s blood.  One of these is the 
ability of the liver to produce enzymes (substances which speed up chemical 
reactions).  These enzymes are responsible for the metabolism (breakdown) of drugs 
which are then passed out of the body.  
 
Some people produce more powerful enzymes than others and they are therefore 
able to break down drugs more quickly than other people.  This is because different 
people have differences in the genes which control how these enzymes are made. 
These variations in the genetic material of individuals are known as polymorphisms.  
This could possibly help us in the future to predict which children are likely to develop 
very high (which may be dangerous) or very low (the drug doesn’t work) 
concentrations, based on their genetic makeup. If we know their genetic makeup, we 
could perhaps take precautions or use a lower or higher dose of these drugs.  
 
Why has your child been invited to participate? 
  Your child has been invited to participate because you have shown interest 
in the main part of our study and so we are going to measure blood 
concentrations of antituberculous drugs in your child. Performing genetic 
testing on your child will therefore help us determine if genetic differences 
(polymorphisms) can lead to high or low blood concentrations as explained 
above. 
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What procedures will be involved in this research? 
Your child will not be required to give any additional blood or participate in additional 
procedures. The blood obtained from the main study will be used to perform genetic 
testing. 
 
Are there any risks involved in genetic research? 
In this study, we will be focusing on those genes which are responsible for the 
production of enzymes which break down or metabolize the drugs your child is 
receiving or drugs which broken down by the same kind of enzymes.  
This study therefore will not identify any diseases your child may develop or genetic 
problems which may lead to diseases later in life. 
 
Are there any benefits to your taking part in this study and will you get told 
your results? 
Your child will not benefit directly from taking part in this genetic research study. You 
will not be informed of the results. Blood will be stored and only tested at a later date 
once more is known about the enzymes responsible for drug breakdown and the 
genetic polymorphisms possibly involved.  
It is possible that in the future we can use the study results to predict which children 
are likely to develop very high (which may be dangerous) or very low (the drug 
doesn’t work) concentrations. If we know their genetic composition, we could perhaps 
take precautions or use a lower or higher dose of these drugs.  
 
How long will your blood be stored and where will it be stored? 
The blood will be stored in the Division of Clinical Pharmacology and analysed by the 
University of Stellenbosch. 
 
If your blood is to be stored is there a chance that it will be used for other 
research? 
Your blood will only be used for genetic research that is directly related to the 
metabolism of antituberculosis drugs.  Also if the researchers wish to use your stored 
blood for additional research in this field they will be required to apply for permission 
to do so from the Human Research Ethics Committee at Stellenbosch University. 
If you do not wish your blood specimen to be stored after this research study is 
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completed you will have an opportunity to request that it be discarded when you sign 
the consent form. 
 
How will your confidentiality be protected? 
The blood for DNA analysis will be labelled with your child’s participant number and 
not name, prior to storage. It will be labelled because we wish to compare your 
child’s blood concentration to their genetic results and so these must be linked by a 
participant number. 
All study records and samples will be kept confidentially in a sealed and locked area 
only accessible to the investigators. No one other than the investigators or the ethics 
committee of Stellenbosch University will have access to your child’s personal 
information. In the publication of results, your child’s name or identifying information 
will not be used 
 
Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study. 
 
Important information: In the unlikely event that this research leads to the 
development of a commercial application or patent, you or your family will not 
receive any profits or royalties 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
genetic research study entitled (insert title of study). 
 
  
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  D :  I n f o r m e d  c o n s e n t  o f  S t u d y  1  | 195 
 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I have received a signed duplicate copy of this consent form for my 
records. 
 
Tick the option you choose: 
 
 I agree that my blood or tissue sample can be stored indefinitely/ stored 
for,     ………years, but I can choose to request at any time that my 
stored sample be destroyed. My sample will be identified with a special 
study code that will remain linked to my name and contact details. I have 
the right to receive confirmation that my request has been carried out.  
(NB This option can be excluded completely if the genetic research has 
no clinical relevance to the patient and you plan to completely and 
permanently anonymise all samples) 
 
OR 
 Please destroy my blood sample as soon as the current research project 
has been completed.   
 
 
Signed at (place)  ...................................................  on (date)  ...............................................  
 
 ...................................................................   .................................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
 I explained the information in this document to 
…………………..……………... 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
 I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2005. 
 
 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by Interpreter 
 
I (name) ………………………………………………… declare that: 
 
 I assisted the investigator (name) …………………………. to explain the 
information in this document to (name of participant) 
…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
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 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2005. 
 
 ...................................................................   .................................................................  
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH  
 
Title of research project: Pharmacokinetics and dosing rationale of terizidone and 
para-aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
 
Principal Investigator:  Prof Bernd Rosenkranz 
Address: Faculty of Health Sciences, Stellenbosch University, Francie van Zijl Drive, 
Tygerberg, 7505 
Contact Numbers: Tel +27-21-938 9331 (Office); Cellular phone: +27-82-9550017 
 
You are invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not 
fully understand.  It is very important that you are fully satisfied that you clearly 
understand what this research entails and how your child could be involved.  Also, 
your participation is entirely voluntary and you are free to decline to participate.  If 
you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do initially agree to take part. 
This study has been approved by the Committee for Human Research at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines 
for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
Introduction 
Tuberculosis (TB) is a very important health problem in South Africa and is often 
complicated by disseminated forms of TB such as meningitis or widespread lesions 
(miliary) TB, and resistance to the commonly used medicines. PAS, a second-line 
medicine is mostly used in combination with the commonly used drugs for the 
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treatment of extensively resistant TB. When resistance is present other medicines 
(second-line medicines) must be used. These are not as effective as the medicines 
usually given for TB and they have more complications than the commonly used 
(first-line) medicines.  The medicines used to treat extensively resistant TB almost 
always include PAS. The second-line drugs such as PAS are not as effective as first-
line TB drugs and it is therefore important that PAS be given in the best possible 
dosage. There is only very little information available regarding the amount of PAS 
that gets into the blood. Such information would make it possible for doctors to give 
much more accurate dosages of PAS than is possible at present.  This study aims to 
determine the amount of PAS that gets into the blood of TB patients following the 
currently recommended and used dose of PAS.   
Before you decide if you want to be a part of this study, we want you to know about 
the study. You may choose not to be part of this study. No health care will be 
withheld for you should you choose not to be part of the study. You will still receive 
the standard treatment for drug-resistant tuberculosis at this hospital.  
This is a consent form. It gives you information about this study.  The study staff will 
talk with you about this information.  You are free to ask questions about this study at 
any time.  If you agree to take part in this study, you will be asked to sign this consent 
form. You will get a copy to keep. 
 
Why is this study being done? 
The purpose of this study is to evaluate the absorption of the antituberculosis 
medicine PAS when given in the currently recommended dose in patients with drug-
resistant TB.  
What will happen to me and what will I have to do if I participate in this study? 
If you decide to take part in this study, a number of investigations will be done. The 
absorption of the medicines will be studied by placing a needle in a vein and taking a 
small amount of blood 10 times soon after the medicines have been given. The 
amount of the medicine in the blood will then be measured. All of the above 
investigations will mean taking the volume of about 2 teaspoons of blood from you at 
two occasions approximately a month apart. 
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How many patients will take part in the study? 
Up to 40 patients will be enrolled in the study. 
How long will you be in the study? 
The investigations will be completed as soon after being admitted to Brooklyn Chest 
Hospital as possible and the examination by the doctor and the blood investigations 
should be completed within a day and will be repeated about a month later.  
Why might the doctor not admit me to this study? 
The study doctor may decide that you are too sick to take part in the study.  The 
study might also be cancelled by the site’s Ethics Committee (the committee that 
watches over the safety and rights of research subjects). 
What are the risks of the study? 
Your participation in this study will not increase the risk that you might be affected by 
PAS, but will increase the chance that such reactions will be detected early. A small 
amount of bleeding may occur at the site where the blood is taken from and this may 
leave a bruise which should soon heal. 
Are there benefits to taking part in this study? 
It is likely that you may derive no benefit from being in this study. Information from 
this study may, however, will help experts decide what dosage of PAS should be 
recommended for use.  
What other choices do I have besides this study? 
Should you decide that you do not want to take part in this study your treatment will 
be unaffected and will continue as usual.  Please talk to your doctor about the study if 
you should be uncertain as to whether you should take part in the study.   
What about confidentiality? 
Every effort will be made to keep your personal information confidential, however we 
cannot guarantee absolute confidentiality. Your personal information may be 
disclosed if required by law. On our study record we will use codes instead of your 
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name. Only the study staff will know these codes. The study workers will not give out 
any information about you without written consent from you. Your family’s privacy will 
be respected. The public health authorities will be notified as usual if you have TB. 
Any publication of this study will not use your name or identify you personally. 
Your study records may be inspected by the South African Department of Health, 
study staff or study monitors. The study records will be kept separate from the normal 
medical records. 
What are the costs to me? 
There is no cost to you resulting from participation in the study. All medical care will 
be provided by the study doctor.  
Will I receive any payment? 
We will re-imburse your transportation money to enable you to attend the hospital on 
the day that the study. 
What happens if I get injured? 
If you get injured as a result of being in this study, you will be given immediate 
treatment for your injuries at no cost to you. 
What are my rights as a research subject? 
Participation in this study is completely voluntary. You may choose not to take part in 
this study or withdraw from the study at any time. You will be treated the same no 
matter what you decide, there will be no penalty. 
We will tell you about new information from this or other studies that may affect your 
health, welfare or willingness to stay in this study.  If you want the results of the study 
inform the study staff. 
What do I do if I have questions or problems? 
For questions about this study or a research-related injury, contact either Prof Bernd 
Rosenkranz at the above address or the person who gave you this form.  
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You can contact the Committee for Human Research at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your child’s 
study doctor. 
You will receive a copy of this information and consent form for your own records. 
 
Declaration by patient 
 
By signing below, I ……………………………...……. agree to take part in a research 
study entitled: Pharmacokinetics and dosing rationale of terizidone and para-
aminosalicylic acid (PAS) in children and the evaluation of the in vitro 
metabolism of ethionamide, terizidone and PAS. 
I declare that: 
 
 I have read or had read to me this information and consent form and that it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to withdraw from the study at any time and will not be penalised 
or prejudiced in any way. 
 I may be asked to leave the study before it has finished if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan as 
agreed to. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....………..  
 
 
 ...................................................................   .................................................................  
Signature of parent/legal guardian Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understand all aspects of the research, 
as discussed above 
 I did/did not use an interpreter (if an interpreter is used, then the interpreter 
must sign the declaration below). 
 
 
Signed at (place) ......................…........…………….. On (date) …………....………..  
 
 
 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………….…………………………. to 
explain the information in this document to (name of parent/legal guardian) 
……...………………………... using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
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 I am satisfied that the parent/legal guardian fully understands the content of 
this informed consent document and has had all his/her questions 
satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....………..  
 
 
 
 ...................................................................   .................................................................  
Signature of interpreter ...............................                                Signature of witness 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
 
 
TITLE OF RESEARCH PROJECT: Pharmacokinetics and dosing rationale of 
terizidone and para-aminosalicylic acid (PAS) in children and the evaluation of the in 
vitro metabolism of ethionamide, terizidone and PAS. 
 
PRINCIPAL INVESTIGATOR: Prof Bernd Rosenkranz 
 
ADDRESS: Faculty of Health Sciences, Stellenbosch University, Francie van 
Zijl Drive, Tygerberg, 7505 
CONTACT NUMBER: Tel +27-21-938 9331 (Office); Cellular phone: +27-82-
9550017 
 
We would like to invite you to participate in a research study that involves genetic 
analysis and possible long-term storage of blood or tissue specimens.  Please take 
some time to read the information presented here which will explain the details of this 
project.  Please ask the study staff or doctor any questions about any part of this 
project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how your child 
could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect your child negatively in any 
way whatsoever.  You are also free to withdraw your child from the study at any 
point, even if you do agree to take part initially.  
 
If you do not wish to participate in this genetic analysis part of the study, they can still 
be part of the main study of antituberculosis drug levels in the blood. The genetic 
analysis will then not be performed on your blood. 
 
This research study has been approved by the ethics Committee for Human 
Research at Stellenbosch University and it will be conducted according to 
international and locally accepted ethical guidelines for research, namely the 
Declaration of Helsinki, and the SA Department of Health’s 2004 Guidelines: Ethics 
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in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA or RNA, is usually obtained from a small blood 
sample.   Genes are found in every cell in the human body.  Our genes determine 
what we look like and sometimes what kind of diseases we may be susceptible to.  
Worldwide, researchers in the field of genetics are continuously discovering new 
information that may be of great benefit to future generations and also that may 
benefit people today, who suffer from particular diseases or conditions. 
 
What does this particular research study involve? 
 
In the main part of the study the amount of antituberculosis drug in the blood will be 
measured at various time points. A number of factors can affect the amount of drug 
in a patient’s blood.  One of these is the ability of the liver to produce enzymes 
(substances which speed up chemical reactions).  These enzymes are responsible 
for the metabolism (breakdown) of drugs which are then passed out of the body.  
 
Some people produce more powerful enzymes than others and they are therefore 
able to break down drugs more quickly than other people.  This is because different 
people have differences in the genes which control how these enzymes are made. 
These variations in the genetic material of individuals are known as polymorphisms  
  
This could possibly help us in the future to predict which patients are likely to develop 
very high (which may be dangerous) or very low (the drug doesn’t work) 
concentrations, based on their genetic makeup. If we know your genetic makeup, we 
could perhaps take precautions or use a lower or higher dose of these drugs.  
 
Why have I been invited to participate? 
 
You have been invited to participate because you have shown interest in the main 
part of our study and so we are going to measure blood concentrations of 
antituberculous drugs in you. Performing genetic testing on will therefore help us 
determine if genetic differences (polymorphisms) can lead to high or low blood 
concentrations as explained above. 
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What procedures will be involved in this research? 
 
You will not be required to give any additional blood or participate in additional 
procedures. The blood obtained from the main study will be used to perform genetic 
testing. 
 
Are there any risks involved in genetic research? 
 
In this study, we will be focusing on those genes which are responsible for the 
production of enzymes which break down or metabolize the drugs your child is 
receiving or drugs which broken down by the same kind of enzymes.  
 
This study therefore will not identify any diseases or genetic problems which may 
lead to diseases later in life. 
 
 
 
Are there any benefits to your taking part in this study and will you get told 
your results? 
 
You will not benefit directly from taking part in this genetic research study. You will 
not be informed of the results. Blood will be stored and only tested at a later date 
once more is known about the enzymes responsible for drug breakdown and the 
genetic polymorphisms possibly involved.  
 
It is possible that in the future we can use the study results to predict which patients 
are likely to develop very high (which may be dangerous) or very low (the drug 
doesn’t work) concentrations. If we know your genetic composition, we could perhaps 
take precautions or use a lower or higher dose of these drugs.  
 
 
How long will your blood be stored and where will it be stored? 
 
The blood will be stored in the Division of Clinical Pharmacology and analysed by the 
University of Stellenbosch. 
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If your blood is to be stored is there a chance that it will be used for other 
research? 
 
Your blood will only be used for genetic research that is directly related to 
the metabolism of antituberculosis drug PAS. If you do not wish your blood specimen 
to be stored after this research study is completed you will have an opportunity to 
request that it be discarded when you sign the consent form. 
 
 
How will your confidentiality be protected? 
 
The blood for DNA analysis will be labelled with your participation number and not 
name, prior to storage. It will be labelled because we wish to compare your child’s 
blood concentration to their genetic results and so these must be linked by a 
participant number. 
 
All study records and samples will be kept confidentially in a sealed and locked area 
only accessible to the investigators. No one other than the investigators or the ethics 
committee of Stellenbosch University will have access to your child’s personal 
information. In the publication of results, your child’s name or identifying information 
will not be used 
 
Will you or the researchers benefit financially from this research? 
 
You will not be paid to take part in this study. 
 
Important information: In the unlikely event that this research leads to the 
development of a commercial application or patent, you or your family will not 
receive any profits or royalties. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
genetic research study entitled (insert title of study). 
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I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I have received a signed duplicate copy of this consent form for my 
records. 
 
Tick the option you choose: 
 
 I agree that my blood sample can be stored indefinitely/ stored for     
………years, but I can choose to request at any time that my stored 
sample be destroyed. My sample will be identified with a special study 
code that will remain linked to my name and contact details. I have the 
right to receive confirmation that my request has been carried out 
OR 
 Please destroy my blood sample as soon as the current research project 
has been completed.   
 
Signed at (place)  ...................................................  on (date)  ...............................................  
 
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
 I explained the information in this document to 
…………………..……………... 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
 I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) 
…………...20................... 
 
 
 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by Interpreter 
 
I (name) ………………………………………………… declare that: 
 
 I assisted the investigator (name) …………………………. to explain the 
information in this document to (name of participant) 
…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
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 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
Signed at (place) ......................…........…………….. On (date) ……........ 
20................... 
 
 ...................................................................   .................................................................  
Signature of interpreter                                     Signature of a witness 
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Appendix E: CRF of Study 1 
 
STELLENBOSCH UNIVERSITY 
Case record form 
 
Title of the project: Pharmacokinetics and dosing rationale of terizidone 
and para-aminosalicylic acid (PAS) in children and the evaluation of the 
in vitro metabolism of ethionamide, terizidone and PAS. 
Project No…………………………… 
Date………………………………….. 
Patient name………………………………………………… 
Date of birth………………………. 
Sex…………….. 
Race………………………………. 
Diagnosis………………………………………………………………………………
………….. 
Measurements: 
Height (cm)…………………. 
Weight (kg)………………….. 
Mid upper arm circumference (cm)…………….. 
Drug for measurement (name)………………………………….Dose 
(mg)……………. 
Dosage time……………… 
Sample Sampling time (min) Time 
(received) 
Remarks 
Planned Actual 
sampling 
1 
 
    
2 
 
    
3 
 
    
4     
5     
6 
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Details of the co-administered drugs 
Drug (name) Dose(mg) Dosage time Duration of Rx 
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Appendix F: Informed consent of Study 2 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
 
Pharmacokinetics of twice daily vs. once daily dosing with granular slow-release 
para-aminosalicylic acid (PAS) in adults on second-line anti-tuberculosis and 
antiretroviral treatment 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR:  
Lizanne de Kock 
 
ADDRESS: 
Division of Pharmacology  
Department of Medicine  
University of Stellenbosch  
PO Box 19063  
Tygerberg, Cape Town, 7505  
South Africa  
 
 
CONTACT NUMBER: 
Phone: 021 9389336 
Fax: 021-932 6958 
E-mail: 15180271@sun.ac.za 
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You are being invited to take part in a research project.  Please take some time to 
read the information presented here, which will explain the details of this project. 
Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand.  It is very important that you are fully satisfied that you 
clearly understand what this research entails and how you could be involved. Also, 
your participation is entirely voluntary and you are free to decline to participate. If 
you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines 
for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
Why have you been invited to participate? 
 You have been invited to take part in this study because you meet the 
requirements for the study i.e. adult, M/XDR-TB etc. 
 
What is this research study all about? 
 Forty eight (48) adults will sign up for the study at Brooklyn Hospital for Chest 
Diseases and/or D.P. Marais Hospital, Cape Town, South Africa. 
 PAS is known to cause nausea, bloating, diarrhoea, and abdominal pain; and 
with the use of multiple medicines, we want to see if it is possible to decrease 
the daily dosing of PAS from twice daily to once daily. In addition we want to 
look at possible interactions of PAS and HIV/AIDS treatment. 
 Procedure   
You will take part in the study for three weeks. You will receive PAS once 
daily or twice daily, depending on your group. You will follow the prescribed 
dosing for eight (8) days. On day 8 a blood samples will be taken before you 
will receive your prescribed medication. After that, three millilitre (3ml) blood 
samples will be taken at 10 time points during the day. Thirty millilitres (30ml) 
of blood will be taken at every sampling day. For the following 8 days you will 
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follow the once-daily dosing if you were on the twice-daily and visa versa 
(cross-over), before blood samples will be taken again. You will still be on 
your other prescribed medicines, which will be recorded. Only the PAS dosing 
will change. Each day you will be asked to fill in a self-rating form, where you 
must rate discomfort in your stomach, nausea, a feeling of fullness or any 
other symptoms you may be experiencing.  
 
What will your responsibilities be? 
 To co-operate with the research nurse and personal involved in the study. To 
complete the self-rating forms each day. 
 
Will you benefit from taking part in this research? 
 You and future patients may potentially benefit from the once daily dosing, in 
that less frequent dosing is needed.  The study will provide important valuable 
information for the optimal dose regimen.  
 
Are there in risks involved in your taking part in this research? 
 
You will be treated as usual by the attending doctor, you will be already on 
PAS before enrolment and your treatment will not change, except for whether 
you take PAS once a day or twice a day. You may experience side effects by 
using PAS such as nausea, abdominal pain etc. and will be treated 
accordingly. There may be a risk that you will experience pain, bruising 
and/or bleeding at the side of 20-gauge angiocatheter insertion. In addition, 
there is a risk that you may experience unexpected side-affects and that the 
once-daily dosage may not be as effective as the standard dosage. However, 
you will be monitored for side- affect by your attending nurse or doctor. For 
any trial related emergency please contact Dr AH Diacon at 021 938 9392 or 
082 420 1677 
 
Who will have access to your medical records? 
 The research nurse and study personal will have access to your information. 
The information collected and results obtained will be treated as confidential 
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and protected by using a subject numbers.  If this information is used in a 
publication or thesis, your identity will remain anonymous.  
 
Will you be paid to take part in this study and are there any costs involved? 
 
You will be compensation for inconvenience. There will be no costs involved 
for you, if you do take part. You will receive R 150 per sampling day.  
Is there anything else that you should know or do? 
 
 You can contact Dr AH Diacon at tell 021 938 9392 or 082 420 1677 if you 
have any further queries or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if 
you have any concerns or complaints that have not been adequately 
addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own 
records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (insert title of study). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not 
been pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
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 I may be asked to leave the study before it has finished, if the study 
doctor or researcher feels it is in my best interests, or if I do not follow the 
study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2012. 
 
 ...................................................................   .................................................................  
Signature of participant Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2012. 
 
 
 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
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 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
Signed at (place) ......................…........…………….. on (date) 
…………....……………….. 
 
 ...................................................................   .................................................................  
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION AND INFORMED CONSENT FORM FOR 
RESEARCH INVOLVING GENETIC STUDIES 
 
 
TITLE OF RESEARCH PROJECT: 
 
Pharmacokinetics of twice daily vs. once daily dosing with granular slow-release 
para-aminosalicylic acid (PAS) in adults on second-line anti-tuberculosis and 
antiretroviral treatment 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR:  
Lizanne de Kock 
 
ADDRESS: 
Division of Pharmacology  
Department of Medicine  
University of Stellenbosch  
PO Box 19063  
Tygerberg, Cape Town, 7505  
South Africa  
  
 
CONTACT NUMBER: 
Phone: 021 9389336 
Fax: 021-932 6958 
E-mail: 15180271@sun.ac.za 
 
We would like to invite you to participate in a research study that involves genetic 
analysis and possible long-term storage of blood or tissue specimens.  Please take 
some time to read the information presented here which will explain the details of this 
project.  Please ask the study staff or doctor any questions about any part of this 
project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how you could be 
involved.  Also, your participation is entirely voluntary and you are free to decline to 
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participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to 
take part initially.  
 
This research study has been approved by the ethics Health Research Ethics 
Committee at Stellenbosch University and it will be conducted according to 
international and locally accepted ethical guidelines for research, namely the 
Declaration of Helsinki, and the SA Department of Health’s 2004 Guidelines: Ethics 
in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA or RNA, is usually obtained from a small blood 
sample.  Occasionally genetic material is obtained from other sources such as saliva 
or biopsy specimens. (A biopsy is a tiny piece of tissue that is cut out e.g. from the 
skin or from a lump, to help your doctor make a diagnosis.)   Genes are found in 
every cell in the human body.  Our genes determine what we look like and 
sometimes what kind of diseases we may be susceptible to.  Worldwide, researchers 
in the field of genetics are continuously discovering new information that may be of 
great benefit to future generations and also that may benefit people today, who suffer 
from particular diseases or conditions. 
 
Why have you been invited to participate? 
You have been invited to take part in this study because you meet the requirements 
of the study i.e. adult, M/XDR-TB, etc. 
 
What does this particular research study involve? 
 
 PAS is known to cause nausea, bloating, diarrhoea, and abdominal pain; and 
with the use of multiple medicines, we want to compare once daily dosing of 
PAS with twice daily.  In addition we want to look at possible interactions 
between PAS and HIV/AIDS treatment. Variations in the genes may influence 
your response to certain medicines. We hope to find the specific variations 
which influence how your body response to the medicine. 
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What procedures will be involved in this research? 
 
 No additional blood is required for genotyping 
 
Are there any risks involved in genetic research? 
 There are no risks related to the study. 
 
Are there any benefits to your taking part in this study and will you get told 
your results? 
 
Your personal results will be made known to you only if they indicate that you may: 
 Have a definite risk for developing a particular disorder. 
 Have a condition or predisposition to developing a condition that is treatable 
or avoidable e.g. by a lifestyle modification. 
 Need genetic counselling. 
 
 
How long will your blood be stored and where will it be stored? 
 
The sample will be stored for 2 years depending on the results of the study. 
Your specimen will be stored at the University of Stellenbosch Medical School in a 
dedicated fridge or freezer for at least 2 years or at the laboratory that performed the 
same test(s) as a routine service. 
 
If your blood is to be stored is there a chance that it will be used for other 
research? 
 
Your specimen will only be used for the genetic research as indicated above and any 
further testing will only be done after obtaining full written consent. Also, if the 
researchers wish to use your stored specimen for additional research in this field 
they will be required to apply for permission to do so from the Human Research 
Ethics Committee at Stellenbosch University (that can be contacted at telephone 
number 021 938 9657). 
 
If you do not wish your blood specimen to be stored after this research study is 
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completed you will have an opportunity to request that it be discarded when you sign 
the consent form. 
 
How will your confidentiality be protected? 
 
The specimens will be given a subject number and only the researchers, clinicians 
and laboratory personnel involved in the study will have access to the self-rating 
scales and consent forms. Specimens sent to other laboratories locally or abroad will 
be shipped only with the subject and sample number attached to them and your 
name will not be disclosed to the collaborator. If ever information comes to light that 
could be important to you or your descendants, all possible attempts will be made to 
contact you and your counsel. The results of the study will be presented at 
congresses/workshops/ professional forums and included in scientific articles and 
student theses, without revealing the identity of the study participants. 
 
 
Will you or the researchers benefit financially from this research? 
 
 You will be compensation for inconvenience. There will be no costs involved 
for you, if you do take part. 
 The researchers will not financial benefit from the study, but there may be 
indirect financial benefits such as publications etc. to the investigators. 
 
Important information: In the unlikely event that this research leads to the 
development of a commercial application or patent, you or your family will not 
receive any profits or royalties 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
genetic research study entitled (insert title of study). 
 
 
  
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  F :  I n f o r m e d  c o n s e n t  o f  S t u d y  2  | 224 
 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I have received a signed duplicate copy of this consent form for my 
records. 
 
Tick the option you choose: 
 
 I agree that my blood or tissue sample can be stored indefinitely/ stored 
for, ……years, but I can choose to request at any time that my stored 
sample be destroyed. My sample will be identified with a special study 
code that will remain linked to my name and contact details. I have the 
right to receive confirmation that my request has been carried out.  (NB 
This option can be excluded completely if the genetic research has no 
clinical relevance to the patient and you plan to completely and 
permanently anonymise all samples) 
OR 
I agree that my blood or tissue sample can be stored indefinitely/ stored 
for,………years after the project is completed but that it is anonymised 
with all possible links to my identity removed, and that the researchers 
may then use it for additional research in this or a related field. Once my 
sample is anonymised, my rights to that sample are waivered. My sample 
may be shipped to another laboratory in SA or abroad to be used in other 
research projects in this or a related field 
 
OR 
 Please destroy my blood sample as soon as the current research project 
has been completed.   
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Signed at (place)  ...................................................  on (date)  ...............................................  
 
 ...................................................................   .................................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
 
 I explained the information in this document to 
…………………..……………... 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research as discussed above. 
 I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 
2012. 
 
 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
 
Declaration by Interpreter 
 
I (name) ………………………………………………… declare that: 
 
 I assisted the investigator (name) …………………………. to explain the 
information in this document to (name of participant) 
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  F :  I n f o r m e d  c o n s e n t  o f  S t u d y  2  | 226 
 
 
…………………………….. Using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 
2012.
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Patient subject 
number 
Appendix G: CRF of Study 2 
 
 
 
 
 
 
 
 
Title of the Project: Pharmacokinetics of twice daily vs. once daily dosing with 
granular slow-release para-aminosalicylic acid in adults on second-line anti-
tuberculosis and antiretroviral treatment 
 
BASELINE MEASUREMENTS 
Mark with an X 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DATE D D M M Y Y Y Y 
A CONSENT 
 Explained the study and procedures to the study subject 
 Encourage the study subject to asked any questions 
 Received VERBAL consent for the study 
 Received WRITTEN informed consent for the study 
 Patient received a copy of the consent 
 Copy of the consent is in patient file 
  
B GENERAL 
Language   
Date of Birth  
Gender   
Race  
  
C MEASUREMENTS 
Weight  kg 
Height/length  cm 
   
D DIAGNOSES 
 MDR-TB  Pre- XDR-TB  XDR-TB 
      
E HIV STATUS 
 Positive  Negative  
PAS ONCE DAILY VS TWICE DAILY PK STUDY 
BASELINE RECORDING FORM 
 
M12/01/006 
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F CHEMISTRY RANGE DATE REF RANGE 
POTASSIUM   3.3-5.3 
CREATININE   64-104 
HAEMAGLOBIN   13.0-17.0 
THYROID 
STIMULATING 
HORMONE 
  0.49-5.66 
ALANINE 
TRANSAMINASE 
(ALT) 
  5-40 
    
G CONCURRENT ILLNESS 
ILLNESS DATE 
  
  
  
  
  
  
  
H MEDICATION USED 
PLEASE FIND ATTACHED  
 
 
 
 
 
DATE SIGNATURE 
INVESTIGATOR D D M M Y Y Y Y  
INVESTIGATOR          
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Patient subject 
number 
  
 
 
 
 
 
 
 
 
Title of the Project: Pharmacokinetics of twice daily vs. once daily dosing with 
granular slow-release para-aminosalicylic acid in adults on second-line anti-
tuberculosis and antiretroviral treatment 
 
 
 
 
 
 
 
 
 
 
 
PK DATE D D M M Y Y Y Y 
PK SAMPLING 
VISIT  
1 2 
A STUDY GROUP 
1 1x 8g GSR-PAS 2 2x 4g GSR-PAS 
B GENERAL 
Date of Birth  
Gender  
Race  
  
C MEASUREMENTS 
1 Weight  kg 
2 Height/Length  cm 
3 Blood pressure   
 
D 
PAS DOSING 
 PAS DOSING  TIME 1 
YOGHURT 
FLAVOUR 
TIME 2 
YOGHURT 
FLAVOUR 
COMMENTS 
1 1x 8g GSR-PAS     
2 2x 4g GSR-PAS      
       
PAS ONCE DAILY VS TWICE DAILY PK STUDY 
Case Report form 
M12/01/006 
Stellenbosch University http://scholar.sun.ac.za
A p p e n d i x  G :  C R F  o f  S t u d y  2  | 230 
 
 
Patient subject 
number 
 
 
 
 
 
 
 
 
 
 
PK DATE D D M M Y Y Y Y 
E PHARMACOKINETIC SAMPLING 
Tubes Sampling time COMMENTS 
time 
Tube name 
e.g. 1/DI50T1 
Planned Actual  
(t0) T0    
DOSE TIME 1    
1 T1    
2 T2    
3 T3    
4 T4    
6 T6    
8 T8    
12 T12    
DOSE TIME 2    
24 T24    
PAS ONCE DAILY VS TWICE DAILY PK 
STUDY 
Case Report form 
M12/01/006 
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Patient subject 
number 
 
 
 
 
PK DATE D D M M Y Y Y Y 
F DRUGS, DOSAGES, FORMULATIONS ON SAMPLING DAY 
DRUGS DOSAGE (mg) DOSING TIME 
ADMINISTRATION 
 
1 – IM 
2 – Oral 
TB 
Amikacin     
Capreomycin    
Clarythromycin    
Dapsone     
Ethambutol    
Ethionamide     
INH    
Kanamycin    
Levofloxacin    
Moxifloxacin    
Ofloxacin    
Pyrazinamide PZA    
Terizidone    
    
ARVs 
Efavirenz (EFV)    
Stavudine (d4T)    
Lamivudine (3TC)    
Zidovudine (AZT)    
Aluvia    
    
PAS ONCE DAILY VS TWICE DAILY PK STUDY 
Case Report form 
M12/01/006 
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Patient subject 
number   
OTHER 
    
    
    
    
    
    
    
    
    
DRUGS (mg) DOSAGE DOSING TIME 
ADMINISTRATION   
1 – IM  
2– Oral 
ANTI-PSYCHOTICS 
Amitriptyline    
Trepilene     
Modecote     
Haloperidol    
    
    
    
    
PK DATE D D M M Y Y Y Y 
PAS ONCE DAILY VS TWICE DAILY PK 
STUDY 
Case Report form 
M12/01/006 
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Patient subject 
number 
 
 
  
 
 
 
  
PK DATE D D M M Y Y Y Y 
G MEALS 
MORNING Time Breakfast given H H m m  
Mark  if applicable Porridge with milk and sugar :  Oats/Maize meal Quantity ¼ ½ 
Full 
Mark  if applicable Sandwich with margarine Slices of bread  
Mark  if applicable Other Specify 
LUNCH 
Mark  if applicable  
Mark  if applicable  
Mark  if applicable  
EVENING 
Mark  if applicable  
Mark  if applicable  
Mark  if applicable  
Mark  if applicable  
Tea 
Mark  if applicable Rooibos 
Mark  if applicable Ceylon 
Mark  if applicable Other Specify 
Mark  if applicable Milk 
Mark  if applicable Juice 
Mark  if applicable Other Meal Specify 
   
 
 
   
H SIDE-EFFECTS 
1 
Was there any significant vomiting/regurgitation/reflux noted? 
0 - No 1 - Yes -5 - Unknown 
(Note : If Yes, medications require re-administration as deemed clinically relevant) 
  
PAS ONCE DAILY VS TWICE DAILY PK 
STUDY 
Case Report form 
M12/01/006 
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Patient subject 
number 
 
 
 
 
 
 
 
 
COMMENT: 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………………………………………………………………………………………………..…
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
 
 
 
 
 
 
DATE SIGNATURE 
INVESTIGATOR/NURSE D D M M Y Y Y Y  
INVESTIGATOR/NURSE D D M M Y Y Y Y  
PAS ONCE DAILY VS TWICE DAILY PK 
STUDY 
Case Report form 
M12/01/006 
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Patient subject 
number 
Appendix H: Dosing form for PAS in Study 2 
 
 
 
 
 
 
 
 
 
Title of the Project: Pharmacokinetics of twice daily vs. once daily dosing with 
granular slow-release para-aminosalicylic acid in adults on second-line anti-
tuberculosis and antiretroviral treatment 
 
 
 
PK DATE D D M M Y Y Y Y 
A STUDY GROUP 
1 1x 8g GSR-PAS 2 2x 4g GSR-PAS 
B PAS DOSING 
 PAS DOSING TIME 1 TIME 2 
1 1x 8g GSR-PAS    
2 2x 4g GSR-PAS     
 
C TAKE PAS WITH 
 PAS DOSNING AMOUNT FLAVOUR COMMENTS 
1  YOGHURT    
2 YOGHURT    
 
 
 
 
 
 
 
 
 
 
    
D COMPLETED VAS FORM 
1 YES 2 NO 
  
 
 
 
 
 
  
 
Was there any significant vomiting/regurgitation/reflux noted? 
0 - No 1 - Yes -5 - Unknown 
(Note : If Yes, medications require re-administration as deemed clinically relevant) 
 
 
 
 
 
DATE SIGNATURE 
INVESTIGATOR/NURSE D D M M Y Y Y Y  
INVESTIGATOR/NURSE D D M M Y Y Y Y  
PAS ONCE DAILY VS TWICE DAILY PK STUDY 
 Dosing and VAS forms 
 M12/01/006 
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Appendix I: VAS form for Study 2 
 
 
 
 
 
 
 
 
 
 
 
 
PLEASE COMPLETE THE FOLLOWING SCALE BY PLACING A VERTICAL  
MARK ON THE LINES BELOW TO INDICATE HOW YOU FEEL TODAY:  
 
0: No side effects 
5: Moderate side effects 
10: Worst extreme side effects 
 
Did you experience any abdominal pain or cramps today and how will 
you classify it? 
  
 
  
  
 
 
 
 
 
 
 
Did you experience nausea today and how will you classify it? 
  
 
  
  
 
 
 
 
 
 
 
 
RATING DATE D D M M Y Y Y Y 
 Morning   Mid-Day  Evening 
 Morning   Mid-Day  Evening 
MDR PK STUDY 
 
0-10 VAS NUMERIC SCALES:  
GASTROINTESTINAL AND OTHER INTOLERANCES 
Version 2012-01-16 
SUBJECT NUMBER 
NO 
PAIN 
VERY SEVERE 
PAIN 
0 10 
NOT 
NAUSEOUS 
 
UNBEARABLY  
NAUSEOUS AND 
VOMITTED 
 
0 10 
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Did you vomit today, if ‘Yes’ how many times? 
 
 1  2  3  4-5 
 
 
 
Did you experience any diarrhoea today and how will you classify it? 
  
 
  
  
 
 
 
 
 
 
 
Are/were you bloated today and how will you classify it? 
  
 
  
  
 
 
 
 
 
 
 
 
 Morning   Mid-Day  Evening 
 Morning   Mid-Day  Evening 
Please comment on any other adverse events  
Comments:…………………………………………………………………………………………………………………………………
…………………………………………………………………………………..……………………………………………………………
……………………………………………………………………………………………………………………………………………….. 
Investigator/Nurse’s signature:…..…………………………………………………….. 
NO 
DIARRHOEA 
EXCESSIVE  
DIARRHOEA 
0 10 
NOT 
BLOATED 
UNCOMFORTABLY 
BLOATED 
0 10 
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Appendix J: Individual pharmacokinetic parameters of Study 1 
Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the first occasion 
Parameter 
PK Parameters of GSR-PAS 
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
Cmax, μg/ml 25.8 48.95 38.8 29.05 48.4 93.1 48.95 37.3 87.05 44.65 61.05 42.75 
tmax,h 6.08 5 5 6.08 5 8 5 6.08 5 8 4 0 
Cmin, μg/ml 1.8 8.77 4.05 3.27 4.83 31.05 8.77 12.25 24.95 12.6 16.75 13.5 
tmin,h 12 12 12 0 0 0 12 12 8 3 12 5 
Clast, μg/ml 1.8 8.77 4.05 7.61 9.1 91.5 8.77 12.25 37.2 15.8 16.75 29.35 
tlast,h 12 12 12 12 12 12 12 12 12 12 12 12 
C0, μg/ml 2.18 31.2 6.99 3.27 4.83 31.05 31.15 27.55 32.2 26.4 31 42.75 
C12, μg/ml 1.8 8.77 4.05 7.61 9.1 91.5 8.77 12.25 37.2 15.8 16.75 29.35 
C24, μg/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 146.97 295.89 242.24 188.81 294.94 852.06 295.84 310.63 570.2 324.35 543.33 290.3 
AUC12, μg.h/ml 146.97 295.89 242.24 188.81 294.94 852.06 295.84 310.63 570.2 324.35 543.33 290.3 
AUC24, μg.h/ml 150.9 327.82 253.01 220.73 331.56 Missing 327.77 367.83 776.64 Missing 615.25 Missing 
AUC, μg.h/ml 150.88 331.85 252.99 223.74 333.06 Missing 331.8 372.79 857.52 Missing 619.16 Missing 
t1/2, h 1.51 2.84 1.84 3.18 2.9 Missing 2.84 3.52 5.35 Missing 3.14 Missing 
CLss/F, L/h 27.22 13.52 16.51 21.19 13.56 4.69 13.52 12.88 7.02 12.33 7.36 13.78 
Vz/Fobs, L 57.65 49.42 42 82.06 50.32 Missing 49.43 54.44 36.03 Missing 29.25 Missing 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the first occasion 
Parameter 
PK Parameters of GSR-PAS 
1 2 3 4 5 6 7 8 9 10 11 12 
Cmax, μg/ml 106.5 44.6 Missing 72.15 80.65 32.2 23.15 17.05 119 35.1 13.35 45.45 
tmax,h 6 2.92 Missing 2 6 1 8 0 6 5 2.02 4.18 
Cmin, μg/ml 51.7 16.3 Missing 38.7 6.54 6.27 0.23 0.3 57.8 4.21 2.16 17.55 
tmin,h 2 0 Missing 0 1 6 4 3.05 0 0 8 0 
Clast, μg/ml 66.1 29.95 Missing 55.9 73.15 18.8 23.15 7.39 89.3 31.6 2.16 30.5 
tlast,h 8 7.92 Missing 8 8 8 8 8 8 8 8 8 
C0, μg/ml 55.55 16.3 Missing 38.7 7.14 27.9 2.68 17.05 57.8 4.21 11 17.55 
C12, μg/ml 43.3 8.46 Missing 21.2 56.1 29.15 8.56 5.93 53.55 19.8 0.93 26.2 
C24, μg/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 557.78 228.44 Missing 459.25 292.1 141.05 63.56 66.82 726.8 211.76 56.38 268.03 
AUC12, μg.h/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 61.92 368.69 
AUC24, μg.h/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 65.08 507.73 
AUC, μg.h/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 65.24 562.29 
t1/2, h Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 2.85 6.69 
CLss/F, L/h Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 68.61 13.46 
Vz/Fobs, L Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 252.16 68.63 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the first occasion 
Parameter 
PK Parameters of GSR-PAS 
13 14 15 16 17 18 19 20 21 22 23 24 
Cmax, μg/ml 41.3 38.5 30.2 20.4 51.1 88.35 71.9 77.5 31.95 84.85 56.45 32.35 
tmax,h 0 4 3 4.02 6 4 4 5.03 6 4 4 8 
Cmin, μg/ml 32.85 1.19 1.32 7.87 24.75 44.2 21 27.45 1.49 25.3 2.25 4.23 
tmin,h 8 0 0 0 0 0 0 2 2 0 0 0 
Clast, μg/ml 32.85 22.3 15.8 11.95 43.8 69.1 56.95 60.1 25.6 47.35 20.45 32.35 
tlast,h 8 8 8 8 8 8 8 8 8 8 8 8 
C0, μg/ml 41.3 1.19 1.32 7.87 24.75 44.2 21 30.2 4.35 25.3 2.25 4.23 
C12, μg/ml 51.1 44.85 48.55 30.2 28.4 73.15 36.05 17.75 71.3 17.1 1.55 93.45 
C24, μg/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 289 192.64 143.92 107.33 331.85 566.42 440.55 461.2 133.93 508.23 276.85 173.15 
AUC12, μg.h/ml Missing 262.17 187.03 143.41 Missing Missing Missing 664.37 Missing 653.58 321.65 Missing 
AUC24, μg.h/ml Missing 340.28 232.41 185.25 Missing Missing Missing 976.45 Missing 809.65 335.48 Missing 
AUC, μg.h/ml Missing 358.99 247.22 197.87 Missing Missing Missing 
1138.6
2 
Missing 843.86 335.22 Missing 
t1/2, h Missing 5.17 4.53 5.25 Missing Missing Missing 7.81 Missing 4.91 1.98 Missing 
CLss/F, L/h Missing 18.72 25.45 33.85 Missing Missing Missing 7.71 Missing 7.24 13.58 Missing 
Vz/Fobs, L Missing 83.12 105.78 153.17 Missing Missing Missing 39.6 Missing 33.6 34.06 Missing 
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Individual pharmacokinetic parameters for patients administered 4 g twice-
daily GSR-PAS on the first occasion 
Parameter 
PK Parameters of GSR-PAS 
25 26 27 28 29 
Cmax, μg/ml 39 86.7 53.15 42.8 55.4 
tmax,h 8 5 6 3 6 
Cmin, μg/ml 2.63 35.4 27.2 2.2 22.65 
tmin,h 2 0 2 0 0 
Clast, μg/ml 39 70.05 45.25 13.25 54.65 
tlast,h 8 8 8 8 8 
C0, μg/ml 5.18 35.4 35.75 2.2 22.65 
C12, μg/ml 57.05 44.85 22.3 0.6 53.85 
C24, μg/ml Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 154.9 511.03 344.08 228.3 324.38 
AUC12, μg.h/ml Missing Missing Missing 257.27 Missing 
AUC24, μg.h/ml Missing Missing Missing 266.04 Missing 
AUC, μg.h/ml Missing Missing Missing 265.83 Missing 
t1/2, h Missing Missing Missing 1.96 Missing 
CLss/F, L/h Missing Missing Missing 16.68 Missing 
Vz/Fobs, L Missing Missing Missing 42.62 Missing 
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 Summary pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the first occasion 
Parameter 
PK Parameters of GSR-PAS 
N Mean SD Min Median Max CV% Geometric Mean 
Cmax, μg/ml 40 52.42 25.46 13.35 45.05 119 49 46.61 
tmax,h 40 4.66 2.15 0 5 8 46 Missing 
Cmin, μg/ml 40 15.71 15.17 0.23 10.51 57.8 97 8.12 
tmin,h 40 3.2 4.42 0 0.5 12 138 Missing 
Clast, μg/ml 40 33.29 24.49 1.8 29.65 91.5 74 23.44 
tlast,h 40 9.2 1.86 7.92 8 12 20 9.03 
C0, μg/ml 40 20.89 16.04 1.19 21.83 57.8 77 13.04 
C12, μg/ml 40 30.21 24.81 0.6 24.25 93.45 82 18.28 
C24, μg/ml 0 Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 40 315.38 182.72 56.38 291.2 852.06 58 263.61 
AUC12, μg.h/ml 21 346.46 198.98 61.92 295.84 852.06 57 295.71 
AUC24, μg.h/ml 18 393.88 247.72 65.08 329.69 976.45 63 326.75 
AUC, μg.h/ml 18 416.05 281.91 65.24 332.46 1138.62 68 338.58 
t1/2, h 18 3.79 1.76 1.51 3.16 7.81 46 3.43 
CLss/F, L/h 21 17.57 13.73 4.69 13.56 68.61 78 14.47 
Vz/Fobs, L 18 70.18 54.89 29.25 49.87 252.16 78 58.43 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the second occasion 
Parameter 
PK Parameters of GSR-PAS 
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
Cmax, μg/ml 35.8 32.45 38 40.3 21.05 52.65 29 16.35 69.5 50.6 50.3 15.7 
tmax,h 8 0 4 4 8 8 4 8 5 5 6.08 2 
Cmin, μg/ml 9.86 4.97 6.71 3.6 0.26 1.58 4.84 3.9 25.55 0.31 13.55 1.23 
tmin,h 2 2 0 12 0 2 12 6 3 0 2 8 
Clast, μg/ml 34 19.8 6.82 3.6 6.63 15.95 4.84 5.4 28.95 2.52 34.3 2.33 
tlast,h 12 12 12 12 12 12 12 12 12 12 12 12 
C0, μg/ml 17.65 32.45 6.71 6.63 0.26 3.33 16.7 14 27.2 0.31 15.4 7.57 
C12, μg/ml 34 19.8 6.82 3.6 6.63 15.95 4.84 5.4 28.95 2.52 34.3 2.33 
C24, μg/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 267.97 164.73 248.55 176.59 103.06 285.93 172.36 109.23 540.21 231.45 407.06 64.97 
AUC12, μg.h/ml 267.97 164.73 248.55 176.59 103.06 285.93 172.36 109.23 540.21 231.45 407.06 64.97 
AUC24, μg.h/ml Missing Missing 274.61 187.49 Missing Missing 194.22 Missing 706.52 236.59 Missing 73 
AUC, μg.h/ml Missing Missing 276.19 188.29 Missing Missing 196.19 Missing 743.1 236.6 Missing 75.65 
t1/2, h Missing Missing 2.81 2.25 Missing Missing 3.41 Missing 4.86 1.42 Missing 3.18 
CLss/F, L/h 14.93 24.28 16.09 22.65 38.81 13.99 23.21 36.62 7.4 17.28 9.83 61.57 
Vz/Fobs, L Missing Missing 58.7 69.06 Missing Missing 100.4 Missing 37.73 34.68 Missing 242.51 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the second occasion 
Parameter 
PK Parameters of GSR-PAS 
1 2 3 4 5 6 7 8 9 10 11 12 
Cmax, μg/ml 119 55.75 55.75 52.65 40.35 65.5 36.8 33.85 69.65 30.5 27.25 12.8 
tmax,h 6 4 4 3 0 4 4 4 4 5 5 4 
Cmin, μg/ml 57.8 16.2 16.2 8.85 8.52 2.35 0.45 7.44 22.35 10.4 9.44 7.77 
tmin,h 0 0 0 0 6 0 0 1 1 8 8 2 
Clast, μg/ml 89.3 47.5 47.5 20.25 36.95 33.65 4.84 16.85 34.75 10.4 9.44 7.99 
tlast,h 8 8 8 8 8 8 8 8 8 8 8 8 
C0, μg/ml 57.8 16.2 16.2 8.85 40.35 2.35 0.45 8.11 26.1 11.25 22.6 8.59 
C12, μg/ml 53.55 26.1 26.1 2 34.1 10.8 2.76 2.99 7.56 1.74 0.52 52.8 
C24, μg/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 726.8 295.8 297.08 276.75 181.34 305 110.08 189.4 369.13 158.93 170.04 81.01 
AUC12, μg.h/ml Missing Missing Missing 336.51 Missing 404.5 117.44 235.99 470.12 180.86 190.09 106.82 
AUC24, μg.h/ml Missing Missing Missing 384.88 Missing 494.94 118.91 270.03 558.91 186.66 195.43 139.15 
AUC, μg.h/ml Missing Missing Missing 388.47 Missing 507.7 119.18 273 571.18 186.47 195.22 148.97 
t1/2, h Missing Missing Missing 3.82 Missing 4.18 1.3 3.44 4.03 1.84 1.85 5.9 
CLss/F, L/h Missing Missing Missing 13.51 Missing 11.89 35.27 19.53 9.97 23.83 22.45 45.12 
Vz/Fobs, L Missing Missing Missing 56.81 Missing 47.46 63.16 72.7 40.72 56.82 54.66 228.38 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the second occasion 
Parameter 
PK Parameters of GSR-PAS 
13 14 15 16 17 18 19 20 21 22 23 24 
Cmax, μg/ml 41.5 71 38.2 74.1 39.85 Missing Missing 80.25 21.45 80.5 56.3 40.1 
tmax,h 8 5 3 3 5 Missing Missing 5 6 4 8 4 
Cmin, μg/ml 11.45 9.93 16.4 23.75 12.95 Missing Missing 21.35 0.37 46.3 0.54 0.54 
tmin,h 5 0 2 0 0 Missing Missing 2 2 8 0 0 
Clast, μg/ml 41.5 38.75 25.7 49.4 30.95 Missing Missing 61.05 20.5 46.3 56.3 17.4 
tlast,h 8 8 8 8 8 Missing Missing 8 8 8 8 8 
C0, μg/ml 30.75 9.93 18.7 23.75 12.95 Missing Missing 25.35 1.78 48.9 0.54 0.54 
C12, μg/ml 33.55 32.3 5.29 79.95 8.97 Missing Missing 18.05 51.2 12.25 68.1 61.85 
C24, μg/ml Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 161.33 328.91 228.9 459.3 221 Missing Missing 426.33 71.06 498.5 140.55 164.8 
AUC12, μg.h/ml Missing 435.47 311.11 617.07 325.93 Missing Missing 630.76 Missing 645.83 Missing 212.92 
AUC24, μg.h/ml Missing 516.33 416.16 818.68 488.21 Missing Missing 935.08 Missing 811.49 Missing 246.24 
AUC, μg.h/ml Missing 525.43 451.4 886.71 573.85 Missing Missing 1081.3 Missing 847.71 Missing 248.28 
t1/2, h Missing 3.52 6 6 7.9 Missing Missing 7.44 Missing 5.23 Missing 3.33 
CLss/F, L/h Missing 10.99 15.8 7.91 15.95 Missing Missing 8.25 Missing 7.37 Missing 22.12 
Vz/Fobs, L Missing 38.61 76.72 39.03 79.47 Missing Missing 39.69 Missing 35.59 Missing 77.29 
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Individual pharmacokinetic parameters for patients administered 4 g twice-
daily GSR-PAS on the second occasion 
Parameter 
PK Parameters of GSR-PAS 
25 26 27 28 29 
Cmax, μg/ml 54.7 36.55 50.3 25.85 11.25 
tmax,h 3 8 4.03 5 0 
Cmin, μg/ml 2.89 0.21 14.75 0.5 1.03 
tmin,h 0 0 8 2 8 
Clast, μg/ml 30.65 36.55 14.75 6.76 1.03 
tlast,h 8 8 8 8.05 8 
C0, μg/ml 2.89 0.21 15.6 0.76 11.25 
C12, μg/ml 59.35 19.61 1.18 0.45 6.24 
C24, μg/ml Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 284.64 167.21 287.94 92.73 42.09 
AUC12, μg.h/ml 378.02 Missing 322.46 105.35 44.64 
AUC24, μg.h/ml 476.4 Missing 335.6 107.82 45.58 
AUC, μg.h/ml 497.28 Missing 335.44 107.78 45.5 
t1/2, h 4.81 Missing 2.23 1.54 2.3 
CLss/F, L/h 12.77 Missing 13.29 40.81 92.91 
Vz/Fobs, L 55.81 Missing 38.4 82.63 291.16 
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Summary pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS on the second occasion 
Parameter 
PK Parameters of GSR-PAS 
N Mean SD Min Median Max CV% Geometric Mean 
Cmax, μg/ml 39 45.47 22.13 11.25 40.3 119 49 40.22 
tmax,h 39 4.62 2.14 0 4 8 46 Missing 
Cmin, μg/ml 39 10.44 12.25 0.21 7.77 57.8 117 4.57 
tmin,h 39 2.87 3.61 0 2 12 126 Missing 
Clast, μg/ml 39 25.7 19.86 1.03 20.5 89.3 77 17.11 
tlast,h 39 9.23 1.87 8 8 12 20 9.06 
C0, μg/ml 39 14.64 13.76 0.21 11.25 57.8 94 7.06 
C12, μg/ml 39 21.65 21.92 0.45 12.25 79.95 101 10.74 
C24, μg/ml 0 Missing Missing Missing Missing Missing Missing Missing 
AUClast, μg.h/ml 39 243.81 145.57 42.09 221 726.8 60 204.66 
AUC12, μg.h/ml 31 285.29 169.26 44.64 248.55 645.83 59 234.88 
AUC24, μg.h/ml 25 368.76 249.11 45.58 274.61 935.08 68 286.46 
AUC, μg.h/ml 25 388.28 276.3 45.5 276.19 1081.3 71 296.01 
t1/2, h 25 3.78 1.85 1.3 3.44 7.9 49 3.35 
CLss/F, L/h 31 23.11 18.21 7.37 16.09 92.91 79 18.63 
Vz/Fobs, L 25 80.73 68.26 34.68 56.82 291.16 85 65.33 
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Appendix K: Individual pharmacokinetic parameters of Study 2 
 
Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS 
Parameter 
PK Parameters of GSR-PAS 
MM01 CT03 EVW04 HVW05 JJ06 MB07 ES08 GS09 SB10 FF12 FA13 AS14 
Cmax, μg/ml 62 38.6 27.6 47.1 43.5 48.2 31 66.6 65.8 65.4 78.5 52.4 
tmax,h 6 0 4 3 11.98 4 8 8 3 8.03 7.98 1.98 
Cmin, μg/ml 28.5 23.1 6.66 2.02 25.4 3.87 21.4 27.8 21.6 36.5 45.5 3.79 
tmin,h 1 5.97 11.95 11.97 6 11.95 11.97 0 11.98 0 3.98 0 
Clast, μg/ml 26.6 27.9 6.66 2.02 43.5 3.87 21.4 36.4 21.6 39.9 62.8 12 
tlast,h 12.02 11.97 11.95 11.97 11.98 11.95 11.97 11.97 11.98 11.98 11.98 12 
C0, μg/ml 35.6 38.6 12.1 11.6 42.2 12.7 23.9 27.8 24.3 36.5 72.6 3.79 
C12, μg/ml 26.6 27.9 6.66 2.02 43.5 3.87 21.4 36.4 21.6 39.9 62.8 12 
C24, μg/ml 41.1 71.6 11.7 17.2 31.6 17.7 20 40.4 36.5 44.3 50.6 12.1 
AUClast, μg.h/ml 557.36 340.49 197.41 304.83 413.74 293.2 315.94 617.08 503.09 586.15 799.94 383.35 
AUC12, μg.h/ml 556.91 Missing 197.73 304.91 Missing 293.4 Missing Missing 503.45 Missing Missing 383.35 
AUC24, μg.h/ml 710.77 Missing 229.7 308.89 Missing 303.99 Missing Missing 626.47 Missing Missing 438.93 
AUC, μg.h/ml 743.91 Missing 234.45 308.8 Missing 304 Missing Missing 651.93 Missing Missing 444.17 
t1/2, h 4.86 Missing 3.85 1.36 Missing 1.94 Missing Missing 4.78 Missing Missing 3.51 
CLss/F, L/h 7.18 Missing 20.23 13.12 Missing 13.63 Missing Missing 7.95 Missing Missing 10.43 
Vz/Fobs, L 37.71 Missing 94.88 25.42 Missing 36.74 Missing Missing 42.28 Missing Missing 45.64 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS  
Parameter 
PK Parameters of GSR-PAS 
WJ15 FS16 VA17 NT18 JJ19 MC20 EK22 BB24 LD25 ST26 FF27 ZL28 
Cmax, μg/ml 61.6 112 84.7 68.2 93.2 60.8 60.7 72.9 93.4 20.4 37.6 9.92 
tmax,h 4.03 1.97 3 4 6 6.08 0 8 8 12 3 11.95 
Cmin, μg/ml 35.7 51.2 6.5 12.7 31.3 8.45 1.73 39.8 21.3 3.22 13.2 0.8 
tmin,h 0 11.95 11.97 11.97 1 11.98 11.97 2.1 0 7.97 11.97 4.03 
Clast, μg/ml 22.3 51.2 6.5 12.7 48.8 8.45 1.73 47 25.4 20.4 13.2 9.92 
tlast,h 12.07 11.95 11.97 11.97 11.98 11.98 11.97 12 11.97 12 11.97 11.95 
C0, μg/ml 35.7 100 22 28.4 37.7 14.9 60.7 49.3 21.3 17.3 33.2 1.46 
C12, μg/ml 22.3 51.2 6.5 12.7 48.8 8.45 1.73 47 25.4 20.4 13.2 9.92 
C24, μg/ml 50.4 81.9 16.2 26.6 32.9 16.5 2.36 40.6 22.4 7.38 11.2 37.2 
AUClast, μg.h/ml 539.32 931.53 554.42 496.23 810.7 428.12 353.23 657.33 572.53 119.3 324.31 49.77 
AUC12, μg.h/ml 537.82 934.09 554.64 496.66 811.53 428.27 353.28 657.33 Missing 119.3 324.75 Missing 
AUC24, μg.h/ml 660.84 1370.86 572.44 541.35 1134.89 452.48 356.75 Missing Missing Missing 398.32 Missing 
AUC, μg.h/ml 684.17 1784.04 572.53 542.54 1241.08 452.49 356.74 Missing Missing Missing 414.12 Missing 
t1/2, h 4.5 11.54 1.93 2.53 6.11 2 1.41 Missing Missing Missing 4.72 Missing 
CLss/F, L/h 7.44 4.28 7.21 8.05 4.93 9.34 11.32 6.09 Missing 33.53 12.32 Missing 
Vz/Fobs, L 37.98 37.33 19.47 26.89 28.42 25.49 22.77 Missing Missing Missing 65.71 Missing 
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Individual pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS 
Parameter 
PK Parameters of GSR-PAS 
WM29 JB30 LM31 FP33 AB34 MS02 EB23 
Cmax, μg/ml 52.9 39.7 54.4 33.4 105 Missing 62.5 
tmax,h 6 0 3.12 6 0 Missing 2.03 
Cmin, μg/ml 15.4 18.9 10.7 5.07 63.2 Missing 8.41 
tmin,h 11.98 6 12 0 11.97 Missing 12 
Clast, μg/ml 15.4 28.6 10.7 8.75 63.2 Missing 8.41 
tlast,h 11.98 11.97 12 11.98 11.97 Missing 12 
C0, μg/ml 19.8 39.7 15.9 5.07 105 Missing 13.7 
C12, μg/ml 15.4 28.6 10.7 8.75 63.2 Missing 8.41 
C24, μg/ml 13.7 18.6 16.1 5.76 67 Missing 22.6 
AUClast, μg.h/ml 459.46 326.85 398.14 220.18 1020.35 Missing 415.12 
AUC12, μg.h/ml 459.72 Missing 398.14 220.33 Missing Missing 415.12 
AUC24, μg.h/ml 526.85 Missing 458.46 256.34 Missing Missing 458.13 
AUC, μg.h/ml 531.32 Missing 461.92 258.55 Missing Missing 459.27 
t1/2, h 3.23 Missing 4.13 3.04 Missing Missing 3.64 
CLss/F, L/h 8.7 Missing 10.05 18.15 Missing Missing 9.64 
Vz/Fobs, L 35.13 Missing 51.62 67.84 Missing Missing 45.73 
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Summary pharmacokinetic parameters for patients administered 4 g twice-daily GSR-PAS  
Parameter 
PK Parameters of GSR-PAS 
N Mean SD Min Median Max 
CV
% 
Geometric Mean 
Cmax, μg/ml 30 58.33 24.16 9.92 60.75 112 41 52.59 
tmax,h 30 5.04 3.5 0 4.02 12 70 Missing 
Cmin, μg/ml 30 19.79 16.18 0.8 17.15 63.2 82 12.66 
tmin,h 30 7.25 5.19 0 9.96 12 72 Missing 
Clast, μg/ml 30 23.58 17.93 1.73 20.9 63.2 76 16.6 
tlast,h 30 11.98 0.02 11.95 11.98 12.07 0 11.98 
C0, μg/ml 30 32.09 25.1 1.46 26.05 105 78 23.28 
C12, μg/ml 30 23.58 17.93 1.73 20.9 63.2 76 16.6 
C24, μg/ml 30 29.47 20.04 2.36 22.5 81.9 68 22.88 
AUClast, μg.h/ml 30 466.32 223.91 49.77 421.62 1020.35 48 404.99 
AUC12, μg.h/ml 20 447.54 198.46 119.3 421.69 934.09 44 404.53 
AUC24, μg.h/ml 18 544.8 293.76 229.7 458.29 1370.86 54 487.85 
AUC, μg.h/ml 18 580.34 379.36 234.45 460.6 1784.04 65 503.64 
t1/2, h 18 3.84 2.34 1.36 3.58 11.54 61 3.33 
CLss/F, L/h 20 11.18 6.62 4.28 9.49 33.53 59 9.89 
Vz/Fobs, L 18 41.5 18.96 19.47 37.52 94.88 46 38.14 
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Individual pharmacokinetic parameters for patients administered 8 g once-daily GSR-PAS  
Parameter 
PK Parameters of GSR-PAS 
MM01 CT03 EVW04 HVW05 JJ06 MB07 ES08 GS09 SB10 FF12 FA13 AS14 
Cmax, μg/ml 80 118 73 66.6 67.7 61.7 65 108 91.8 125 20.7 113 
tmax,h 3 12.05 4 12 4 4 8 8 8 8 12 3.07 
Cmin, μg/ml 0.19 6.58 1.58 0 0.94 0.18 0.27 0.44 1.17 0.07 5.64 1.24 
tmin,h 0 0 0 0 0 0 0 23.98 0 24 6 0 
Clast, μg/ml 0.55 10.7 2.63 0.03 1.31 0.42 1.23 0.44 1.38 0.07 41.7 2.61 
tlast,h 24 24.75 24 24 23.98 24 24 23.98 24 24 24.17 24 
C0, μg/ml 0.19 6.58 1.58 0 0.94 0.18 0.27 1.51 1.17 0.23 20.1 1.24 
C12, μg/ml 23.6 118 30.2 66.6 38.5 20.6 63.4 60.8 77.1 68.6 20.7 40 
C24, μg/ml 0.55 10.7 2.63 0.03 1.31 0.42 1.23 0.44 1.38 0.07 41.7 2.61 
AUClast, μg.h/ml 799.81 1769.21 715.13 769.25 814.95 578.65 824.91 1299.29 1216.12 1307.71 540.69 1215.79 
AUC12, μg.h/ml 654.94 946.07 518.15 369.48 576.42 452.73 437.13 932.36 745.24 895.66 161.09 960.75 
AUC24, μg.h/ml 799.81 1758.81 715.13 769.25 814.97 578.65 824.91 1299.3 1216.12 1307.71 533.76 1215.79 
AUC, μg.h/ml 801.62 Missing 729.18 Missing 820.27 580.14 829.53 1300.52 1221.06 1307.86 Missing 1227.68 
t1/2, h 2.29 Missing 3.7 Missing 2.82 2.49 2.6 1.93 2.48 1.42 Missing 3.16 
CLss/F, L/h 10 4.55 11.19 10.4 9.82 13.83 9.7 6.16 6.58 6.12 14.99 6.58 
Vz/Fobs, L 32.96 Missing 58.59 Missing 39.63 49.44 36.18 17.11 23.47 12.51 Missing 29.7 
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Individual pharmacokinetic parameters for patients administered 8 g once-daily GSR-PAS  
Parameter 
PK Parameters of GSR-PAS 
WJ15 FS16 VA17 NT18 JJ19 MC20 EK22 BB24 LD25 ST26 FF27 ZL28 
Cmax, μg/ml 114 132 105 59.3 128 135 81.8 121 70.1 62.5 73.4 47.8 
tmax,h 4 8 6 12 6 8 4 8 7.98 8.02 8 12 
Cmin, μg/ml 16.7 21.3 1.12 0.93 2.86 0.21 0.85 0.43 0.25 0.3 0.77 3.36 
tmin,h 24 0 0 0 0 24 23.97 24 24 24 0 4.07 
Clast, μg/ml 16.7 23.7 2.53 3.44 6.27 0.21 0.85 0.43 0.25 0.3 1.44 16.9 
tlast,h 24 24 24 24 24 24 23.97 24 24 24 24.08 23.95 
C0, μg/ml 20.5 21.3 1.12 0.93 2.86 0.34 0.95 5.95 0.36 0.55 0.77 5.87 
C12, μg/ml 55.8 121 59.5 59.3 82.9 91.3 64.7 90.3 44.1 26.4 56.2 47.8 
C24, μg/ml 16.7 23.7 2.53 3.44 6.27 0.21 0.85 0.43 0.25 0.3 1.44 16.9 
AUClast, μg.h/ml 1299.27 1892.72 1275.01 684.07 1532.19 1604.4 1118.83 1574.76 875.03 412.52 904.24 686.62 
AUC12, μg.h/ml 864.27 1024.52 902.83 307.63 997.17 1055.37 726.65 1016.6 608.93 252.31 555.99 300.04 
AUC24, μg.h/ml 1299.27 1892.72 1275.01 684.07 1532.19 1604.4 1118.86 1574.76 875.03 412.52 904.1 Missing 
AUC, μg.h/ml 1462.27 2100.77 1285.75 Missing 1568.62 1604.88 1121.66 1575.9 875.7 413.4 909.82 Missing 
t1/2, h 6.77 6.08 2.94 Missing 4.03 1.61 2.32 1.85 1.87 2.02 2.69 Missing 
CLss/F, L/h 6.16 4.23 6.27 11.69 5.22 4.99 7.15 5.08 9.14 19.39 8.85 Missing 
Vz/Fobs, L 53.4 33.43 26.41 Missing 29.63 11.61 23.91 13.54 24.68 56.44 34.07 Missing 
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Individual pharmacokinetic parameters for patients administered 8 g once-daily GSR-PAS  
Parameter 
PK Parameters of GSR-PAS 
WM29 JB30 LM31 FP33 AB34 MS02 EB23 CW21 
Cmax, μg/ml 74.5 52.7 111 84.4 76.6 125 Missing 62.7 
tmax,h 8 4 6 6 12 8.1 Missing 6 
Cmin, μg/ml 0.98 0.7 0.33 1.21 28.6 3.19 Missing 0.19 
tmin,h 0 0 0 0 0 0 Missing 0 
Clast, μg/ml 1.28 1.89 0.28 1.36 53.6 33.2 Missing 0.89 
tlast,h 24 24 24.07 24.08 24 23.92 Missing 24 
C0, μg/ml 0.98 0.7 0.33 1.21 28.6 3.19 Missing 0.19 
C12, μg/ml 64 21.5 32 20.9 76.6 112 Missing 54.4 
C24, μg/ml 1.28 1.89 0.28 1.36 53.6 33.2 Missing 0.89 
AUClast, μg.h/ml 1043.63 436.05 1082.98 761.4 1357.25 1949.23 Missing 886.54 
AUC12, μg.h/ml 651.95 295.38 888.22 626.91 576.05 1080.78 Missing 554.81 
AUC24, μg.h/ml 1043.63 436.05 1082.96 761.28 1357.25 1952.03 Missing 886.54 
AUC, μg.h/ml 1048.36 447.98 1083.74 767.26 Missing 2325.85 Missing 889.67 
t1/2, h 2.56 4.38 1.85 2.99 Missing 7.86 Missing 2.45 
CLss/F, L/h 7.67 18.35 7.39 10.51 5.89 4.1 Missing 9.02 
Vz/Fobs, L 28.2 112.72 19.74 44.96 Missing 39.02 Missing 31.73 
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Summary pharmacokinetic parameters for patients administered 8 g once-daily GSR-PAS  
Parameter 
PK Parameters of GSR-PAS 
N Mean SD Min Median Max CV% Geometric Mean 
Cmax, μg/ml 31 87.33 29.31 20.7 80 135 34 81.79 
tmax,h 31 7.36 2.88 3 8 12.05 39 6.79 
Cmin, μg/ml 31 3.31 6.66 0 0.93 28.6 201 Missing 
tmin,h 31 6.52 10.55 0 0 24 162 Missing 
Clast, μg/ml 31 7.37 13.36 0.03 1.36 53.6 181 1.66 
tlast,h 31 24.03 0.14 23.92 24 24.75 1 24.03 
C0, μg/ml 31 4.22 7.51 0 0.98 28.6 178 Missing 
C12, μg/ml 31 58.35 28.53 20.6 59.3 121 49 51.35 
C24, μg/ml 31 7.37 13.36 0.03 1.36 53.6 181 1.66 
AUClast, μg.h/ml 31 1071.88 419.73 412.52 1043.63 1949.23 39 990.92 
AUC12, μg.h/ml 31 675.37 271.1 161.09 651.95 1080.78 40 611.3 
AUC24, μg.h/ml 30 1084.23 420.6 412.52 1063.3 1952.03 39 1002.52 
AUC, μg.h/ml 25 1131.98 467.68 413.4 1083.74 2325.85 41 1041.33 
t1/2, h 25 3.09 1.62 1.42 2.56 7.86 53 2.79 
CLss/F, L/h 30 8.7 3.91 4.1 7.53 19.39 45 7.98 
Vz/Fobs, L 25 35.32 20.78 11.61 31.73 112.72 59 30.9 
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Appendix L: Individual genetic results of Study 1 
Summary of the genetic variants of NAT1 in study 1 
Gender Race NAT1 alleles  Phenotype 
Female Coloured 1*4/1*4 Fast 
Male Coloured 1*4/1*4 Fast 
Male Coloured 1*4/1*4 Fast 
Male Coloured 1*4/1*4 Fast 
Female Coloured 1*4/1*4 Fast 
Female Coloured 1*4/1*4 Fast 
Female Coloured 1*4/1*4 Fast 
Male Black 1*4/1*4 Fast 
Male Black 1*4/1*4 Fast 
Male Coloured 1*4/1*3 Unknown 
Female Coloured 1*4/1*27 Fast 
Male Coloured 1*4/1*27 Fast 
Female Coloured 1*4/1*10 Unknown 
Female Black 1*4/1*10 Unknown 
Female Coloured 1*4/1*10 Unknown 
Male Coloured 1*4/1*10 Unknown 
Male Coloured 1*4/1*10 Unknown 
Male Coloured 1*4/1*10 Unknown 
Male Black 1*4/1*10 Unknown 
Male Black 1*4/1*10 Unknown 
Male Coloured 1*4/1*10 Unknown 
Male Black 1*4/1*10 Unknown 
Female Coloured 1*4/1*10 Unknown 
Female Coloured 1*4/1*10 Unknown 
Male Black 1*4/1*10 Unknown 
Female Coloured 1*3/1*3 Unknown 
Female Coloured 1*10/1*10 Unknown 
Male Coloured 1*10/1*10 Unknown 
Male Black 1*10/1*10 Unknown 
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Appendix M: Individual genetic results of Study 2 
Summary of the genetic variations of NAT1 and NAT2 in study 2 
Gender Race NAT1 alleles  Phenotype NAT 2 Alleles NAT 2 
Phenotype 
Male Coloured 1*4/1*4 Fast 2*4/2*4 FAST 
Male Coloured 1*4/1*4 Fast 2*4/2*4 FAST 
Male Coloured 1*4/1*4 Fast 2*4/2*4 FAST 
Male Coloured 1*4/1*4 Fast 2*5/2*5 SLOW 
Male Coloured 1*4/1*4 Fast 2*4/2*6 INTERMED. 
Female Black 1*4/1*4 Fast 2*4/2*6 INTERMED. 
Female Coloured 1*4/1*4 Fast 2*5/2*5 SLOW 
Male Coloured 1*4/1*14A Unknown 2*4/2*5 INTERMED. 
Male Coloured 1*4/1*14A Unknown 2*4/2*7 INTERMED. 
Female Coloured 1*4/1*10 Unknown 2*6/2*7 SLOW 
Female Coloured 1*4/1*10 Unknown 2*6/2*7 SLOW 
Female Coloured 1*4/1*10 Unknown 2*4/2*5 INTERMED. 
Male Coloured 1*4/1*10 Unknown 2*4/2*5 INTERMED. 
Female Coloured 1*4/1*10 Unknown 2*4/2*4 FAST 
Female Coloured 1*4/1*10 Unknown 2*4/2*6 INTERMED. 
Female Coloured 1*4/1*10 Unknown 2*4/2*4 FAST 
Male Coloured 1*4/1*10 Unknown 2*4/2*4 FAST 
Male Black 1*4/1*10 Unknown 2*5/2*6 SLOW 
Female Coloured 1*4/1*10 Unknown 2*4/2*5 INTERMED. 
Female Coloured 1*4/1*10 Unknown 2*4/2*14 INTERMED. 
Male Coloured 1*4/1*10 Unknown 2*6/2*6 SLOW 
Male Black 1*4/1*10 Unknown 2*4/2*6 INTERMED. 
Male Black 1*4/1*10 Unknown 2*6/2*6 SLOW 
Female Coloured 1*3/1*10 Unknown 2*5/2*14 SLOW 
Male Coloured 1*10/1*10  Unknown  2*4/2*5 INTERMED. 
Female Coloured 1*10/1*10 Unknown 2*6/2*7 SLOW 
Female Coloured 1*10/1*10 Unknown 2*4/2*4 FAST 
Male Coloured 1*10/1*10 Unknown 2*4/2*5 INTERMED. 
Female Coloured 1*10/1*10 Unknown 2*4/2*5 INTERMED. 
Male Black 1*10/1*10 Unknown 2*6/2*6 SLOW 
Male Coloured 1*10/1*10 Unknown 2*5/2*5 SLOW 
Male Coloured 1088AA  not defined 2*4/2*6 INTERMED. 
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